<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">APMIS</journal-id>
<journal-id journal-id-type="iso-abbrev">APMIS</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1600-0463</journal-id>
<journal-id journal-id-type="publisher-id">APM</journal-id>
<journal-title-group>
<journal-title>Apmis</journal-title>
</journal-title-group>
<issn pub-type="ppub">0903-4641</issn>
<issn pub-type="epub">1600-0463</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31124204</article-id>
<article-id pub-id-type="pmc">6851586</article-id>
<article-id pub-id-type="doi">10.1111/apm.12934</article-id>
<article-id pub-id-type="publisher-id">APM12934</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases</article-title>
<alt-title alt-title-type="left-running-head">Litman</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="apm12934-cr-0001">
<name>
<surname>Litman</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="apm12934-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="apm12934-aff-0002">
<sup>2</sup>
</xref>
<address>
<email>tlitman@sund.ku.dk</email>
<email>TYLDK@leo-pharma.com</email>
</address>
</contrib>
</contrib-group>
<aff id="apm12934-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Immunology and Microbiology</named-content>
<institution>University of Copenhagen</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff>
<aff id="apm12934-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Explorative Biology, Skin Research</named-content>
<institution>LEO Pharma A/S</institution>
<city>Ballerup</city>
<country country="DK">Denmark</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>Thomas Litman, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. e‐mail: <email>tlitman@sund.ku.dk</email> and Explorative Biology, Skin Research, LEO Pharna A/S, Ballerup, Denmark. e‐mail: <email>TYLDK@leo-pharma.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2019</year>
</pub-date>
<volume>127</volume>
<issue>5</issue>
<issue-id pub-id-type="doi">10.1111/apm.2019.127.issue-5</issue-id>
<issue-title content-type="special-issue-title">Personalized Medicine</issue-title>
<fpage>386</fpage>
<lpage>424</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 APMIS Published by John Wiley & Sons Ltd <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 The Authors. APMIS published by John Wiley &amp; Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:APM-127-386.pdf"></self-uri>
<abstract id="apm12934-abs-0001">
<p>The current state, tools, and applications of personalized medicine with special emphasis on inflammatory skin diseases like psoriasis and atopic dermatitis are discussed. Inflammatory pathways are outlined as well as potential targets for monoclonal antibodies and small‐molecule inhibitors.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="apm12934-kwd-0001">Atopic dermatitis</kwd>
<kwd id="apm12934-kwd-0002">endotypes</kwd>
<kwd id="apm12934-kwd-0003">immunology</kwd>
<kwd id="apm12934-kwd-0004">inflammatory skin diseases</kwd>
<kwd id="apm12934-kwd-0005">personalized medicine</kwd>
<kwd id="apm12934-kwd-0006">precision medicine</kwd>
<kwd id="apm12934-kwd-0007">psoriasis</kwd>
<kwd id="apm12934-kwd-0008">targeted therapy</kwd>
</kwd-group>
<counts>
<fig-count count="7"></fig-count>
<table-count count="2"></table-count>
<page-count count="39"></page-count>
<word-count count="25994"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.1 mode:remove_FC converted:13.11.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="apm12934-cit-1001" publication-type="journal">
<string-name>
<surname>Litman</surname>
<given-names>T</given-names>
</string-name>. <article-title>Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases</article-title>. <source xml:lang="en"/>APMIS
<year>2019</year>; <volume>127</volume>: <fpage>386</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">31124204</pub-id></mixed-citation>
</p>
</notes>
</front>
<body id="apm12934-body-0001">
<sec id="apm12934-sec-0001">
<title>Introduction – why?</title>
<p>
<italic>One size does not fit all!</italic> Or does it? For treatment of many – if not most – inflammatory skin conditions, the dermatologists’ first choice over the last 50+ years has been a topical glucocorticoid <xref ref-type="ref" rid="apm12934-bib-0001">1</xref>, most often yielding astonishing anti‐inflammatory effects: rapid relief of itch and ease of rash, bringing the inflamed skin back to a ‘near‐normal’ state within a few days (Box <xref ref-type="boxed-text" rid="apm12934-fea-0001">1</xref>).</p>
<boxed-text content-type="Box" id="apm12934-fea-0001" orientation="portrait" position="float">
<label>Box 1</label>
<caption>
<title>Size matters</title>
</caption>
<sec id="apm12934-sec-0025">
<p>
<italic>One size fits all</italic>, the paradigm of traditional medicine.</p>
<p>
<italic>One size does not fit all</italic>, a mantra of personalized medicine, the goal of which is to provide ‘The right dose of the right drug for the right indication for the right patient at the right time.’ This is another mantra of personalized medicine, a much publicized quote ascribed to former FDA Genomics associate director, Felix Frueh, when he captured the essence of personalized medicine at the Annual FDA Science Forum in 2005 <xref ref-type="ref" rid="apm12934-bib-0002">2</xref>. A variant of the above principles can be found in the ‘5R framework’ for improving research and development productivity in the pharma industry, with focus on ‘right target, right tissue, right safety, right patients, and right commercial potential’ <xref ref-type="ref" rid="apm12934-bib-0003">3</xref>.</p>
</sec>
</boxed-text>
<p>But if such an efficient, universal, and inexpensive treatment is already available, where, then, is the unmet need for personalized medicine and targeted therapy? One may even argue that treatment with glucocorticoids <italic>is</italic> targeted therapy! Because glucocorticoids specifically bind to their molecular target, the cytosolic glucocorticoid receptor, and thereby induce downstream anti‐inflammatory effects. These effects are brought about via several mechanisms: non‐genomic direct activation of anti‐inflammatory proteins, DNA‐dependent (genomic) induction of anti‐inflammatory proteins, and protein interference (via transcription factors, such as NF‐κB) causing repression of inflammatory proteins <xref ref-type="ref" rid="apm12934-bib-0004">4</xref>, <xref ref-type="ref" rid="apm12934-bib-0005">5</xref>. Now, as glucocorticoid receptor activation produces pleiotropic (multiple and diverse) effects, and because the receptor is universally expressed – albeit to a varying degree – in most cell types, this accounts both for the high anti‐inflammatory efficacy, the broad mode of action, and for the adverse effects associated with – in particular: long‐term – glucocorticoid treatment. One such major adverse effect is skin <italic>atrophy</italic>, possibly mediated by the glucocorticoid receptor chaperone FKBP51 <xref ref-type="ref" rid="apm12934-bib-0006">6</xref>, but also <italic>systemic</italic> side‐effects are observed, such as suppression of the hypothalamus‐pituitary‐adrenal (HPA) axis, due to percutaneous glucocorticoid absorption <xref ref-type="ref" rid="apm12934-bib-0007">7</xref>. Moreover, if large areas of the skin are covered with lesions, topical treatment is not a feasible solution. Therefore, and because of extensive disease heterogeneity – not all patients (especially, those with severe disease) respond to glucocorticoids, and all patients differ with respect to their genetic makeup – there is still a need for better, and more targeted therapy. In particular, the two most common inflammatory skin diseases, atopic dermatitis (AD) and psoriasis (PSO), have both a complex pathogenesis including several pathophysiological mechanisms <xref ref-type="ref" rid="apm12934-bib-0008">8</xref>, and a multitude of clinical manifestations <xref ref-type="ref" rid="apm12934-bib-0009">9</xref>, <xref ref-type="ref" rid="apm12934-bib-0010">10</xref>, which make them exemplary diseases for a personalized medicine strategy calling for improved stratification, development of targeted treatment, and prevention <xref ref-type="ref" rid="apm12934-bib-0011">11</xref>, <xref ref-type="ref" rid="apm12934-bib-0012">12</xref>.</p>
<p>Often, the term ‘personalized medicine’ is used synonymously and sometimes confused with precision/stratified/individualized/tailored/P4 medicine, targeted therapy, and pharmacogenomics. Here, I will mainly use ‘personalized medicine’, though, for clarity, the conceptual nuances of this and its related terms are summarized in Box <xref ref-type="boxed-text" rid="apm12934-fea-0002">2</xref>.</p>
<boxed-text content-type="Box" id="apm12934-fea-0002" orientation="portrait" position="float">
<label>Box 2</label>
<caption>
<title>WHAT? The different flavors of personalized medicine</title>
</caption>
<sec id="apm12934-sec-0026">
<p>Numbers in parentheses correspond to count of Google hits as per February 19th 2019</p>
<p>Both American ‘‐ized’ and British ‘‐ised’ spellings have been included.</p>
</sec>
<sec id="apm12934-sec-0027">
<title>Personalized medicine</title>
<p>(5.2M) is an approach to both <italic>preventive</italic> care (e.g. identifying genetic risk factors to guide behavioral changes and preventive treatment, such as statins for hypercholesterolemia) and to drug <italic>therapy</italic> (e.g. early and accurate diagnostic tests that can guide targeted treatment and diminish side‐effects) based on the individual's genetic (and other relevant) information.</p>
<p>The term ‘personalized medicine’ – albeit with a slightly different, ethical connotation – can be found already in a 1971 article by W.M. Gibson, who envisages the family practitioner's role as a scientist‐physician who ‘Within a few years will likely have available to him a computer programmed for medicine providing him with a great store of knowledge literally at his fingertips’ <xref ref-type="ref" rid="apm12934-bib-0013">13</xref>. Thus, in the early years, personalized medicine focused on the ethical dimensions of patient‐centered practice <xref ref-type="ref" rid="apm12934-bib-0014">14</xref>. But actually, the foundation for personalized medicine can be traced all the way back to <bold>Hippocrates</bold> (460–370 BCE), who famously said ‘It's far more important to know what person the disease has than what disease the person has’, thus introducing the patient‐centric concept <xref ref-type="ref" rid="apm12934-bib-0015">15</xref>. Interestingly, today, such <italic>patient‐centricity</italic> is widely embraced by the pharma industry, which is increasingly engaging in a dialog with patients during the drug development process <xref ref-type="ref" rid="apm12934-bib-0016">16</xref>.</p>
<p>Due to concern that ‘personalized medicine’ can be misinterpreted as implying that a unique treatment can be designed for each individual, the National Research Council preferred the term ‘precision medicine’ in their 2011 report <italic>Toward Precision Medicine</italic>
<xref ref-type="ref" rid="apm12934-bib-0017">17</xref>.</p>
</sec>
<sec id="apm12934-sec-0028">
<title>Precision medicine</title>
<p>(5.5M) is defined as ‘tailoring of medical treatment to the individual characteristics of each patient’. <xref ref-type="ref" rid="apm12934-bib-0017">17</xref> But this does not mean that drugs are being developed uniquely for a patient, rather, it means that individual patients can be classified into subpopulations that differ in their response to a specific treatment. Thus, the focus is on identifying which treatments will work for which patients based on their individual genetic – and epigenetic – characteristics (for example, treatment of breast cancer patients with herceptin will only work for patients that overexpress HER2). An issue with the term precision, however, is that interpreted technically, it is a measure of statistical variability, and as such, it can be argued that medicine is not precise <xref ref-type="ref" rid="apm12934-bib-0018">18</xref>.</p>
</sec>
<sec id="apm12934-sec-0029">
<title>Targeted therapy</title>
<p>(3.6M) is often used synonymously with <italic>molecularly targeted therapy, molecular medicine</italic>, and <italic>biologic therapy</italic>, mainly to distinguish it from traditional chemotherapy in the context of cancer treatment. However, targeted therapy is neither limited to cancer, nor to biologics, as today, both small molecules and monoclonal antibodies are used in the targeted treatment of a wide variety of diseases, including asthma, atopic dermatitis, and psoriasis. The target concept is an old one and marks the beginning of modern pharmacology; it was developed by Paul Ehrlich around 1900, when he was studying antibodies and envisioned a hypothetical drug that would reach and kill its target (microbe) without harming the host; the <italic>magic bullet</italic> (German: Zauberkugel) <xref ref-type="ref" rid="apm12934-bib-0019">19</xref>. Indeed, today Ehrlich's vision has become a reality, where numerous highly specific monoclonal antibody‐based therapies are being applied or are in clinical development.</p>
</sec>
<sec id="apm12934-sec-0030">
<title>Pharmacogenomics</title>
<p>(2.9M) refers to the study of how genes affect an individual's response to drugs. The term is a combination of pharmacology and genomics, with the aim of developing safe and effective treatments. When it is applied to the study of drug metabolism, it is largely termed <italic>pharmacogenetics</italic>, while pharmacogenomics is a broader term encompassing all genes that may impact drug response <xref ref-type="ref" rid="apm12934-bib-0020">20</xref>. A typical use includes identification of fast and slow metabolizers due to single nucleotide polymorphisms (SNPs) in the CYP450 system, where the former will achieve suboptimal drug levels, while the latter will have increased risk of adverse drug reactions, and in worst case, death <xref ref-type="ref" rid="apm12934-bib-0021">21</xref>.</p>
</sec>
<sec id="apm12934-sec-0031">
<title>Individualized medicine</title>
<p>(357K) is the term preferred by Eric Topol (founder and director of the Scripps Translational Science Institute), mainly because it relates both to the medicine and the medical information – including both omics and digital technology – that is particularized to an individual, and because it is supposedly less ambiguous compared to the terms personalized and precision medicine <xref ref-type="ref" rid="apm12934-bib-0022">22</xref>. Note, however, that individualized medicine can also be understood as ‘truly’ individualized, such as a cancer vaccine based on the patient's particular tumor. In this respect, individualized medicine lies in one end of the therapeutic continuum, empirical medicine is at the other end, while the field of stratified medicine lies in between <xref ref-type="ref" rid="apm12934-bib-0023">23</xref>.</p>
</sec>
<sec id="apm12934-sec-0032">
<title>Stratified medicine</title>
<p>(112K) aims at matching a therapy with a specific patient population – who will have a therapeutically meaningful benefit of the treatment – by use of clinical biomarkers, which are, therefore, of utmost importance (e.g. as companion diagnostics, such as the FDA‐approved HercepTest that quantifies HER2, identifying patients who are likely to benefit from Herceptin), because they link the patient subpopulation with the therapy <xref ref-type="ref" rid="apm12934-bib-0023">23</xref>.</p>
</sec>
<sec id="apm12934-sec-0033">
<title>P4 medicine</title>
<p>(40K) stands for <italic>predictive, preventive, personalized, and participatory</italic> medicine. The term was coined by Leroy Hood (a pioneer of systems biology and co‐founder of the Institute for Systems Biology in Seattle) with special emphasis on the <italic>participatory</italic> part. The idea is that the digital revolution and rise of the Internet will empower consumers, who by their use of social media, mobile healthcare apps and wearables <xref ref-type="ref" rid="apm12934-bib-0024">24</xref> generate the big data needed for systems medicine <xref ref-type="ref" rid="apm12934-bib-0025">25</xref>. Thus, Hood envisaged the emergence of a whole new healthcare system based on systems biology, big data, and networked consumers, who focus on both disease and wellness care, moving toward a holistic view on biological complexity.</p>
</sec>
<sec id="apm12934-sec-0034">
<title>Tailored medicine</title>
<p>(15K) emphasizes the move from the ‘one size fits all’ paradigm of traditional drug development and usage, to personalized medicine, where stratification of patient populations allows identification of responder subpopulations. One ethical issue with such an approach is that most participants in clinical trials in the US are white from higher socioeconomic levels, while ethnic minorities, who make up 40% of the population, are underrepresented. This disparity is problematic because certain diseases are more prevalent among ethnic minorities, who have a different genetic makeup and thus are likely to differ both in pathophysiology and response to treatment <xref ref-type="ref" rid="apm12934-bib-0026">26</xref>.</p>
</sec>
</boxed-text>
</sec>
<sec id="apm12934-sec-0002">
<title>From Disease Understanding to Biomarkers, Endotypes, and Targeted Treatment</title>
<sec id="apm12934-sec-0003">
<title>Theory</title>
<p>In theory, the logic is simple: If we can understand a disease, then we can also treat it. In particular, if we gain sufficient knowledge of its underlying molecular pathophysiology, then we can identify disease‐driving pathways and target relevant proteins. Or, better yet, it may be possible to take <italic>preventive</italic> measures even before the disease has manifested. Today, preventive medicine is made possible with the advent of new omics technologies, in particular, <italic>next‐generation sequencing</italic> (NGS) that enables determination of an individual's entire DNA sequence (six billion base‐pairs in a human diploid genome) in less than a day.<xref ref-type="fn" rid="apm12934-note-1001">1</xref> For the 6000+ human (mostly rare) diseases caused by a single gene mutation, including the more than 600 known monogenic dermatoses <xref ref-type="ref" rid="apm12934-bib-0027">27</xref>, a correct molecular (genetic) diagnosis is crucial, both in terms of counseling and preventive measures [e.g. statin treatment of familial hypercholesterolemia) and in terms of avoiding ineffective and often stressful, even deadly treatments (such as cancer chemotherapy for multidrug resistant tumors <xref ref-type="ref" rid="apm12934-bib-0028">28</xref>]. In the best‐case scenario, it may even guide treatment. A striking example of such a case was recently reported for a seven‐year‐old boy suffering from a life‐threatening skin disease, junctional epidermolysis bullosa. After genetic analysis revealed the cause to be a splice‐site mutation in the LAMB3 gene, the patient was treated successfully with transgenic keratinocyte stem cells, which resulted in regeneration of the entire epidermis <xref ref-type="ref" rid="apm12934-bib-0029">29</xref>.</p>
</sec>
<sec id="apm12934-sec-0004">
<title>Practice</title>
<p>In practice, most disorders are not as simple as that; they are polygenic, complex, and multifactorial, meaning that multiple genetic, epigenetic, lifestyle, and environmental factors play a role in the clinical manifestation of the disease. Such diseases include diabetes, cancer, and hypertension, as well as many inflammatory conditions, including asthma, inflammatory bowel disease (IBD), psoriasis, and atopic dermatitis. In these cases, a genomic ‘DNA fingerprint’ will give a <italic>static</italic> picture of the genetic susceptibility of an individual,<xref ref-type="fn" rid="apm12934-note-1002">2</xref> but will not fully capture the <italic>dynamic</italic> nature of cells or diseases.</p>
<p>To this end, one needs to identify other relevant and robust <italic>biomarkers</italic> that reflect the various clinical phenotypes, and which eventually can form the basis for stratification of <italic>endotypes</italic>.<xref ref-type="fn" rid="apm12934-note-1003">3</xref>
</p>
<p>Biomarkers for personalized medicine can be classified as <italic>diagnostic</italic>,<italic> prognostic</italic>, or <italic>predictive</italic>.</p>
</sec>
<sec id="apm12934-sec-0005">
<title>Diagnostic biomarkers</title>
<p>Ideally, <italic>diagnostic</italic> biomarkers can detect diseases before they become symptomatic. Examples include early detection of prostate cancer by evaluation of serum prostate‐specific antigen (PSA) [albeit with relatively low sensitivity and specificity <xref ref-type="ref" rid="apm12934-bib-0035">35</xref> and detection of other cancers by measuring circulating tumor cells in liquid biopsies <xref ref-type="ref" rid="apm12934-bib-0036">36</xref>]. But diagnostic biomarkers are more than just binary indicators of the absence or presence of disease. If they reflect the molecular pathology of the disease, then they may be able to precisely define and stratify its endotypes, and thus guide selection of the most effective targeted therapy. This also points to a need for improved <italic>molecular disease taxonomy</italic>
<xref ref-type="ref" rid="apm12934-bib-0011">11</xref>, <xref ref-type="ref" rid="apm12934-bib-0037">37</xref>, because currently, for most diseases – including inflammatory skin diseases – endotypes are not incorporated in the WHO's latest revision of International Classification of Diseases, ICD‐11 <xref ref-type="ref" rid="apm12934-bib-0038">38</xref>.</p>
</sec>
<sec id="apm12934-sec-0006">
<title>Prognostic biomarkers</title>
<p>
<italic>Prognostic</italic> biomarkers can, in principle, project the <italic>disease trajectory</italic>, i.e. indicate the likelihood of progression, remission, and future clinical events.<xref ref-type="fn" rid="apm12934-note-1004">4</xref> In oncology, classical clinicopathologic biomarkers are tumor size, number of tumor‐positive lymph nodes, and distant metastases, which are used for staging and prognosis indication. In clinical trials, prognostic biomarkers are used to enrich for populations that are more likely to progress, as this increases statistical power and thus, reduces cost of drug development, and also guides decisions regarding the aggressiveness of the treatment <xref ref-type="ref" rid="apm12934-bib-0040">40</xref>.</p>
</sec>
<sec id="apm12934-sec-0007">
<title>Predictive biomarkers</title>
<p>
<italic>Predictive</italic> biomarkers are most important for guiding personalized medicine, because they have the potential to identify individuals that are more or less likely to respond to a given treatment. In clinical trials, predictive biomarkers are used to stratify the study population into biomarker positive (likely responders) and negative (non‐responders) patients, with the hope of meeting the clinical primary endpoint in the biomarker positive group <xref ref-type="ref" rid="apm12934-bib-0040">40</xref>.<xref ref-type="fn" rid="apm12934-note-1005">5</xref> Examples of predictive biomarkers include polymorphisms in the cytochrome P450 superfamily [responsible for the hepatic – as well as extrahepatic – metabolism of most drugs, and thus, of immense importance for their pharmacokinetics <xref ref-type="ref" rid="apm12934-bib-0042">42</xref>] and variants of the human leukocyte antigen B (HLA‐B, associated with several hypersensitivity reactions, including toxic epidermal necrolysis); many more such gene variant–drug relationships can be found in <italic>PharmGKB</italic> (The Pharmacogenomics Knowledge Base, <ext-link ext-link-type="uri" xlink:href="http://www.pharmgkb.org">http://www.pharmgkb.org</ext-link>), a public, knowledge‐sharing resource that captures, curates, and integrates pharmacogenomics data, and which currently contains around 21 000 variant annotations and 132 PK/PD focused drug‐pathway diagrams <xref ref-type="ref" rid="apm12934-bib-0043">43</xref>. As targeted therapies, e.g. those based on monoclonal antibodies, are expensive and display variable response rates both in AD and PSO, it is important to identify and validate biomarkers for prediction of treatment outcome, as recently reviewed by Ovejero‐Benito et al. <xref ref-type="ref" rid="apm12934-bib-0044">44</xref>.</p>
</sec>
<sec id="apm12934-sec-0008">
<title>Biomarker combinations</title>
<p>Because heterogeneous treatment responses can be due to a combination of factors, including disease complexity (multiple endotypes), genetic, epigenetic, and environmental effects, a <italic>single</italic> biomarker has only limited ability to capture all these aspects into a prediction of a patient's response to a given drug. Therefore, patient stratification may rely on the identification of <italic>multiple</italic> biomarkers, entailing multivariate statistical analysis and machine learning for finding the optimal linear and non‐linear biomarker <italic>combinations</italic>
<xref ref-type="ref" rid="apm12934-bib-0045">45</xref>, i.e. those with highest sensitivity and specificity (maximizing the AUC of the ROC analysis) for a given classification. For example, we recently identified and validated a diagnostic miRNA classifier based on a linear combination of three miRNAs (miR‐155, miR‐203, and miR‐205) that could discriminate cutaneous T‐cell lymphoma (CTCL) from benign inflammatory skin diseases with 95% classification accuracy <xref ref-type="ref" rid="apm12934-bib-0046">46</xref>, <xref ref-type="ref" rid="apm12934-bib-0047">47</xref>. One advantage of using a biomarker panel as opposed to a single biomarker is that individual differences in the baseline levels of the biomarkers can be accounted for, in particular if the biomarkers of interest are normalized to a set of reference biomarkers. Other recent examples include a plasma protein (MMP‐2, sTNF‐R2, TSLP) panel for identification of ischemic stroke <xref ref-type="ref" rid="apm12934-bib-0048">48</xref>, a cell surface protein (CD25, CD64, CD69) panel for flow cytometric detection of sepsis <xref ref-type="ref" rid="apm12934-bib-0049">49</xref>, and a serum nuclear magnetic resonance (NMR) metabolomics‐derived biomarker (alanine, pyruvate, glycine, sarcosine) panel for early detection and grading of prostate cancer <xref ref-type="ref" rid="apm12934-bib-0050">50</xref>. For atopic dermatitis, Thijs et al. applied a panel of 147 serum biomarkers to stratify 193 AD patients into four main clusters, which may represent endotypes <xref ref-type="ref" rid="apm12934-bib-0051">51</xref>, although their analysis suggests that AD is very heterogeneous and may even reflect a disease spectrum rather than distinct endotypes.</p>
<p>Note, however, that the above examples only consider combinations of biomarkers of the <italic>same</italic> biological type or layer, such as genomic (DNA), transcriptomic (RNA), proteomic (proteins), or metabolomic (amino acids) markers. With the explosive development, both in omics technologies (summarized in Box <xref ref-type="boxed-text" rid="apm12934-fea-0003">3</xref>) and in bioinformatics and computational tools, the natural next step is to move <italic>out</italic> of and <italic>across (between)</italic> the individual layers, <italic>integrating</italic> the various orthogonal (independent) biologic approaches in an integrative ‘multi‐omics’, systems biology strategy, also referred to as <italic>integromics</italic>
<xref ref-type="ref" rid="apm12934-bib-0052">52</xref>, <xref ref-type="ref" rid="apm12934-bib-0053">53</xref>, <xref ref-type="ref" rid="apm12934-bib-0054">54</xref>. Conceptually, the layers in such an integrative approach can be compared to Google Maps (maps.google.com), which render a multilayered visualization of both <italic>spatial</italic> (locations, streets, landmarks) and real‐time <italic>temporal</italic> (traffic) data <xref ref-type="ref" rid="apm12934-bib-0022">22</xref>. And this is exactly the ambition of integromics<xref ref-type="fn" rid="apm12934-note-1006">6</xref> on a human scale; to be able to visualize the various layers (mapping the genomic, epigenomic, transcriptomic, proteomic, metabolomic, etc. landscapes) of biologic pathways, as well as to be able to predict the dynamic effects of perturbations, such as targeting central molecules in the pathways, creating ‘roadblocks’ that will stop or diverge the traffic (information, signaling) flow in the system, to remain in the Google Maps analogy.</p>
<boxed-text content-type="Box" id="apm12934-fea-0003" orientation="portrait" position="float">
<label>Box 3</label>
<caption>
<title>Omics technologies for integrative, personalized medicine</title>
</caption>
<sec id="apm12934-sec-0035">
<title>Genomics</title>
<p>Next‐generation sequencing (NGS) is key to generating the vast amounts of DNA data for whole‐genome sequencing (WGS) and whole‐exome sequencing (WES) projects <xref ref-type="ref" rid="apm12934-bib-0055">55</xref>. Because the exome only comprises 1.5% (40 Mb) of our genome, it can be sequenced at a deeper coverage (&gt;100× compared to 30×), faster (hours compared to days), and at lower price compared to WGS. However, it appears that most (80%) of the loci involved in complex diseases are located in the 98.5% noncoding – but important regulatory – regions of the genome <xref ref-type="ref" rid="apm12934-bib-0022">22</xref>. Therefore, and because the price of WGS continues to drop, it is today cost‐efficient to perform WGS for single‐nucleotide polymorphism (SNP) analysis, genotyping, pharmacogenomics and genome‐wide association studies (GWAS). If cost is a concern, then microarray‐ or bead‐based SNP analysis can be considered, albeit with considerably lower coverage than WGS.</p>
<p>A powerful tool to reveal the cellular complexity of in particular tumors <xref ref-type="ref" rid="apm12934-bib-0056">56</xref>, but also of individual genomic variation (mosaicism), is single‐cell sequencing, which is gaining momentum as the methodologies for whole‐genome amplification (WGA) and sequencing mature <xref ref-type="ref" rid="apm12934-bib-0057">57</xref>. This technique (as well as scRNA‐seq, see below) can also be used to profile T‐ and B‐cell receptor repertoires at the single‐cell level, thus enabling a full picture of the immune landscape and its dynamics <xref ref-type="ref" rid="apm12934-bib-0058">58</xref>.</p>
</sec>
<sec id="apm12934-sec-0036">
<title>Transcriptomics</title>
<p>Since the late 1990s, global gene expression analysis has been performed by use of microarrays <xref ref-type="ref" rid="apm12934-bib-0059">59</xref>. Today, due to improvements in next‐generation sequencing (NGS) technology (longer and more reads) and a concomitant drop in price,<xref ref-type="fn" rid="apm12934-note-1007">7</xref> RNA sequencing (RNA‐seq) is the preferred method for transcriptomic profiling <xref ref-type="ref" rid="apm12934-bib-0060">60</xref>. A major advantage of quantifying gene expression is that it reflects the <italic>dynamics</italic> of the cellular system under investigation. This is also a major caveat, because what is measured is a <italic>snapshot</italic> of the transcriptome, which tends to vary extensively with time and space. Thus, when comparing transcriptomic profiles of biologic samples it is of utmost importance that the experimental conditions are as standardized as possible (a notion that also applies to proteomics, and, in particular, metabolomics); i.e. the specimens should be comparable, both with respect to <italic>location</italic> (more on this later, with special reference to skin biopsies), and timing, including sampling time and time from sampling to freezing and RNA extraction. Optimally, a <italic>time course</italic> experiment (multiple samples taken at different time points) should be performed to investigate the expression profiles’ temporal dependence <xref ref-type="ref" rid="apm12934-bib-0060">60</xref>, <xref ref-type="ref" rid="apm12934-bib-0061">61</xref>, which is also of importance for the selection of biomarkers, as some may display transient expression, while others are more stable, and therefore more robust in a clinical setting. Just as for DNA sequencing, single‐cell RNA‐sequencing (scRNA‐seq) is now opening a window to the cellular phenotype, as it allows for unprecedented detail analysis of cellular heterogeneity and development <xref ref-type="ref" rid="apm12934-bib-0062">62</xref>, <xref ref-type="ref" rid="apm12934-bib-0063">63</xref>. Finally, novel <italic>in situ</italic> sequencing techniques such as fluorescent <italic>in situ</italic> sequencing of RNA (FISSEQ) <xref ref-type="ref" rid="apm12934-bib-0064">64</xref> and STARmap <xref ref-type="ref" rid="apm12934-bib-0065">65</xref> allow for determination of the actual, 3‐dimensional location of gene expression in cells and tissues <xref ref-type="ref" rid="apm12934-bib-0066">66</xref>.</p>
</sec>
<sec id="apm12934-sec-0037">
<title>Epigenomics</title>
<p>At least three types of epigenetic systems co‐exist: DNA methylation, histone modification, and noncoding RNA (ncRNA, including miRNA, lncRNA, snoRNA, and many more).</p>
<p>DNA methylation is typically assessed by bisulfite treatment of the DNA – converting non‐methylated C's to U's, while methylated C's are protected from this conversion – followed by either microarray analysis or WGS (which captures all 29 million CpGs in the human genome, albeit at 10 times the cost of methylation arrays) enabling epigenome‐wide association studies (EWAS; <xref ref-type="ref" rid="apm12934-bib-0067">67</xref>). The interpretation of such studies, however, can be difficult, in particular if the starting material contains a mixture of different cell types, each with their own, highly cell‐type specific epigenome. Thus, it is necessary to perform cell‐type specific deconvolution of the signal in order to identify relevant epigenetic changes rather than just a shift in proportion of cell types <xref ref-type="ref" rid="apm12934-bib-0066">66</xref>, <xref ref-type="ref" rid="apm12934-bib-0068">68</xref>.<xref ref-type="fn" rid="apm12934-note-1008">8</xref>
</p>
<p>For studying the ‘histone code’, genome‐wide histone modification assays apply chromatin immunoprecipitation (ChIP) and histone modification‐specific antibodies (to precipitate the DNA–histone complexes), followed by NGS (ChIP‐seq) to identify the bound DNA fragments. This has resulted in mapping of several human epigenomes <xref ref-type="ref" rid="apm12934-bib-0069">69</xref> with promise for identification of epigenetic biomarkers <xref ref-type="ref" rid="apm12934-bib-0070">70</xref> and with implications for epigenetic drugs, such as histone deacetylase (HDAC) inhibitors <xref ref-type="ref" rid="apm12934-bib-0070">70</xref>, <xref ref-type="ref" rid="apm12934-bib-0071">71</xref>.</p>
<p>Numerous microRNAs have already been identified – by microarrays, qRT‐PCR, and small RNA‐seq – as potential diagnostic, prognostic, and predictive biomarkers in cancer <xref ref-type="ref" rid="apm12934-bib-0072">72</xref>, <xref ref-type="ref" rid="apm12934-bib-0073">73</xref>, <xref ref-type="ref" rid="apm12934-bib-0074">74</xref>, <xref ref-type="ref" rid="apm12934-bib-0075">75</xref>, <xref ref-type="ref" rid="apm12934-bib-0076">76</xref>, <xref ref-type="ref" rid="apm12934-bib-0077">77</xref>, diabetes <xref ref-type="ref" rid="apm12934-bib-0078">78</xref>, and many other diseases, including inflammatory skin conditions like psoriasis <xref ref-type="ref" rid="apm12934-bib-0079">79</xref>, <xref ref-type="ref" rid="apm12934-bib-0080">80</xref> and atopic dermatitis <xref ref-type="ref" rid="apm12934-bib-0081">81</xref>, <xref ref-type="ref" rid="apm12934-bib-0082">82</xref>. What remains to be seen is the potential of an emerging class of ncRNA, namely the long ncRNA (lncRNA, of which around 16 000 human variants have been found so far), in precision medicine, cancer <xref ref-type="ref" rid="apm12934-bib-0083">83</xref> and inflammatory diseases <xref ref-type="ref" rid="apm12934-bib-0084">84</xref>.</p>
</sec>
<sec id="apm12934-sec-0038">
<title>Proteomics</title>
<p>Studying the proteome–by various mass spectroscopy methods – is important because gene expression levels are only approximations of the corresponding protein levels <xref ref-type="ref" rid="apm12934-bib-0085">85</xref>. Firstly, because not all mRNA is translated into protein – sometimes because miRNAs bind to the 3′UTR of their target genes, thus blocking translation <xref ref-type="ref" rid="apm12934-bib-0085">85</xref>, <xref ref-type="ref" rid="apm12934-bib-0086">86</xref>, and secondly, because post‐translational modifications, such as phosphorylation/dephosphorylation, are important determinants of protein function, which is why phospho‐proteomics is a relevant measure of protein function and dynamics of cellular signaling <xref ref-type="ref" rid="apm12934-bib-0087">87</xref>.</p>
</sec>
<sec id="apm12934-sec-0039">
<title>Metabolomics</title>
<p>The analysis – either by NMR or GC–MS – of the complete set of small‐molecule intermediates, including lipids (the lipidome, a subset of the metabolome) in a biological sample, provides a sensitive snapshot of its physiology, and can thus guide discovery of biomarkers <xref ref-type="ref" rid="apm12934-bib-0053">53</xref>, <xref ref-type="ref" rid="apm12934-bib-0087">87</xref>, <xref ref-type="ref" rid="apm12934-bib-0088">88</xref>. Application examples include ‘breathomics’, breath‐based metabolomics, where quantification of volatile organic compounds has diagnostic potential <xref ref-type="ref" rid="apm12934-bib-0089">89</xref>, urine metabolite‐based diagnosis of urinary tract symptoms <xref ref-type="ref" rid="apm12934-bib-0090">90</xref>, as well as assessment of glucocorticoid‐induced changes of the lipid profile of human skin <xref ref-type="ref" rid="apm12934-bib-0091">91</xref>. In particular, when combined with other – orthogonal – omics technologies, one can obtain mechanistic insight, e.g. on metabolic and inflammatory pathways <xref ref-type="ref" rid="apm12934-bib-0053">53</xref>.</p>
</sec>
<sec id="apm12934-sec-0040">
<title>Glycomics</title>
<p>The study of glycans (polysaccharides) includes analysis of glycosylated proteins (glycoproteins) and lipids (glycolipids), mainly by MS or HPLC. Since most human proteins are glycosylated, and glycans play important roles in many cellular processes, including cell adhesion, trafficking, and inflammation, individual variations in glycosylation patterns may serve as biomarkers for disease risk and response to therapy <xref ref-type="ref" rid="apm12934-bib-0092">92</xref>, <xref ref-type="ref" rid="apm12934-bib-0093">93</xref>. For example, heterogeneity in N‐glycosylation of immunoglobulin G (IgG) can modulate its inflammatory effect, with implications for regulation of the immune system <xref ref-type="ref" rid="apm12934-bib-0094">94</xref>.</p>
</sec>
<sec id="apm12934-sec-0041">
<title>Phenomics</title>
<p>A detailed description of the <italic>phenome</italic>, i.e. an account of the phenotypic traits of an organism, is crucial for building the translational bridge from genome‐scale biology to disease understanding, i.e. for establishing the genotype–phenotype relationship <xref ref-type="ref" rid="apm12934-bib-0095">95</xref>. In practice, it entails <italic>deep phenotyping</italic> of individuals, including collection of multidimensional clinical data (e.g. biochemical tests, pathology reports, physical examination, family history, demographics, and imaging), and importantly, a precise, comprehensive, and standardized description (metadata) of such data. This makes the data accessible and searchable and facilitates its integration with omics data for translation into disease endotypes and eventually, personalized medicine <xref ref-type="ref" rid="apm12934-bib-0096">96</xref>. To aid in connecting genomics and phenomics, a formal ontology (standardized vocabulary and annotation of phenotypes and relations to diseases) has been proposed by The Human Phenotype Ontology (HPO) project <xref ref-type="ref" rid="apm12934-bib-0097">97</xref>, which today links more than 13 000 phenotypic terms and over 156 000 disease annotations. Additionally, phenomics can be applied for construction of large‐scale <italic>disease trajectories</italic> based on information on <italic>comorbidities</italic> pulled from real‐world data (RWD) <xref ref-type="ref" rid="apm12934-bib-0098">98</xref>, such as observational data from disease registries and electronic health records (EHR). One such study used the Danish National Patient Registry (covering the whole population of Denmark, 6.2 million patients followed over 15 years) for generation of disease trajectories that can prove useful for predicting (and ultimately, preventing) disease progression of individual patients <xref ref-type="ref" rid="apm12934-bib-0099">99</xref>.</p>
</sec>
<sec id="apm12934-sec-0042">
<title>Microbiomics</title>
<p>A growing research field, initiated by the human microbiome project <xref ref-type="ref" rid="apm12934-bib-0100">100</xref>, and with potential for personalized medicine is the study (by NGS) of our <italic>microbiome</italic>, which is the sum of microorganisms (bacteria, archaea, fungi, and viruses) in and on our body (skin, mouth, nose, lung, gut, and vagina). In particular, the gut microbiome has been extensively researched and shown to play an important role in nutrition, metabolism, immune function, and numerous diseases, including inflammatory bowel disease (IBD), type II diabetes, cardiovascular disease, asthma, atopy <xref ref-type="ref" rid="apm12934-bib-0101">101</xref>, <xref ref-type="ref" rid="apm12934-bib-0102">102</xref>, and autism <xref ref-type="ref" rid="apm12934-bib-0103">103</xref>. The microbiome is also implied in drug interactions – studied by pharmacomicrobiomics <xref ref-type="ref" rid="apm12934-bib-0104">104</xref>, <xref ref-type="ref" rid="apm12934-bib-0105">105</xref> – and e.g. digoxin has been shown to be metabolized and inactivated by specific gut bacteria <xref ref-type="ref" rid="apm12934-bib-0106">106</xref>. In the context of chronic, inflammatory skin diseases, dysbiosis of the skin microbiome has been associated with both PSO <xref ref-type="ref" rid="apm12934-bib-0107">107</xref> and AD <xref ref-type="ref" rid="apm12934-bib-0108">108</xref>, <xref ref-type="ref" rid="apm12934-bib-0109">109</xref>. This opens possibilities for targeted, preventive intervention, such as administration of prebiotics (non‐digestible food components, like fibers) and probiotics (live microorganisms, such as Lactobacillus strains). Notably, the microbiome is <italic>dynamic</italic>; it undergoes temporal (e.g. circadian) and spatial fluctuations, both in composition and metabolic activity <xref ref-type="ref" rid="apm12934-bib-0110">110</xref>. The question of composition is addressed by targeted 16S rDNA taxonomic profiling and by – more comprehensive – <italic>metagenomics</italic> shotgun strategies (whole‐metagenome sequencing). But to capture the true dynamics of the microbiome, a full functional analysis must include both <italic>metatranscriptomics</italic> and <italic>metabolomics</italic>. The former addresses the question of which genes are expressed (collectively by the microbiome at a given time and condition), while the latter provides important information on which metabolites (both microbiota‐ and host‐derived) are present and interplay at the host–microbiome interface <xref ref-type="ref" rid="apm12934-bib-0111">111</xref>.</p>
</sec>
<sec id="apm12934-sec-0043">
<title>Exposomics</title>
<p>Genetic factors alone explain only a fraction of what we consider genetic diseases, including cancer <xref ref-type="ref" rid="apm12934-bib-0112">112</xref>. The remainder, perhaps more than 90%, can be attributed to environmental factors, also known as the exposome. The term <italic>exposome</italic> was coined by CP Wild in 2005, who broadly defines it as ‘every exposure to which an individual is subjected from conception to death’ <xref ref-type="ref" rid="apm12934-bib-0113">113</xref>. It encompasses three domains: internal, specific external, and general external. The internal exposome consists of endogenous factors, including circulating metabolites, hormones, lipids, oxidative stress, and our microbiome <xref ref-type="ref" rid="apm12934-bib-0114">114</xref>. The specific external factors include radiation, infections, contaminants, pollutants, diet, medicine, tobacco, and alcohol, while the general external factors encompass socioeconomic status, education, stress, environment (urban/rural), and climate, among others. Thus, due to the diversity of the exposome, and because it is in constant flux, the challenge is to decide what (which biomarkers of exposure are available, if any) and when to measure <xref ref-type="ref" rid="apm12934-bib-0113">113</xref>. One approach has been to apply metabolomics on consecutive saliva samples, assessing the ‘saliva exposome’, as it is easy to collect and measure, and can be used to monitor individual health trajectories <xref ref-type="ref" rid="apm12934-bib-0115">115</xref>. Biomarkers of exposure also enable <italic>exposome‐wide association studies</italic> (EWAS)<xref ref-type="fn" rid="apm12934-note-1009">9</xref>
<xref ref-type="ref" rid="apm12934-bib-0116">116</xref>, <xref ref-type="ref" rid="apm12934-bib-0117">117</xref>, which have promise in the near future. Why? Because the digital revolution has opened for disruptive technologies, such as continuous, cloud‐based tracking of big data [such as the Internet of Things, IoT, with a plethora of physical devices that connect, collect, and exchange data for IoT‐enabled health care <xref ref-type="ref" rid="apm12934-bib-0118">118</xref>], generated by wearable, environmental monitors and biosensors coupled to our smartphones – a realization of the ‘quantified self’ <xref ref-type="ref" rid="apm12934-bib-0119">119</xref>.</p>
</sec>
<sec id="apm12934-sec-0044">
<title>Integromics</title>
<p>Also known as integrated/integrative omics, combine two or more omics layers in order to identify relevant overlaps between these. For example, a five‐layer approach may include genomics, epigenomics (three sublayers: DNA methylation, histone code, miRNA), transcriptomics, proteomics, and metabolomics, which coupled to phenotype (phenomics) data appears as an ‘obvious’ integrative omics approach, and one that we are currently exploring. However, so far, most published studies are limited to three layers, namely genomics–transcriptomics–proteomics, which will capture post‐transcriptional regulatory mechanisms, whenever there is discrepancy between gene and protein expression <xref ref-type="ref" rid="apm12934-bib-0052">52</xref>, but which do not take advantage of the orthogonal information that e.g. metabolomics adds to the (almost) full picture <xref ref-type="ref" rid="apm12934-bib-0052">52</xref>, <xref ref-type="ref" rid="apm12934-bib-0053">53</xref>. A major concern about integromics analysis and sharing of such big medical data is the difficult question regarding privacy and security <xref ref-type="ref" rid="apm12934-bib-0120">120</xref>, which needs to be solved before a massive open online medical (MOOM) repository can become a reality <xref ref-type="ref" rid="apm12934-bib-0022">22</xref>.</p>
</sec>
</boxed-text>
<p>Next, let us see how the above considerations apply to personalized medicine in inflammatory skin diseases, with special emphasis on atopic dermatitis and psoriasis.<xref ref-type="fn" rid="apm12934-note-1010">10</xref>
</p>
</sec>
<sec id="apm12934-sec-0009">
<title>Personalized medicine in inflammatory skin diseases</title>
<p>See Box <xref ref-type="boxed-text" rid="apm12934-fea-0004">4</xref>.</p>
<boxed-text content-type="Box" id="apm12934-fea-0004" orientation="portrait" position="float">
<label>Box 4</label>
<caption>
<title>Basic characteristics of PSO and AD</title>
</caption>
<sec id="apm12934-sec-0045">
<p>
<table-wrap id="nlm-table-wrap-1" orientation="portrait" position="anchor" xml:lang="en"><table frame="above" rules="groups"><col span="1" style="border-right:solid 1px #000000"/><col span="1" style="border-right:solid 1px #000000"/><col span="1" style="border-right:solid 1px #000000"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="1" rowspan="1" valign="top"></th><th align="left" colspan="1" rowspan="1" valign="top">PSO</th><th align="left" colspan="1" rowspan="1" valign="top">AD</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">
<p>ICD‐10</p>
<p>CM codes</p>
</td><td align="left" colspan="1" rowspan="1">
<p>L40 Psoriasis; L40.0 Psoriasis vulgaris, plaque PSO (90%)</p>
<p>L40.1 Generalized pustular PSO (GPP, rare)</p>
<p>L40.4 Guttate PSO (2%); L40.8 Other</p>
</td><td align="left" colspan="1" rowspan="1">
<p>L20.9 Atopic dermatitis, unspecified</p>
<p>L20.8 Other atopic dermatitis</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Epidemiology &amp; Comorbidity</td><td align="left" colspan="1" rowspan="1">
<p>Affects 1–8% of the adult population <xref ref-type="ref" rid="apm12934-bib-0121">121</xref>,</p>
<p>amounting to at least 130 million people worldwide.</p>
<p>Two peaks in age of onset: 20–30 years and 50–60 years.</p>
<p>PSO is a systemic condition with several serious comorbidities, including psoriatic arthritis (20–30%), inflammatory bowel disease, metabolic syndrome, and cardiovascular diseases <xref ref-type="ref" rid="apm12934-bib-0122">122</xref>.</p>
</td><td align="left" colspan="1" rowspan="1">
<p>Affects 10–25% of all children and 2–10% of the adult population <xref ref-type="ref" rid="apm12934-bib-0123">123</xref>, corresponding to at least 320 million people worldwide,<xref ref-type="fn" rid="apm12934-note-1011">11</xref> and with wide regional variation <xref ref-type="ref" rid="apm12934-bib-0125">125</xref>.</p>
<p>85–95% of all cases begin before the age of 5 years <xref ref-type="ref" rid="apm12934-bib-0126">126</xref>
</p>
<p>Prevalence has more than doubled within the last 50 years <xref ref-type="ref" rid="apm12934-bib-0127">127</xref>, which suggests environmental effects,<xref ref-type="fn" rid="apm12934-note-1012">12</xref> including lifestyle changes – such as ‘Westernization’ and the hygiene hypothesis <xref ref-type="ref" rid="apm12934-bib-0128">128</xref>.</p>
<p>AD is associated with other atopic diseases, including asthma (50% risk), food allergy (30% risk), and allergic rhinitis/hay fever (up to 75% risk), which underlines its systemic nature <xref ref-type="ref" rid="apm12934-bib-0127">127</xref>.</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Disease burden</td><td align="left" colspan="2" rowspan="1">Overall, measured by disability‐adjusted life years (DALYs, excluding mortality; i.e. years of healthy life lost due to disease/disability), skin diseases are the fourth leading cause of disability worldwide <xref ref-type="ref" rid="apm12934-bib-0129">129</xref>. Due to the chronic and pruritic nature of both PSO and AD, they negatively impact quality of life (QoL) of most patients (and their families) and impose a major socioeconomic burden <xref ref-type="ref" rid="apm12934-bib-0130">130</xref>.</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Etiology</td><td align="left" colspan="1" rowspan="1">Unknown, but high heritability and numerous susceptibility loci suggest complex, polygenic predisposition combined with environmental triggering factors, autoantigens, and systemic inflammation <xref ref-type="ref" rid="apm12934-bib-0131">131</xref>.</td><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Unknown, but high heritability and several susceptibility loci suggest a complex genetic disease including epidermal barrier dysfunction, immune dysregulation, and environmental triggers <xref ref-type="ref" rid="apm12934-bib-0132">132</xref>.</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Risk factors and triggers</td><td align="left" colspan="1" rowspan="1">Family history (genetics, HLA‐Cw6), psychogenic stress, skin injury (Koebner phenomenon), streptococcal infections, medications, smoking, obesity <xref ref-type="ref" rid="apm12934-bib-0131">131</xref>.</td><td align="left" colspan="1" rowspan="1">Family history, FLG mutations, cold dry climate, irritants (detergents, wool), infections (S. aureus), allergens (house dust mites, pollen), cats <xref ref-type="ref" rid="apm12934-bib-0133">133</xref>, food allergens <xref ref-type="ref" rid="apm12934-bib-0132">132</xref>.</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Pathogenesis</td><td align="left" colspan="1" rowspan="1">
<p>IL‐23/Th17 axis key driver <xref ref-type="ref" rid="apm12934-bib-0134">134</xref>
</p>
<p>For details, see Fig. <xref ref-type="fig" rid="apm12934-fig-0001">1</xref>.</p>
</td><td align="left" colspan="1" rowspan="1">
<p>Th2 axis (IL‐4/IL‐13/IL‐5/IL‐31) dominating <xref ref-type="ref" rid="apm12934-bib-0134">134</xref>
</p>
<p>For details, see Fig. <xref ref-type="fig" rid="apm12934-fig-0002">2</xref>.</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Genetics</td><td align="left" colspan="1" rowspan="1">
<p>Concordance rate, monozygotic twins: 33%</p>
<p>Concordance rate, dizygotic twins: 17%</p>
<p>Heritability: 60–75% <xref ref-type="ref" rid="apm12934-bib-0135">135</xref>
</p>
</td><td align="left" colspan="1" rowspan="1">
<p>Concordance rate, monozygotic twins: 44–86%</p>
<p>Concordance rate among dizygotic twins: 10–23%</p>
<p>Heritability: 69–86% <xref ref-type="ref" rid="apm12934-bib-0136">136</xref>
</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">GWAS</td><td align="left" colspan="1" rowspan="1">
<p>HLA‐Cw6: strongest known risk allele, OR 4.32 <xref ref-type="ref" rid="apm12934-bib-0126">126</xref>
</p>
<p>Nine PSO susceptibility regions, PSORS1‐9, containing mostly immune‐related genes</p>
<p>+60 PSO susceptibility regions <xref ref-type="ref" rid="apm12934-bib-0137">137</xref>
</p>
</td><td align="left" colspan="1" rowspan="1">
<p>FLG: strongest known risk factor <xref ref-type="ref" rid="apm12934-bib-0138">138</xref>, more than 40 LOF mutations described <xref ref-type="ref" rid="apm12934-bib-0139">139</xref> OR 1.61–1.92 <xref ref-type="ref" rid="apm12934-bib-0140">140</xref>
</p>
<p>31 susceptibility loci, most related to innate immune system <xref ref-type="ref" rid="apm12934-bib-0141">141</xref> OR 0.90–1.14 (except for FLG)</p>
<p>+70 gene variants (population‐specific) described <xref ref-type="ref" rid="apm12934-bib-0139">139</xref>, <xref ref-type="ref" rid="apm12934-bib-0142">142</xref>
</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Transcriptomics</td><td align="left" colspan="1" rowspan="1">
<p>+2600 DEG between lesional PSO and healthy skin <xref ref-type="ref" rid="apm12934-bib-0143">143</xref>
</p>
<p>~1800 DEG between lesional and non‐lesional skin <xref ref-type="ref" rid="apm12934-bib-0144">144</xref>
</p>
</td><td align="left" colspan="1" rowspan="1">
<p>+1300 DEG between lesional AD and healthy skin <xref ref-type="ref" rid="apm12934-bib-0145">145</xref>
</p>
<p>~ 600 DEG between lesional and non‐lesional skin <xref ref-type="ref" rid="apm12934-bib-0146">146</xref>
</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Potential biomarkers</td><td align="left" colspan="1" rowspan="1">
<p>IL‐19 blood levels correlate with disease activity <xref ref-type="ref" rid="apm12934-bib-0147">147</xref>
</p>
<p>IL‐2, IL‐5, IL‐10, IL‐12, IL‐22, GM‐CSF serum levels correlate with treatment effect <xref ref-type="ref" rid="apm12934-bib-0148">148</xref>
</p>
<p>Skin transcriptome response to etanercept <xref ref-type="ref" rid="apm12934-bib-0149">149</xref>, ixekizumab <xref ref-type="ref" rid="apm12934-bib-0150">150</xref>, brodalumab <xref ref-type="ref" rid="apm12934-bib-0151">151</xref>, guselkumab <xref ref-type="ref" rid="apm12934-bib-0152">152</xref>, risankizumab vs ustekinumab <xref ref-type="ref" rid="apm12934-bib-0153">153</xref>
</p>
</td><td align="left" colspan="1" rowspan="1">
<p>FLG stratifies for early‐onset persistent AD <xref ref-type="ref" rid="apm12934-bib-0154">154</xref>
</p>
<p>IgE blood levels stratify for intrinsic/extrinsic AD <xref ref-type="ref" rid="apm12934-bib-0155">155</xref>
</p>
<p>TARC (CCL17) in serum correlates with disease activity <xref ref-type="ref" rid="apm12934-bib-0155">155</xref>
</p>
<p>IL‐31 levels associated with itch <xref ref-type="ref" rid="apm12934-bib-0155">155</xref>
</p>
<p>IL‐33 serum levels correlate with disease severity <xref ref-type="ref" rid="apm12934-bib-0156">156</xref>
</p>
<p>Skin transcriptome response to UVB <xref ref-type="ref" rid="apm12934-bib-0157">157</xref>, cyclosporin A <xref ref-type="ref" rid="apm12934-bib-0158">158</xref>, dupilumab <xref ref-type="ref" rid="apm12934-bib-0159">159</xref>, apremilast <xref ref-type="ref" rid="apm12934-bib-0160">160</xref>, fezakinumab (IL‐22) <xref ref-type="ref" rid="apm12934-bib-0161">161</xref>.</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Top‐20 targets<xref ref-type="fn" rid="apm12934-note-1013">13</xref>
</td><td align="left" colspan="1" rowspan="1">CARD14 TYK2 IL12B TRAF3IP2 JAK2 PDE4A ITGB2 TNF IL17RA IL17A VDR ERAP1 IL23R TNFAIP3 NOD2 JAK1 JAK3 IL23A CD2 NR3C1</td><td align="left" colspan="1" rowspan="1">
<p>IL13 FLG IL4R RXRA SPINK5 PPIA JAK2</p>
<p>FKBP1A CD2 NR3C1 VDR HRH1 CYSLTR1 JAK1 PLA2G7 IGHE RXRB PDE4B RARG RXRG</p>
</td></tr><tr><td align="left" colspan="1" rowspan="1" style="padding-left:10%">Current treatment guidelines</td><td align="left" colspan="1" rowspan="1">
<p>
<italic>Topical coal tar:</italic> antipruritic, combined with UVB <xref ref-type="ref" rid="apm12934-bib-0162">162</xref>
</p>
<p>
<italic>Topical corticosteroids</italic>: anti‐inflammatory</p>
<p>
<italic>Topical vitamin D analogues:</italic> calcipotriol (often in combination with betamethasone dipropionate) inhibits epidermal hyperproliferation, induces differentiation, anti‐inflammatory</p>
<p>
<italic>Topical salicylic acid:</italic> keratolytic effect</p>
<p>
<italic>Oral</italic>: methotrexate, cyclosporin A, acitretin (for severe PSO), apremilast (PDE4 inhibitor), fumaric acid esters</p>
<p>
<italic>Biologics:</italic> etanercept, infliximab, adalimumab (TNF‐α); ustekinumab (IL‐12/IL‐23); secukinumab, ixekizumab (IL‐17A); brodalumab (IL‐17RA); guselkumab, tildrakizumab (IL‐23)</p>
</td><td align="left" colspan="1" rowspan="1">
<p>
<italic>Emollients:</italic> for moisturizing the skin (lipid‐rich)</p>
<p>
<italic>Antiseptics</italic>: bleach (sodium hypochlorite 0.0005%) bath <xref ref-type="ref" rid="apm12934-bib-0163">163</xref>
</p>
<p>
<italic>Topical corticosteroids</italic>: anti‐inflammatory, relieve itch, e.g. hydrocortisone, betamethasone valerate, clobetasol</p>
<p>
<italic>Topical calcineurin inhibitors</italic>: tacrolimus (Protopic) or pimecrolimus (Elidel)</p>
<p>
<italic>Oral calcineurin inhibitor:</italic> cyclosporin A (severe AD)</p>
<p>
<italic>Antibiotic creams</italic>: to fight skin infections, e.g. fucidin/fucicort</p>
<p>
<italic>Biologics (monoclonal antibodies), injectable</italic>: targeted therapy, e.g. dupilumab (anti‐IL‐4R)</p>
</td></tr></tbody></table></table-wrap>
</p>
</sec>
</boxed-text>
</sec>
<sec id="apm12934-sec-0010">
<title>Psoriasis</title>
<p>Psoriasis typically presents as thick, erythematous, scaly plaques due to hyperproliferation of keratinocytes. Therefore, it was originally considered an epidermal, keratinocyte‐specific disorder, and it was not until the mid‐1980s, when first, immunosuppression by cyclosporine <xref ref-type="ref" rid="apm12934-bib-0164">164</xref> and later, bone marrow transplantation <xref ref-type="ref" rid="apm12934-bib-0165">165</xref> resulted in remarkable clearance of psoriatic plaques that a major paradigm shift occurred, and psoriasis appeared as a Th1 cell driven, systemic disease <xref ref-type="ref" rid="apm12934-bib-0131">131</xref>. Another paradigm shift was precipitated by the discovery of a new T‐cell subset of IL‐23‐regulated IL‐17‐producing Th17 cells in the experimental autoimmune encephalomyelitis (EAE) mouse model <xref ref-type="ref" rid="apm12934-bib-0166">166</xref>. This, together with the findings of increased levels of Th17 cells <xref ref-type="ref" rid="apm12934-bib-0167">167</xref> and of IL‐23, the ‘master’ regulator of Th17 development, in psoriatic lesions <xref ref-type="ref" rid="apm12934-bib-0168">168</xref>, identified psoriasis as a mixed Th1/Th17 disease.</p>
<p>Today, the central role of the IL‐23/Th17 inflammatory pathway in the immunopathogenesis of PSO (summarized in Fig. <xref ref-type="fig" rid="apm12934-fig-0001">1</xref>) is firmly established and has paved the way for development of novel targeted therapies that disrupt IL‐23/IL‐17 signaling (Fig. <xref ref-type="fig" rid="apm12934-fig-0001">1</xref>A) <xref ref-type="ref" rid="apm12934-bib-0012">12</xref>, <xref ref-type="ref" rid="apm12934-bib-0169">169</xref>. And the results are impressive: For moderate‐to‐severe plaque psoriasis, PASI 75<xref ref-type="fn" rid="apm12934-note-1014">14</xref> was obtained for 75–91% of patients treated for 12 weeks with the IL‐17A antagonists ixekizumab or secukinumab, PASI 90 was reached for 54–73% <xref ref-type="ref" rid="apm12934-bib-0172">172</xref>, <xref ref-type="ref" rid="apm12934-bib-0173">173</xref>, while 78% and 53% of patients treated with the IL‐17RA inhibitor brodalumab achieved PASI 90 and PASI 100 (complete clearance), respectively, after 52 weeks <xref ref-type="ref" rid="apm12934-bib-0174">174</xref>. Brodalumab blocks signaling by the five IL‐17 dimers (IL‐17A/F/C/E/AF) through the IL‐17RA subunit (Fig. <xref ref-type="fig" rid="apm12934-fig-0003">3</xref>A). This causes inhibition of the downstream pleiotropic effects of IL‐17RA and probably explains the potentially higher clinical efficacy obtainable by receptor blockade compared to neutralization of a single ligand <xref ref-type="ref" rid="apm12934-bib-0175">175</xref>, <xref ref-type="ref" rid="apm12934-bib-0176">176</xref>, <xref ref-type="ref" rid="apm12934-bib-0177">177</xref>. In line with the efficacy of blocking downstream cytokine signaling are the impressive Phase II data on the TYK2 inhibitor BMS‐986165, where PASI75 was obtained for 75% of patients at week 12 <xref ref-type="ref" rid="apm12934-bib-0178">178</xref>.</p>
<fig fig-type="Figure" id="apm12934-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Pathways in the pathogenesis of <styled-content style="fixed-case" toggle="no">PSO</styled-content>. Environmental triggers (e.g. drugs, infections, physical and psychological trauma) cause predisposed individuals to develop an autoimmune reaction, although the exact initiation mechanism is still poorly understood. One explanatory model <xref ref-type="ref" rid="apm12934-bib-0258">258</xref> suggests that the autoantigen is <styled-content style="fixed-case" toggle="no">LL</styled-content>37 (cathelicidin antimicrobial peptide, encoded by <styled-content style="fixed-case" toggle="no">CAMP</styled-content>), which complexes with <styled-content style="fixed-case" toggle="no">DNA</styled-content> and <styled-content style="fixed-case" toggle="no">RNA</styled-content> released from stressed keratinocytes. This induces plasmacytoid dendritic cells (<styled-content style="fixed-case" toggle="no">pDC</styled-content>s) to produce <styled-content style="fixed-case" toggle="no">IFN</styled-content>‐α, which activates dermal dendritic cells (<styled-content style="fixed-case" toggle="no">DC</styled-content>s). These cells migrate to skin‐draining lymph nodes, where they secrete <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐23, hereby stimulating naïve T‐cells to differentiate into T<sub>h</sub>1, T<sub>h</sub>17, and T<sub>h</sub>22 cells. The T<sub>h</sub> cells are attracted into the dermis by chemokines (<styled-content style="fixed-case" toggle="no">CCL</styled-content>20, <styled-content style="fixed-case" toggle="no">CCL</styled-content>17, <styled-content style="fixed-case" toggle="no">CCL</styled-content>27, <styled-content style="fixed-case" toggle="no">CXCL</styled-content>9/10/11) released by keratinocytes. T<sub>h</sub>1 cells produce <styled-content style="fixed-case" toggle="no">IFN</styled-content>‐γ and <styled-content style="fixed-case" toggle="no">TNF</styled-content>‐α, while T<sub>h</sub>17 cells release <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17 family cytokines. The latter (<styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A/F) trigger epidermal keratinocytes to a feed‐forward inflammatory response <xref ref-type="ref" rid="apm12934-bib-0169">169</xref>, inducing numerous psoriasis‐associated genes [defensins, S100 proteins, chemokines; keratinocytes also produce <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17 cytokines, shown is a putative, autocrine <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17C loop <xref ref-type="ref" rid="apm12934-bib-0175">175</xref>] and stimulating keratinocyte proliferation. The released chemokines <styled-content style="fixed-case" toggle="no">CXCL</styled-content>1/2/3/5/8 recruit neutrophils (N), which generate <styled-content style="fixed-case" toggle="no">ROS</styled-content> (reactive oxygen species), α‐defensin (<styled-content style="fixed-case" toggle="no">DEFA</styled-content>1), <styled-content style="fixed-case" toggle="no">CXCL</styled-content>8, <styled-content style="fixed-case" toggle="no">CCL</styled-content>20, and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐6. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐23 (released by activated <styled-content style="fixed-case" toggle="no">DC</styled-content>s) stimulates differentiation and expansion of T<sub>h</sub>22 cells, which secrete <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22 that induces <styled-content style="fixed-case" toggle="no">STAT</styled-content>3 and <styled-content style="fixed-case" toggle="no">KRT</styled-content>16 expression. This causes further epidermal hyperplasia and eventually formation of the psoriatic plaque. To the right (punctuated arrows) is shown the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐36/<styled-content style="fixed-case" toggle="no">IL</styled-content>‐1 pathway prevalent in <italic>pustular psoriasis</italic>, which is characterized by accumulation of neutrophils; here, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17 activated neutrophils trigger increased <styled-content style="fixed-case" toggle="no">IL</styled-content>‐36 activity, which stimulates <styled-content style="fixed-case" toggle="no">DC</styled-content>'s to produce <styled-content style="fixed-case" toggle="no">IL</styled-content>‐1β reinforcing the T<sub>h</sub>17 axis <xref ref-type="ref" rid="apm12934-bib-0179">179</xref>. Indicated with ⊣ are targets of approved and emerging drugs, most of which are monoclonal antibodies (see Table <xref ref-type="table" rid="apm12934-tbl-0002">2</xref>). Figure modified, mainly from van de Kerkhof &amp; Nestle in <xref ref-type="ref" rid="apm12934-bib-0131">131</xref>, but also from Noda et al. <xref ref-type="ref" rid="apm12934-bib-0134">134</xref>, and Conrad &amp; Gilliet <xref ref-type="ref" rid="apm12934-bib-0179">179</xref>.</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="APM-127-386-g001"></graphic>
</fig>
<p>Different forms of PSO are associated with different pathways; <italic>chronic plaque psoriasis</italic> (also known as psoriasis vulgaris, the most common form) is dominated by the above‐mentioned IL‐23/Th17 pathway, while <italic>acute, erythrodermic psoriasis</italic> is characterized by Type I interferon (IFN‐α) producing plasmacytoid dendritic cells, and <italic>pustular psoriasis</italic> is associated with the IL‐36/IL‐1 pathway and accumulation of neutrophils<xref ref-type="fn" rid="apm12934-note-1015">15</xref>
<xref ref-type="ref" rid="apm12934-bib-0179">179</xref>. This heterogeneity in immunopathogenesis highlights the complexity of psoriasis, as well as provides guidance – by identification of biomarkers reflecting the different endotypes – for novel and optimized targeted therapies. These therapies include promising new modalities, such as bispecific (e.g. blocking both TNF‐α and IL‐17<xref ref-type="fn" rid="apm12934-note-1016">16</xref>) <xref ref-type="ref" rid="apm12934-bib-0180">180</xref>, <xref ref-type="ref" rid="apm12934-bib-0181">181</xref>, and even <italic>trispecific</italic> antibodies <xref ref-type="ref" rid="apm12934-bib-0182">182</xref>, as well as vaccines <xref ref-type="ref" rid="apm12934-bib-0183">183</xref>. A compilation of these new and emerging treatment options for psoriasis can be found in Table 2.</p>
<p>The basic characteristics of psoriasis are summarized in Box <xref ref-type="boxed-text" rid="apm12934-fea-0004">4</xref>, of which the following are of particular relevance for personalized medicine:</p>
<sec id="apm12934-sec-0011">
<title>Comorbidities</title>
<p>Because PSO is a systemic disease associated with multiple severe comorbidities, including psoriatic arthritis (PsA) and cardiovascular disease (CVD) <xref ref-type="ref" rid="apm12934-bib-0122">122</xref>, targeted treatment of e.g. the IL‐23/Th17 pathway may not only reverse the cutaneous manifestations of the disease, but also the systemic, inflammatory comorbidities.</p>
</sec>
<sec id="apm12934-sec-0012">
<title>Genomics</title>
<p>GWAS (genome‐wide association studies) have already identified more than 60 risk loci, including several psoriasis susceptibility regions (PSORS), most of which contain immune system related genes <xref ref-type="ref" rid="apm12934-bib-0137">137</xref>. The increasing amount of genomic data may allow for identification of new variants (endotypes) of PSO, possibly predict who will develop the disease, identify responders to specific drugs, and guide further development of targeted therapies.</p>
</sec>
<sec id="apm12934-sec-0013">
<title>Epigenomics</title>
<p>EWAS (epigenome‐wide association studies) on PSO are emerging <xref ref-type="ref" rid="apm12934-bib-0184">184</xref> and a recent study on 39 Indian PSO patients suggested that differential DNA methylation (comparing lesional to non‐lesional skin) can regulate the expression of key genes involved in the pathogenesis of PSO <xref ref-type="ref" rid="apm12934-bib-0185">185</xref>. In addition to DNA methylation, <italic>histone modification</italic>, specifically methylation of H3K27 and H3K4, showed some promise as pharmacoepigenetic biomarkers in a study of psoriasis patients’ response to biologics <xref ref-type="ref" rid="apm12934-bib-0186">186</xref>. Common for both of the above cases is that larger independent validation cohorts are needed to confirm the initial findings. Finally, several inflammation‐associated miRNAs, such as miR‐146a, miR‐21, miR‐31, miR‐221, and miR‐222, are consistently found to be upregulated in PSO skin <xref ref-type="ref" rid="apm12934-bib-0187">187</xref>, <xref ref-type="ref" rid="apm12934-bib-0188">188</xref> and may be useful as disease activity biomarkers.</p>
</sec>
<sec id="apm12934-sec-0014">
<title>Transcriptomics</title>
<p>Analysis of the mRNA profiles of lesional, non‐lesional, and healthy skin has identified more than 2000 differentially expressed genes (DEGs), many of which may serve as potential biomarkers for disease progression and response to therapy <xref ref-type="ref" rid="apm12934-bib-0189">189</xref>. For a compilation of such studies with links to the actual data, please see Table <xref ref-type="table" rid="apm12934-tbl-0001">1</xref>.</p>
<table-wrap id="apm12934-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Selected omics studies on psoriasis (PSO) and atopic dermatitis (AD)</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">GEO ID</th>
<th align="left" colspan="1" rowspan="1" valign="top">Year</th>
<th align="left" colspan="1" rowspan="1" valign="top">Dx</th>
<th align="left" colspan="1" rowspan="1" valign="top">Focus (# samples)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Technology</th>
<th align="left" colspan="1" rowspan="1" valign="top">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">GSE16161</td>
<td align="left" colspan="1" rowspan="1">2009</td>
<td align="left" colspan="1" rowspan="1">AD, PSO, NN</td>
<td align="left" colspan="1" rowspan="1">AD‐LS (9), PSO‐LS (15), NN (9)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0277">277</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE32924</td>
<td align="left" colspan="1" rowspan="1">2011</td>
<td align="left" colspan="1" rowspan="1">AD, NN</td>
<td align="left" colspan="1" rowspan="1">LS (13), NL (12), NN (8)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0145">145</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE27887</td>
<td align="left" colspan="1" rowspan="1">2011</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">UVB, LS, NL, w0/w12, 10 pts. (35)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0157">157</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE36842</td>
<td align="left" colspan="1" rowspan="1">2012</td>
<td align="left" colspan="1" rowspan="1">AD, NN</td>
<td align="left" colspan="1" rowspan="1">Acute/chronic, LS, NL, NN, 10 pts (39)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0196">196</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE75890</td>
<td align="left" colspan="1" rowspan="1">2016</td>
<td align="left" colspan="1" rowspan="1">AD, PSO, NN</td>
<td align="left" colspan="1" rowspan="1">Mild ex‐/intrinsic, AD (14), PSO (9), NN (8)</td>
<td align="left" colspan="1" rowspan="1">HG 2.1 ST</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0278">278</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE60709</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">AD, NN</td>
<td align="left" colspan="1" rowspan="1">
<p>Epidermal shave, LS (12), NL (7), NN (14)</p>
<p>DNA methylation, skin and blood</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Illumina HT‐12V3.0</p>
<p>Infinium 27K</p>
</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0223">223</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE107361</td>
<td align="left" colspan="1" rowspan="1">2018</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Infants/adults, LS (39), NL (40), NN (29)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0212">212</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE58558</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Cyclosporin A, LS, NL, w0/w2/w12 (109)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0158">158</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE59294</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Dupilumab, LS, NL, w0/w4 (40)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0159">159</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE120721</td>
<td align="left" colspan="1" rowspan="1">2015</td>
<td align="left" colspan="1" rowspan="1">AD, NN</td>
<td align="left" colspan="1" rowspan="1">LCM, LS (15), NL (15), NN (22), epi/dermis</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0222">222</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE65832</td>
<td align="left" colspan="1" rowspan="1">2015</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">RNA‐seq, LS (20), NL (20)</td>
<td align="left" colspan="1" rowspan="1">Illumina GA IIx</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0279">279</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE81119</td>
<td align="left" colspan="1" rowspan="1">2017</td>
<td align="left" colspan="1" rowspan="1">‘AD’ mice</td>
<td align="left" colspan="1" rowspan="1">Mouse models of inflammation and ‘AD’ (37)</td>
<td align="left" colspan="1" rowspan="1">MG 1.0 ST</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0280">280</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">2018</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Tape strip RNA‐seq, LS (11), NL (18), NN (13)</td>
<td align="left" colspan="1" rowspan="1">Ion Torrent</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0213">213</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE120899</td>
<td align="left" colspan="1" rowspan="1">2018</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Apremilast, LS, NL, w0/w12 (59)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">Not published?</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE99802</td>
<td align="left" colspan="1" rowspan="1">2018</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Fezakinumab, LS, NL, w0/w4/w12 (302)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0161">161</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE121212</td>
<td align="left" colspan="1" rowspan="1">2019</td>
<td align="left" colspan="1" rowspan="1">AD, PSO, NN</td>
<td align="left" colspan="1" rowspan="1">RNA‐seq, AD (27LS, 27NL), PSO (28LS, 27NL), NN (38)</td>
<td align="left" colspan="1" rowspan="1">Illumina GA</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0334">334</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE14905</td>
<td align="left" colspan="1" rowspan="1">2008</td>
<td align="left" colspan="1" rowspan="1">PSO, NN</td>
<td align="left" colspan="1" rowspan="1">LS (33), NL (28), NN (21)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0143">143</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE13355</td>
<td align="left" colspan="1" rowspan="1">2009</td>
<td align="left" colspan="1" rowspan="1">PSO, NN</td>
<td align="left" colspan="1" rowspan="1">LS (58), NL (58), NN (64)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0281">281</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE31037</td>
<td align="left" colspan="1" rowspan="1">2011</td>
<td align="left" colspan="1" rowspan="1">PSO, NN</td>
<td align="left" colspan="1" rowspan="1">miRNA, LS (24), NL (23), NN (20)</td>
<td align="left" colspan="1" rowspan="1">Illumina GA IIx</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0282">282</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE30999</td>
<td align="left" colspan="1" rowspan="1">2012</td>
<td align="left" colspan="1" rowspan="1">PSO, NN</td>
<td align="left" colspan="1" rowspan="1">LS (85), NL (85)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0283">283</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE26866</td>
<td align="left" colspan="1" rowspan="1">2012</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">LCM, LS (20), NL (17), epi/dermis,</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_A 2.0</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0284">284</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE11903</td>
<td align="left" colspan="1" rowspan="1">2009</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Etanercept, LS, NL, w0/1/2/4/12 (89)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0149">149</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE31652</td>
<td align="left" colspan="1" rowspan="1">2012</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ixekizumab, LS, w0/w4 (30)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0150">150</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE55201</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">PSO, NN</td>
<td align="left" colspan="1" rowspan="1">Ixekizumab, blood, LS, NN, w0/w2 (81)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0285">285</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE51440</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Guselkumab, LS, NL, w0/w1/w12 (59)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_PM</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0152">152</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE53552</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Brodalumab, LS, w0/w1/w2/wq6 (99)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0151">151</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE69967</td>
<td align="left" colspan="1" rowspan="1">2016</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Tofacitinib, LS, NL, d0/1/3/w1/2/4/12 (95)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_2</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0286">286</xref>, <xref ref-type="ref" rid="apm12934-bib-0287">287</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE54456</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">PSO, NN</td>
<td align="left" colspan="1" rowspan="1">RNA‐seq, LS (92), NN (82)</td>
<td align="left" colspan="1" rowspan="1">Illumina GA</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0288">288</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE57225</td>
<td align="left" colspan="1" rowspan="1">2014</td>
<td align="left" colspan="1" rowspan="1">PSO‐AD/ACD</td>
<td align="left" colspan="1" rowspan="1">PSO (23), AD (10), ECZ (13), NL (16)</td>
<td align="left" colspan="1" rowspan="1">SurePrint G3 8x60K</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0289">289</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE63741</td>
<td align="left" colspan="1" rowspan="1">2016</td>
<td align="left" colspan="1" rowspan="1">PSO, AD, other</td>
<td align="left" colspan="1" rowspan="1">AD‐LS, PSO‐LS, ACD, LP, NN (30 each)</td>
<td align="left" colspan="1" rowspan="1">PIQOR 2.0</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0290">290</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE80047</td>
<td align="left" colspan="1" rowspan="1">2016</td>
<td align="left" colspan="1" rowspan="1">PSO, PPP(P)</td>
<td align="left" colspan="1" rowspan="1">PPP (3), PPPP (6), PSO (10), NN (31)</td>
<td align="left" colspan="1" rowspan="1">HG‐U133_Plus_PM</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0291">291</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE79704</td>
<td align="left" colspan="1" rowspan="1">2017</td>
<td align="left" colspan="1" rowspan="1">PSO, GPP, NN</td>
<td align="left" colspan="1" rowspan="1">GPP‐LS (32), PSO‐LS (12), NN (20)</td>
<td align="left" colspan="1" rowspan="1">HG 2.1 ST</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0292">292</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE73894</td>
<td align="left" colspan="1" rowspan="1">2017</td>
<td align="left" colspan="1" rowspan="1">PSO, NN</td>
<td align="left" colspan="1" rowspan="1">DNA methylation, LS (135), NL (41), NN (62)</td>
<td align="left" colspan="1" rowspan="1">Infinium 450k</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0293">293</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GSE115797</td>
<td align="left" colspan="1" rowspan="1">2018</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">DNA methylation, LS (24), NL (24)</td>
<td align="left" colspan="1" rowspan="1">Infinium 450k</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0185">185</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot id="apm12934-ntgp-0001">
<fn id="apm12934-note-0001">
<p>ACD, allergic contact eczema; Dx, diagnosis; d, day; epi, epidermis; ECZ, eczema (non‐atopic); GPP, generalized pustular psoriasis; LCM, laser‐capture microdissection; LP, lichen planus; PPP, palmoplantar pustulosis; PPPP (palmoplantar pustular psoriasis); PSO‐AD, patients co‐affected by both PSO and AD; w, week.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="apm12934-sec-0015">
<title>Microbiome</title>
<p>The cutaneous microbiome has been suggested as a factor that could trigger the immune system and initiate development of psoriasis <xref ref-type="ref" rid="apm12934-bib-0107">107</xref>, but as to date, the few and mainly descriptive data have been inconclusive. A recent analysis of the gut microbiome of 52 PSO patients suggested a specific ‘psoriatic core intestinal microbiome’ that differed from what is found in healthy subjects <xref ref-type="ref" rid="apm12934-bib-0190">190</xref>, but since the latter (healthy) data were pulled from the Human Microbiome Project, the analysis is confounded (with study), and calls for confirmation by a direct comparison of PSO patients with age and gender‐matched healthy controls. To establish – or rebut – a possible causative link between the microbiome (and its modulation by antibiotics, pre‐ or probiotics), psoriasis pathogenesis, and therapeutic effect, prospective, longitudinal intervention studies are needed. Also note that current microbiome analyses focus on taxonomic characterization (composition of the microbial community) rather than on functional, integrative studies involving <italic>metatranscriptomics</italic> and <italic>metabolomics</italic>, which eventually may enable in‐depth understanding of the dynamics of the microbiome <xref ref-type="ref" rid="apm12934-bib-0111">111</xref>.</p>
</sec>
</sec>
<sec id="apm12934-sec-0016">
<title>Atopic dermatitis</title>
<p>Atopic dermatitis is the most common chronic, relapsing inflammatory skin disorder, characterized by intense itch (pruritus), redness (erythema), and eventually, thickening (lichenification) of the skin due to chronic rubbing. It affects 10–25% of all children, most with onset before 2 years of age, and 2–10% of adults <xref ref-type="ref" rid="apm12934-bib-0123">123</xref>, with wide regional variation <xref ref-type="ref" rid="apm12934-bib-0125">125</xref>, and with a prevalence that has more than doubled over the last 50 years <xref ref-type="ref" rid="apm12934-bib-0127">127</xref>. Due to its chronic and pruritic nature, AD adversely affects the quality of life (QoL) of most patients, in particular due to sleep disturbance and skin infections, and is also often followed by other atopic diseases, such as food allergy, asthma and allergic rhinitis, known as the ‘atopic march’ <xref ref-type="ref" rid="apm12934-bib-0132">132</xref>. Note, however, that &lt;10% of AD patients travel the full atopic march (i.e. clinical manifestation of all four comorbidities) and that the risk is highest in the early‐onset persistent AD phenotype <xref ref-type="ref" rid="apm12934-bib-0191">191</xref>, <xref ref-type="ref" rid="apm12934-bib-0192">192</xref>.</p>
<p>The pathogenesis of AD is complex (illustrated in Fig. <xref ref-type="fig" rid="apm12934-fig-0002">2</xref>) and multifactorial as it involves genetic, immunologic, and environmental factors <xref ref-type="ref" rid="apm12934-bib-0193">193</xref>, including a defective skin barrier, permissive for entry of allergens that trigger inflammation, immune dysregulation with increased numbers of T‐cells and dendritic cells (DCs) and high levels of inflammatory molecules, and alterations in the cutaneous microbiome with overgrowth of Staphylococcus aureus. AD was first identified as a Th2 (IL‐4, IL‐13, IL‐31) driven disease <xref ref-type="ref" rid="apm12934-bib-0194">194</xref>, and later found to have also a Th22 (IL‐22) component <xref ref-type="ref" rid="apm12934-bib-0195">195</xref> as well as variable Th17 and Th1 immune activation, the latter more pronounced in chronic AD <xref ref-type="ref" rid="apm12934-bib-0196">196</xref>.</p>
<fig fig-type="Figure" id="apm12934-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>Pathways in the pathogenesis of <styled-content style="fixed-case" toggle="no">AD</styled-content>. Epidermal barrier defects, which are partly due to <styled-content style="fixed-case" toggle="no">FLG</styled-content> mutations, are associated with increased trans‐epidermal water loss [<styled-content style="fixed-case" toggle="no">TEWL</styled-content>), increased skin <styled-content style="fixed-case" toggle="no">pH</styled-content>, and penetration of epicutaneous allergens, such as dust mite debris. When the allergens encounter antigen‐presenting epidermal Langerhans cells (<styled-content style="fixed-case" toggle="no">LC</styled-content>s, for an excellent review of the interplay between <styled-content style="fixed-case" toggle="no">LC</styled-content>s and the epidermis, see Clayton et al. <xref ref-type="ref" rid="apm12934-bib-0259">259</xref>] and dermal dendritic cells (<styled-content style="fixed-case" toggle="no">DC</styled-content>s), this causes immune activation and recruitment of inflammatory cells, including <styled-content style="fixed-case" toggle="no">ILC</styled-content>2 [type 2 innate lymphoid cells <xref ref-type="ref" rid="apm12934-bib-0260">260</xref>] and type 2 helper T‐cells (T<sub>h</sub>2) that produce and release <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐5, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐13, and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐31. These cells are considered part of the skin‐associated lymphoid tissue (<styled-content style="fixed-case" toggle="no">SALT</styled-content>), the immunologically active cutaneous microenvironment, a concept which was proposed already in 1983 by Streilein <xref ref-type="ref" rid="apm12934-bib-0261">261</xref>. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐13 suppress expression of terminal differentiation genes (such as <styled-content style="fixed-case" toggle="no">FLG</styled-content>,<styled-content style="fixed-case" toggle="no"> LOR</styled-content>,<styled-content style="fixed-case" toggle="no"> INV</styled-content>), and also of tight junction (<styled-content style="fixed-case" toggle="no">TJ</styled-content>) genes <xref ref-type="ref" rid="apm12934-bib-0208">208</xref> leading to barrier disruption, while <styled-content style="fixed-case" toggle="no">IL</styled-content>‐31 also acts directly on sensory neurons, triggering the itch–scratch cycle. This further damages the epidermis, increasing the risk of penetration by pathogens like Staphylococcus aureus. The stressed keratinocytes release <styled-content style="fixed-case" toggle="no">TSLP</styled-content>,<styled-content style="fixed-case" toggle="no"> IL</styled-content>‐25, and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐33 that also drive T<sub>h</sub>2 differentiation. The T<sub>h</sub>2 cytokines induce IgE production in B cells and subsequently, release of inflammatory mediators (e.g. histamine) from activated (IgE bound) mast cells, basophils, and eosinophils. T<sub>h</sub>22 cells release <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22, which causes epidermal hyperplasia, and also, in synergy with <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17 – released from T<sub>h</sub>17 cells – induces expression of a subset of S100 family proteins. Acute <styled-content style="fixed-case" toggle="no">AD</styled-content> lesions are characterized by a T<sub>h</sub>2 skewed (T<sub>h</sub>2, T<sub>h</sub>17, T<sub>h</sub>22) response, while chronic <styled-content style="fixed-case" toggle="no">AD</styled-content>, which is often lichenified (thickened) by chronic scratching, progressively activates the T<sub>h</sub>1 axis with <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12 release, <styled-content style="fixed-case" toggle="no">IFN</styled-content>‐γ expression and induction of chemokines (like <styled-content style="fixed-case" toggle="no">CXCL</styled-content>9/<styled-content style="fixed-case" toggle="no">CXCL</styled-content>10/<styled-content style="fixed-case" toggle="no">CXCL</styled-content>11). Indicated with ⊣ are targets of approved and emerging drugs (see Table <xref ref-type="table" rid="apm12934-tbl-0002">2</xref> for a detailed list). Figure modified, mainly from Vakharia &amp; Silverberg <xref ref-type="ref" rid="apm12934-bib-0262">262</xref>, based on the original by Leung 2000 <xref ref-type="ref" rid="apm12934-bib-0263">263</xref> and 2004 <xref ref-type="ref" rid="apm12934-bib-0264">264</xref>. For other representations, see Noda et al. <xref ref-type="ref" rid="apm12934-bib-0134">134</xref>, Paller et al. <xref ref-type="ref" rid="apm12934-bib-0265">265</xref>, Weidinger et al. <xref ref-type="ref" rid="apm12934-bib-0009">9</xref>, Lee et al. <xref ref-type="ref" rid="apm12934-bib-0009">9</xref>, <xref ref-type="ref" rid="apm12934-bib-0266">266</xref>, and Brunner et al. <xref ref-type="ref" rid="apm12934-bib-0267">267</xref>, <xref ref-type="ref" rid="apm12934-bib-0268">268</xref>.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="APM-127-386-g002"></graphic>
</fig>
<fig fig-type="Figure" id="apm12934-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>(A) Targeting the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17 family of cytokines and their receptors. The six members of the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17 cytokine family (<styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A/B/C/D/E/F) are shown as functional, disulfide‐linked homodimers, as well as the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A/F heterodimer <xref ref-type="ref" rid="apm12934-bib-0175">175</xref>. Also shown are their respective, heterodimeric receptors, each consisting of different combinations of five homologous receptor subunits (<styled-content style="fixed-case" toggle="no">IL</styled-content>‐17<styled-content style="fixed-case" toggle="no">RA</styled-content>/<styled-content style="fixed-case" toggle="no">RB</styled-content>/<styled-content style="fixed-case" toggle="no">RC</styled-content>/<styled-content style="fixed-case" toggle="no">RD</styled-content>/<styled-content style="fixed-case" toggle="no">RE</styled-content>). <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17F (homodimers) and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A/F (heterodimer) signal through the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17<styled-content style="fixed-case" toggle="no">RA</styled-content>/<styled-content style="fixed-case" toggle="no">RC</styled-content> receptor complex, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17E (also known as <styled-content style="fixed-case" toggle="no">IL</styled-content>‐25) via <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17<styled-content style="fixed-case" toggle="no">RA</styled-content>/<styled-content style="fixed-case" toggle="no">RB</styled-content>,<styled-content style="fixed-case" toggle="no"> IL</styled-content>‐17C via <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17<styled-content style="fixed-case" toggle="no">RA</styled-content>/<styled-content style="fixed-case" toggle="no">RE</styled-content>, while <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17B and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17D signal via yet to be determined receptors. Indicated are also monoclonal antibodies that target either the cytokines or the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17<styled-content style="fixed-case" toggle="no">RA</styled-content> receptor subunit. Because <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17<styled-content style="fixed-case" toggle="no">RA</styled-content> is common to signaling via <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A/F/C/E/<styled-content style="fixed-case" toggle="no">AF</styled-content>, blocking it will inhibit the downstream activities of all five <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17 dimers. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A/F and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17<styled-content style="fixed-case" toggle="no">RA</styled-content> inhibitors have already shown substantial effect in <styled-content style="fixed-case" toggle="no">PSO</styled-content>, and currently, the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17C inhibitor <styled-content style="fixed-case" toggle="no">MOR</styled-content>106 is being tested in a Phase <styled-content style="fixed-case" toggle="no">II</styled-content> clinical trial in moderate to severe <styled-content style="fixed-case" toggle="no">AD</styled-content>
<xref ref-type="ref" rid="apm12934-bib-0269">269</xref>. (B) Targeting <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐23. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12 (p40/p35) and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐23 (p40/p19) are heterodimers that share the same p40 subunit. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12 binds to the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12Rβ1/β2 heterodimeric receptor and stimulates <styled-content style="fixed-case" toggle="no">JAK</styled-content>2‐<styled-content style="fixed-case" toggle="no">TYK</styled-content>2 to phosphorylate mainly <styled-content style="fixed-case" toggle="no">STAT</styled-content>4, inducing <styled-content style="fixed-case" toggle="no">IFN</styled-content>‐γ and a Th1 immune response. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐23 binds to the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12Rβ1/<styled-content style="fixed-case" toggle="no">IL</styled-content>‐23R heterodimeric receptor, and also induces <styled-content style="fixed-case" toggle="no">JAK</styled-content>2‐<styled-content style="fixed-case" toggle="no">TYK</styled-content>2 to phosphorylation, but primarily of <styled-content style="fixed-case" toggle="no">STAT</styled-content>3, leading to Th17 signaling and release of <styled-content style="fixed-case" toggle="no">IL</styled-content>‐17A/F and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22 <xref ref-type="ref" rid="apm12934-bib-0270">270</xref>. Because the p40 subunit is common to both <styled-content style="fixed-case" toggle="no">IL</styled-content>‐12 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐23, targeting it will inhibit the effects of both cytokines <xref ref-type="ref" rid="apm12934-bib-0271">271</xref>, while the p19‐specific antagonists target only the ‘master’ regulator of Th17 development, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐23 <xref ref-type="ref" rid="apm12934-bib-0012">12</xref>. (C) Targeting <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4/<styled-content style="fixed-case" toggle="no">IL</styled-content>‐13, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐31, and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22. The two homologous cytokines, <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐13, drive type 2 inflammation and share many biological activities <xref ref-type="ref" rid="apm12934-bib-0272">272</xref>, the main differences being in their receptor interaction: The <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4R Type I receptor consists of the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4<styled-content style="fixed-case" toggle="no">RA</styled-content> and common‐gamma chain (<styled-content style="fixed-case" toggle="no">IL</styled-content>‐2<styled-content style="fixed-case" toggle="no">RG</styled-content>) subunits, and has <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4 as its exclusive ligand, while the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4R Type <styled-content style="fixed-case" toggle="no">II</styled-content> receptor is composed of the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4<styled-content style="fixed-case" toggle="no">RA</styled-content> and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐13<styled-content style="fixed-case" toggle="no">RA</styled-content>1 chains, and binds both <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐13. The single‐chain <styled-content style="fixed-case" toggle="no">IL</styled-content>‐13<styled-content style="fixed-case" toggle="no">RA</styled-content>2 receptor is thought to function as a decoy receptor as it seems to lack the ability to induce intracellular signaling <xref ref-type="ref" rid="apm12934-bib-0273">273</xref>. As illustrated, targeting the common <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4<styled-content style="fixed-case" toggle="no">RA</styled-content> subunit will inhibit the effects of both <styled-content style="fixed-case" toggle="no">IL</styled-content>‐4 and <styled-content style="fixed-case" toggle="no">IL</styled-content>‐13 signaling. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐31 signals via a heterodimer consisting of <styled-content style="fixed-case" toggle="no">IL</styled-content>‐31<styled-content style="fixed-case" toggle="no">RA</styled-content> and the oncostatin M receptor (<styled-content style="fixed-case" toggle="no">OSMR</styled-content>), which is also common to oncostatin M (<styled-content style="fixed-case" toggle="no">OSM</styled-content>), a member of the homologous <styled-content style="fixed-case" toggle="no">IL</styled-content>‐6 superfamily <xref ref-type="ref" rid="apm12934-bib-0274">274</xref>. The <styled-content style="fixed-case" toggle="no">IL</styled-content>‐31 receptor is found on sensory neurons in the dorsal root ganglia, where the itch sensation originates, which is why targeting <styled-content style="fixed-case" toggle="no">IL</styled-content>‐31 by e.g. nemolizumab can potentially disrupt the itch–scratch cycle of pruritic diseases like <styled-content style="fixed-case" toggle="no">AD</styled-content>
<xref ref-type="ref" rid="apm12934-bib-0275">275</xref>. <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22 signals through the heterodimeric <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22R1/<styled-content style="fixed-case" toggle="no">IL</styled-content>‐10R2 receptor and induces epidermal hyperplasia in <styled-content style="fixed-case" toggle="no">AD</styled-content>, which is why the <styled-content style="fixed-case" toggle="no">IL</styled-content>‐22 antagonist fezakinumab shows some promise in treatment of severe <styled-content style="fixed-case" toggle="no">AD</styled-content>
<xref ref-type="ref" rid="apm12934-bib-0161">161</xref>.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="APM-127-386-g003"></graphic>
</fig>
<p>Compared to PSO, both our molecular disease understanding and treatment options for AD are lagging some 10–15 years behind <xref ref-type="ref" rid="apm12934-bib-0197">197</xref>. For example, the first FDA‐approved biologic for treatment of moderate‐to‐severe AD, namely the much touted IL‐4Ra inhibitor dupilumab, reports response rates in the range of 44–52% EASI 75<xref ref-type="fn" rid="apm12934-note-1017">17</xref>
<xref ref-type="ref" rid="apm12934-bib-0200">200</xref>, comparable to the rather moderate PASI75 response rates of the first generation TNF‐α targeting antibodies. Thus, there is still room for improvement and for development of even more efficacious targeted therapies; therapies that are tailored to the remaining subset(s) of severe AD patients, who may benefit from a personalized, endotype‐specific, treatment.</p>
<p>One reason that AD is a less‐mature field is the high diversity of the atopic landscape, with a wide spectrum of clinical manifestations ranging from localized nummular lesions to generalized exfoliative erythroderma in the most severe cases <xref ref-type="ref" rid="apm12934-bib-0132">132</xref>. Adding to the complexity of the clinical picture are the many possible categorizations of AD, such as:</p>
<p>
<list id="apm12934-list-0001" list-type="order"><list-item><p>infantile/childhood/adolescent/adult stages</p></list-item><list-item><p>early onset/late onset</p></list-item><list-item><p>transient/persistent</p></list-item><list-item><p>acute/subacute/chronic</p></list-item><list-item><p>mild/moderate/severe</p></list-item><list-item><p>intrinsic (low IgE, 20%)/extrinsic (high IgE, 80%)</p></list-item><list-item><p>African/Asian/European American phenotypes</p></list-item><list-item><p>± comorbidities: food allergy/asthma/rhinitis/infections</p></list-item><list-item><p>± genetic risk factors: e.g. FLG mutations</p></list-item><list-item><p>± environmental risk factors: multiple (microbiome/exposome)</p></list-item><list-item><p>± response to a given treatment</p></list-item></list>
</p>
<p>Though some of the categories are overlapping (e.g. all infantile stages are early onset), most of them can be combined (e.g. early/late onset × transient/persistent × mild/severe × low/high IgE × ethnicity × comorbidity × ±FLG mutations), resulting in thousands of possible composite classifications. This does not in itself pose a problem, because most of the above features are phenotypic and therefore relatively easy to record. No, what we would like to understand are the underlying disease endotypes. In other words: which molecular features and pathways characterize the different subtypes of AD <xref ref-type="ref" rid="apm12934-bib-0201">201</xref>, and can we identify relevant endotype‐specific biomarkers that can predict disease trajectories and guide choice and intensity of treatment? That is the question, and a difficult one indeed, because of the both heterogeneous and complex nature of AD, being the result of multiple genetic, environmental, and immunologic factors. This is reflected in our inadequate understanding of the pathogenesis of AD (outlined in Fig. <xref ref-type="fig" rid="apm12934-fig-0002">2</xref>), and the ongoing discussion of whether it is an ‘outside‐in’ (disruption of the epidermal barrier triggers the immune system) or an ‘inside‐out’ (inflammation causes the barrier dysfunction) disease <xref ref-type="ref" rid="apm12934-bib-0193">193</xref>, <xref ref-type="ref" rid="apm12934-bib-0202">202</xref>. But it is not really an either–or question, because current evidence speaks in favor of <italic>both</italic> the above hypotheses, which are therefore not mutually exclusive. Genetic evidence has established that loss‐of‐function mutations in FLG, the gene encoding filaggrin, an important structural protein in the stratum corneum of the epidermis <xref ref-type="ref" rid="apm12934-bib-0203">203</xref>, <xref ref-type="ref" rid="apm12934-bib-0204">204</xref>, are the major predisposing factors for AD <xref ref-type="ref" rid="apm12934-bib-0138">138</xref>. This has been confirmed by twin studies <xref ref-type="ref" rid="apm12934-bib-0140">140</xref>, and GWAS data <xref ref-type="ref" rid="apm12934-bib-0141">141</xref>, showing that FLG mutations, which are present in about 10% of the population, could stratify for the early‐onset persistent subphenotype in children <xref ref-type="ref" rid="apm12934-bib-0154">154</xref>. Between 20 and 50% of moderate‐to‐severe AD patients carry FLG mutations <xref ref-type="ref" rid="apm12934-bib-0136">136</xref>, so this AD subset fits well with the outside‐in hypothesis for initiation of AD. But what then, about the other half of AD patients who do not harbor any FLG mutations? In these patients, it is plausible that immune dysregulation results in secondary epidermal barrier disruption, in line with the inside‐out hypothesis. Or, alternatively, a combination of other genetic, epigenetic, immunological, and environmental factors – the exposome and microbiome included – may trigger and determine the course of AD, in which case, such compound endotypes may be difficult to tease out.</p>
<p>Still, it is beyond doubt that FLG mutation positive AD patients constitute a ‘true’ endotype, and therefore should be treated accordingly, preferably with the aim of reestablishing and maintaining an intact skin barrier as early as possible. This is necessary to prevent allergic sensitization and with this, development of asthma and allergic rhinitis. Ideally, one would like to perform prenatal diagnostics, i.e. WGS on the fetus’ DNA in order to identify all possible – not only skin disease related – genetic risk factors even before birth. Alternatively, and perhaps more feasibly, WGS of the newborn can provide the same information, albeit a little later. In case mutations in skin barrier genes (like FLG) are detected, early intervention schemes can be applied, such as use of emollients soon after birth <xref ref-type="ref" rid="apm12934-bib-0205">205</xref>. In best case, such a personalized preventive strategy may hinder development of AD and its comorbidities (the atopic march) altogether.</p>
<p>Besides FLG mutations, around 100 genes have been identified as AD associated in various studies <xref ref-type="ref" rid="apm12934-bib-0139">139</xref>, <xref ref-type="ref" rid="apm12934-bib-0141">141</xref>, <xref ref-type="ref" rid="apm12934-bib-0142">142</xref>. If one performs a functional enrichment analysis of these genes, it appears that the majority of them are related to inflammation and cytokine activity (Fig. <xref ref-type="fig" rid="apm12934-fig-0004">4</xref>), highlighting the potential importance of immune signaling and T‐cell activation in development of AD.</p>
<fig fig-type="Figure" id="apm12934-fig-0004" orientation="portrait" position="float" xml:lang="en">
<label>Figure 4</label>
<caption>
<p>
<styled-content style="fixed-case" toggle="no">STRING</styled-content>
<xref ref-type="ref" rid="apm12934-bib-0276">276</xref> network representation of 105 genes reported to have genetic associations to <styled-content style="fixed-case" toggle="no">AD</styled-content>. The genes have been compiled from three publications: Paternoster et al. 2015 (31 loci) <xref ref-type="ref" rid="apm12934-bib-0141">141</xref>, Al‐Shobaili et al. 2016 (49 genes) <xref ref-type="ref" rid="apm12934-bib-0139">139</xref>, and Liang et al. 2016 (63 genes) <xref ref-type="ref" rid="apm12934-bib-0142">142</xref>. The clustering was performed with the ‘<styled-content style="fixed-case" toggle="no">MCL</styled-content> inflation parameter’ = 3. The red cluster in the middle of the network represents the cytokine activity enriched gene set. The top enriched biological processes, molecular functions, and <styled-content style="fixed-case" toggle="no">KEGG</styled-content> pathways are shown in the table below the network.</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="APM-127-386-g004"></graphic>
</fig>
<p>What remains is the detailed analysis of the many possible gene–gene and gene–environment interactions that define the complex endotypes of AD. Here, two genetic variants of particular interest will be mentioned:</p>
<p>CD207: encodes langerin, a pattern recognition receptor expressed in epidermal Langerhans cells (LCs) and involved in antigen‐processing and presentation to T‐cells. Defects in langerin function could therefore have implications for cutaneous immunity, in particular with respect to susceptibility to skin infections by viruses and bacteria like S. aureus <xref ref-type="ref" rid="apm12934-bib-0141">141</xref>.</p>
<p>CLDN1: encodes claudin‐1, a tight junction (TJ) protein, expressed by keratinocytes in the stratum granulosum layer of the epidermis and important for maintaining an intact epidermal barrier. In a study from 2011, AD patients (n = 5) were found to have markedly lower expression of CLDN1 compared to healthy controls <xref ref-type="ref" rid="apm12934-bib-0206">206</xref>. This finding has been replicated in other studies, showing that CLDN1 expression can be downregulated by IL‐33 via the STAT3 pathway in keratinocytes <xref ref-type="ref" rid="apm12934-bib-0207">207</xref>, via IL‐13 in bronchial epithelial tissue <xref ref-type="ref" rid="apm12934-bib-0208">208</xref>, and interestingly, that CLDN1 expression can be restored both in human keratinocytes and a murine model of AD by application of the proteasome inhibitor bortezomib <xref ref-type="ref" rid="apm12934-bib-0209">209</xref>.</p>
<p>An intriguing link between tight junction function, the recent 2–3‐fold rise in AD prevalence, and the increased use of detergents has been proposed by Dr. Cezmi A. Akdis and colleagues. They demonstrated that even trace concentrations (10<sup>−6</sup> vol/vol) of commercial detergents were able to directly disrupt tight junctions between keratinocytes in culture and thereby potentially compromise epidermal barrier integrity, thus increasing the risk of allergen penetration and inflammation <xref ref-type="ref" rid="apm12934-bib-0210">210</xref>. Although this variant of the hygiene hypothesis is compelling, it remains to be reproduced in an <italic>in vivo</italic> setting on full thickness skin to determine if the detergents can actually penetrate the protective, outermost stratum corneum layer of the epidermis.</p>
</sec>
<sec id="apm12934-sec-0017">
<title>Gene expression analysis – from molecular pathology to targeted therapy</title>
<p>An important information source on the molecular pathology of AD (and any other skin disease) is transcriptomics analysis performed on skin biopsies. Optimally, the biopsies are obtained from site‐matched lesional and non‐lesional AD skin and from healthy – age and gender‐matched – controls. This enables both intra‐individual comparisons (paired analysis of samples from the same subject) and comparisons between the diseased and healthy population. Notably, individual gene expression patterns may expose not only overall disease signatures, but also the heterogeneity (endotypes and sub‐endotypes) of AD, and of the healthy population. This point is illustrated in Fig. <xref ref-type="fig" rid="apm12934-fig-0005">5</xref>, which is a re‐analysis of the transcriptomic profile of AD reported by Suárez‐Fariñas et al. <xref ref-type="ref" rid="apm12934-bib-0145">145</xref>.</p>
<fig fig-type="Figure" id="apm12934-fig-0005" orientation="portrait" position="float" xml:lang="en">
<label>Figure 5</label>
<caption>
<p>Gene expression analysis of lesional and non‐lesional skin biopsies from 13 <styled-content style="fixed-case" toggle="no">AD</styled-content> patients and from eight healthy controls. (A) Heat‐map and two‐way unsupervised hierarchical clustering based on the 50 most variable genes between the three groups (non‐protein coding and orfs (open reading frames) removed). The samples cluster primarily according to disease (<styled-content style="fixed-case" toggle="no">AD</styled-content> samples to the right and <styled-content style="fixed-case" toggle="no">NN</styled-content> samples in the left cluster) and histology (<styled-content style="fixed-case" toggle="no">LS</styled-content> to the right and <styled-content style="fixed-case" toggle="no">NL</styled-content> in the middle cluster). What one also can see, is that three of the <styled-content style="fixed-case" toggle="no">AD</styled-content> sample pairs (P12, P6, and P10, indicated by red bars below the heat map) cluster together, that is: there are only minor differences between the <styled-content style="fixed-case" toggle="no">LS</styled-content> and <styled-content style="fixed-case" toggle="no">NL</styled-content> samples from the same patient; the <styled-content style="fixed-case" toggle="no">NL</styled-content> P12 sample is ‘lesional’‐like (clusters with the other <styled-content style="fixed-case" toggle="no">LS</styled-content> samples), while the three ‘middle‐group’ (having overall low expression of most of the 50 <styled-content style="fixed-case" toggle="no">DEG</styled-content>) <styled-content style="fixed-case" toggle="no">LS</styled-content> samples (P13, P14, P10) appear more ‘non‐lesional’ like. One <styled-content style="fixed-case" toggle="no">NL</styled-content> sample (P1, indicated with a green bar below the heat‐map) clusters with the normal (<styled-content style="fixed-case" toggle="no">NN</styled-content>) group, and thus, this <styled-content style="fixed-case" toggle="no">AD</styled-content> patient does not appear to have the ‘molecular scar’ typical of non‐lesional <styled-content style="fixed-case" toggle="no">AD</styled-content> skin. The colors in the heat‐map signify high (red) or low (green) expression of the particular gene across samples (z‐scaled values). (B) Scatter plots of 16 selected genes, illustrating both the differences between lesional (<styled-content style="fixed-case" toggle="no">AA</styled-content>), non‐lesional (<styled-content style="fixed-case" toggle="no">AN</styled-content>), and healthy control (<styled-content style="fixed-case" toggle="no">NN</styled-content>) samples, and the variability within the groups, revealing the heterogeneity of both the diseased and ‘normal’ (healthy) population. The <italic>Y</italic>‐axis are log2‐transformed expression values (detection limit: 2–4, saturating concentrations: around 15). The samples are colored according to individual, and the dotted lines connect samples (non‐lesional and lesional) originating from the same individual. All the data used for this illustration can be accessed in <styled-content style="fixed-case" toggle="no">GEO</styled-content> by its accession number, <styled-content style="fixed-case" toggle="no">GSE</styled-content>32924 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse32924">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse32924</ext-link>).</p>
</caption>
<graphic id="nlm-graphic-9" xlink:href="APM-127-386-g005"></graphic>
</fig>
<p>The heat‐map in Fig. <xref ref-type="fig" rid="apm12934-fig-0005">5</xref>A is based on the top‐50 DEG, most of which are inflammatory or epidermis associated, and shows that the three histologies (healthy, non‐lesional, lesional) separate, and also, that the separation is not perfect, as several of the lesional (LS) and non‐lesional (NL) samples co‐cluster, which probably reflects the wide disease spectrum of AD. This heterogeneity is further emphasized when one looks at the individual genes (Fig. <xref ref-type="fig" rid="apm12934-fig-0005">5</xref>B), which display a striking variability in expression, both between and within groups. For example, IL8 (CXCL8, an inflammatory chemokine, involved in neutrophil activation), MMP12 (expressed by macrophages, degrades elastin), TCN1 (highly expressed in neutrophils), and DEFB4A/B (defensin, expressed by neutrophils and keratinocytes, induced by inflammation) all vary widely in expression, from undetectable to saturating concentrations in AD skin. Also, LOR (loricrin) and CDSN (corneodesmosin), which both are terminal differentiation genes, and believed to be downregulated in AD skin, are seen to have highly variable expression, ranging from undetectable (CDSN) to the high levels also found in normal skin. Also note, that not only AD skin but also healthy skin varies extensively in expression of some of the genes shown, such as MMP12, S100A9, and COL6A6, illustrating the variation within the normal population. The high variability, in particular in AD skin, most likely reflects both the extent of disease – the more inflamed skin, the higher the expression of inflammatory genes – and its pathogenesis, where multiple pathways, some associated with keratinocyte defects, some with immune system dysfunction, may coexist, and where proper (and probably problematic) identification of the underlying, dominant disease endotype eventually may guide targeted therapy.</p>
<p>We and others –‐ in particular the laboratories of Emma Guttman‐Yassky at Mount Sinai and James Krueger at Rockefeller University, both in New York, have generated a number of gene expression studies on skin have deposited transcriptomics data on AD and PSO in the public Gene Expression Omnibus Database GEO <xref ref-type="ref" rid="apm12934-bib-0211">211</xref> for further analysis. Table <xref ref-type="table" rid="apm12934-tbl-0001">1</xref> summarizes a selection of AD and PSO studies of interest and also links to the respective datasets.</p>
<p>A closer look at the above table reveals that several of the aforementioned categorization aspects of AD have already been addressed by transcriptomics analyses, including:</p>
<sec id="apm12934-sec-0018">
<title>Early‐onset AD in children vs adult AD</title>
<p>The skin transcriptome of 19 young children (with no known FLG mutations) with early‐onset AD was compared to that of age‐matched healthy controls, as well as to adult AD patients/controls. In common for both child and adult AD patients were alterations in lipid metabolism and tight junction associated genes as well as Th2‐mediated inflammation <xref ref-type="ref" rid="apm12934-bib-0212">212</xref>. In addition, the pediatric patients displayed significant Th17/Th22 polarization, but neither Th1 activation nor downregulation of epidermal differentiation complex genes, which are characteristic features of adult AD. Still, larger cohorts are needed to take ethnic differences (the above study included Asian, African, Hispanic, and Caucasian patients, the former three ethnicities with only 1–2 matching controls) and subgroups with FLG mutations into account. However, because obtaining skin biopsies from children is challenging, in such studies other, less invasive techniques, such as tape‐stripping <xref ref-type="ref" rid="apm12934-bib-0213">213</xref> or blood‐based biomarkers <xref ref-type="ref" rid="apm12934-bib-0214">214</xref>, <xref ref-type="ref" rid="apm12934-bib-0215">215</xref>, are preferable.</p>
</sec>
<sec id="apm12934-sec-0019">
<title>Acute vs chronic AD</title>
<p>Here, sequential biopsies were obtained from 10 patients in their acute and chronic phase of AD. Acute lesions were characterized by a marked increase (compared to non‐lesional skin) in expression of epidermal differentiation complex (EDC) genes, in particular S100A7/A8/A9, which are associated with Th2 (IL‐4, IL‐13, IL‐31) and Th22 (IL‐22) cytokine activation <xref ref-type="ref" rid="apm12934-bib-0196">196</xref>. When progressing to chronic lesions this Th2/Th22 axis was further activated followed by an increase in Th1‐associated products, such as CXCL9/10/11 (see Fig. <xref ref-type="fig" rid="apm12934-fig-0002">2</xref>). In terms of treatment selection, this could point toward targeting Th2/Th22 pathways in acute AD.</p>
<p>The effect of ethnicity on AD has been shown in Asian (Japanese and Korean) patients, who in general display a more psoriasiform AD phenotype and significantly higher Th17/Th22 activation as assessed by cytokine expression (IL‐17A, IL‐19, IL‐22, S100A12), compared to European American AD patients <xref ref-type="ref" rid="apm12934-bib-0212">212</xref>, <xref ref-type="ref" rid="apm12934-bib-0216">216</xref>. This can have implications for the choice of treatment, as the selective blockade of IL‐17/IL‐22 pathways could be indicated in the Asian, ‘psoriasis‐like’ immune phenotype. It will be interesting to see if the reported Japanese/Korean AD phenotype extends to the larger Chinese and Indian populations, and also, to include migration studies (investigating Asian American, Asian European, as well as local Asian AD) to evaluate the genetic, epigenetic, and environmental (exposome/microbiome) effects on the development of AD. The above considerations of course also apply to other non‐European ethnic groups, including the African population, who is likely to have yet other genetic susceptibilities, as recently reviewed by Kaufman et al. <xref ref-type="ref" rid="apm12934-bib-0217">217</xref> and Brunner et al. <xref ref-type="ref" rid="apm12934-bib-0218">218</xref>.</p>
<p>A transcriptomic treatment response signature has been obtained in several clinical intervention studies, such as ultraviolet B (UVB) phototherapy <xref ref-type="ref" rid="apm12934-bib-0157">157</xref>, cyclosporin A <xref ref-type="ref" rid="apm12934-bib-0158">158</xref>, dupilumab <xref ref-type="ref" rid="apm12934-bib-0159">159</xref>, and fezakinumab <xref ref-type="ref" rid="apm12934-bib-0161">161</xref>. In these studies, pre‐ and post‐treatment skin biopsies were obtained from both lesional (AD‐LS) and non‐lesional (AD‐NL) skin. The number of differentially expressed genes (DEGs) between AD‐LS and AD‐NL was found to be lower post‐treatment compared to pre‐treatment, indicating a normalization of the AD disease signature, including suppression of Th1, Th2, and Th22 inflammatory markers <xref ref-type="ref" rid="apm12934-bib-0157">157</xref>. However, because not all genes improve, even after successful clinical remission as assessed by SCORAD, they are defined as comprising a <italic>residual disease genomic profile</italic> (RDGP) <xref ref-type="ref" rid="apm12934-bib-0219">219</xref>. The RDGP concept was originally introduced when the treatment of psoriasis with etanercept resulted in the resolution of disease and normalization of many, but not all psoriasis‐related genes <xref ref-type="ref" rid="apm12934-bib-0220">220</xref>. A subset of 248 genes did not return to baseline (or rather: exhibited less than 75% improvement after treatment) and could be indicative both of incomplete suppression of inflammation – leaving room for improvement – and for a ‘molecular scar’ intrinsic to the disease. Whether the latter represents different endotypes with implications for disease progression and treatment response remains to be determined.</p>
<p>A meta‐analysis derived AD (MADAD) signature identified 595 AD‐associated DEGs across four publicly available transcriptomics studies <xref ref-type="ref" rid="apm12934-bib-0146">146</xref>, and a subset of the most discriminatory of these genes was shown to be applicable as a robust standardized measure of treatment effect in the abovementioned UVB, cyclosporin A, and dupilumab studies. Since the MADAD reference transcriptome captures both immunological (inflammatory genes, cytokines, T‐cell receptor signaling) and barrier defect (epidermal differentiation, lipid metabolism) genes, it may be used for future evaluation of therapeutic response.</p>
<p>All of the above transcriptomic studies have been performed on full thickness punch biopsies of the skin, which is organized in three main layers: the epidermis, the dermis, and the subcutaneous fat (hypodermis). The epidermis contains &gt;90% keratinocytes at different differentiation levels, a few melanocytes, Langerhans cells (LCs), Merkel cells, α‐dendritic cells, and inflammatory cells. The dermis mainly consists of extracellular matrix proteins, primarily collagen fibers produced by fibroblasts, and also dendritic cells/macrophages, mast cells, various unactivated/activated T‐cell subsets, plasma cells, hair follicles, sweat glands, sebaceous and apocrine glands, and endothelial cells <xref ref-type="ref" rid="apm12934-bib-0221">221</xref>. Thus, when we analyze gene expression in whole skin, the resulting average signal will reflect both the cellular distribution, such as the epidermis‐to‐dermis ratio, which is known to vary both in AD and PSO, as well as any up‐ or down‐regulation of differentially expressed genes. Furthermore, in a homogeneous assay the compartmental localization of gene expression is lost and also the expression of low‐abundance genes may become undetectable because of dilution. One way to generate a more refined skin transcriptome is to apply LCM (laser capture microdissection), which enables separation of the skin into its dermal and epidermal components. Such a – and so far only – study based on paired lesional and non‐lesional samples from five AD patients showed that indeed the dermal and epidermal transcriptomes differ, and also, that the AD signature could be expanded with some 1000 DEGs due to the increased signal‐to‐noise ratio, when working with separate compartments <xref ref-type="ref" rid="apm12934-bib-0222">222</xref>. Some of the DEGs now detectable by LCM included IL22, TSLP, IL34, CCL22, CCL26, CLDN4, and CLDN8 (the latter two involved in tight junction (TJ) formation). One reason why LCM is not applied routinely is that it is very labor intensive. Therefore, other methods need to be considered for separating the dermal and epidermal signals. One such method is based on epidermal shaves for transcriptomic profiling <xref ref-type="ref" rid="apm12934-bib-0223">223</xref>, another is tape stripping <xref ref-type="ref" rid="apm12934-bib-0213">213</xref>. A quick comparison of the top‐50 LS/NL DEGs from each of the three studies shows that they have only little overlap (Fig. <xref ref-type="fig" rid="apm12934-fig-0006">6</xref>). This may be partly due to different patient populations, different skin sampling technologies, and different RNA quantification platforms (Affymetrix microarrays, Illumina arrays, Ion Torrent sequencing). In particular, the tape‐stripping experiment displayed some unexpected findings, such as large differences in the expression of numerous keratin‐associated protein (KRTAP) genes (being more than 50‐fold downregulated in LS vs NL epidermis), which could suggest differences in the presence of hair.</p>
<fig fig-type="Figure" id="apm12934-fig-0006" orientation="portrait" position="float" xml:lang="en">
<label>Figure 6</label>
<caption>
<p>Comparison of three studies, assessing the epidermal transcriptomic profile of <styled-content style="fixed-case" toggle="no">AD</styled-content>‐<styled-content style="fixed-case" toggle="no">LS</styled-content> vs <styled-content style="fixed-case" toggle="no">AD</styled-content>‐<styled-content style="fixed-case" toggle="no">NL</styled-content> skin. (A) Top‐50 up <styled-content style="fixed-case" toggle="no">DEG</styled-content> (<styled-content style="fixed-case" toggle="no">LS</styled-content> vs <styled-content style="fixed-case" toggle="no">NL</styled-content>). (B) Top‐50 down <styled-content style="fixed-case" toggle="no">DEG</styled-content> (<styled-content style="fixed-case" toggle="no">LS</styled-content> vs <styled-content style="fixed-case" toggle="no">NL</styled-content>). The three studies included are Tape: Tape‐stripped skin (not in <styled-content style="fixed-case" toggle="no">GEO</styled-content>) <xref ref-type="ref" rid="apm12934-bib-0213">213</xref>; <styled-content style="fixed-case" toggle="no">LCM</styled-content>:<styled-content style="fixed-case" toggle="no"> GSE</styled-content>120721 <xref ref-type="ref" rid="apm12934-bib-0222">222</xref>; Shave: <styled-content style="fixed-case" toggle="no">GSE</styled-content>60709 <xref ref-type="ref" rid="apm12934-bib-0223">223</xref>. For the genes that are up in <styled-content style="fixed-case" toggle="no">LS</styled-content>/<styled-content style="fixed-case" toggle="no">NL</styled-content> epidermis, the overlap in <styled-content style="fixed-case" toggle="no">DEG</styled-content> between <styled-content style="fixed-case" toggle="no">LCM</styled-content> and epidermal shave is 50% (25 out of 50 genes). Fewer genes are in common between the three studies for the down <styled-content style="fixed-case" toggle="no">DEG</styled-content>. For the tape‐stripping study, interestingly, many <styled-content style="fixed-case" toggle="no">KRTAP</styled-content> genes appear as lower expressed in <styled-content style="fixed-case" toggle="no">LS</styled-content> skin. Since <styled-content style="fixed-case" toggle="no">KRTAP</styled-content> genes are associated with the hair shaft, this could suggest that there is less hair in the <styled-content style="fixed-case" toggle="no">LS</styled-content> epidermis region.</p>
</caption>
<graphic id="nlm-graphic-11" xlink:href="APM-127-386-g006"></graphic>
</fig>
</sec>
</sec>
<sec id="apm12934-sec-0020">
<title>Microbiome</title>
<p>Both the gut and skin microbiome have been implicated in the pathogenesis of AD.</p>
<p>The gut microbiome is associated with the <italic>hygiene hypothesis</italic> proposed by Strachan in 1989, who noticed that the number of older children in a household had a striking inverse correlation to the prevalence of hay fever and eczema in their younger siblings <xref ref-type="ref" rid="apm12934-bib-0128">128</xref>. Thus, he hypothesized that smaller family size leads to less unhygienic contact with older siblings and thus, reduced the opportunity for cross infection that supposedly has a protective effect on development of eczema. In addition, higher microbial endotoxin exposure from farm animals was associated with protection against development of allergy, as suggested in the ‘Eat Dirt’ article by Weiss <xref ref-type="ref" rid="apm12934-bib-0224">224</xref>. Finally, because the gut microbiome is important for the prenatal–early‐life maturation of our immune system <xref ref-type="ref" rid="apm12934-bib-0225">225</xref>, it has been intensively studied in relation to allergic diseases, and perturbations in the infant gut microbiome have been linked to the risk of developing AD <xref ref-type="ref" rid="apm12934-bib-0226">226</xref>. However, several probiotic and prebiotic intervention trials have been conducted, and although some protective effect against AD was observed, the differences were small, and no clear gut microbiome–AD association could be demonstrated <xref ref-type="ref" rid="apm12934-bib-0227">227</xref>.</p>
<p>The cutaneous microbiome, on the other hand, is clearly associated with AD, as a vast majority (&gt;90%) of AD patients have their skin colonized with Staphylococcus aureus, compared to only 5% of healthy controls <xref ref-type="ref" rid="apm12934-bib-0132">132</xref>. In addition, S. aureus positive AD patients seem to have more severe disease, higher levels of Type 2 biomarkers (CCL17, POSTN), allergen sensitization (IgE), and barrier dysfunction (higher TEWL) than non‐colonized AD controls <xref ref-type="ref" rid="apm12934-bib-0228">228</xref>. Also, in a prospective study on children with AD, an increase in the proportion of S. aureus and a concomitant decrease in bacterial diversity preceded worsening (flare) of AD <xref ref-type="ref" rid="apm12934-bib-0229">229</xref>. To address the question as to whether the observed colonization of AD skin by S. aureus is potentially driving the disease or merely an epiphenomenon, several intervention trials have been carried out. Such studies applying either antiseptics or antibiotics have demonstrated that a reduction in the level of S. aureus is indeed followed by a reduction in AD severity, further supporting a causal relationship between S. aureus colonization of skin and AD <xref ref-type="ref" rid="apm12934-bib-0227">227</xref>. Additionally, use of emollients in infants at risk for developing AD caused a decrease in skin pH and an increase in bacterial diversity, which may partly explain the preventative effects of emollients <xref ref-type="ref" rid="apm12934-bib-0230">230</xref>.</p>
<p>A mechanistic link to the pathogenesis of AD is suggested by the colonization of AD skin by toxigenic S. aureus strains that produce <italic>superantigens</italic> (SA), which drive the development of a Th2 immune response, and activate Langerhans cells (LCs) and cutaneous dendritic cells (DCs) that bridge innate and adaptive immunity <xref ref-type="ref" rid="apm12934-bib-0231">231</xref>. Moreover, mast cell degranulation is directly stimulated by the S. aureus δ‐toxin (δ‐hemolysin), which also promotes IgE production and Th2‐mediated inflammation <xref ref-type="ref" rid="apm12934-bib-0232">232</xref>. Conversely, Th2 cells enable S. aureus colonization due to IL‐4 and IL‐13 mediated inhibition of antimicrobial peptides (AMPs) and of terminal differentiation proteins important for skin barrier integrity <xref ref-type="ref" rid="apm12934-bib-0233">233</xref>. And in turn, S. aureus amplifies the inflammatory response by stimulating release of IL‐4, IL‐13, IL‐22, IL‐17, IL‐31, and IgE, thus closing the vicious circle <xref ref-type="ref" rid="apm12934-bib-0234">234</xref>. It will be interesting to see whether the topical application of protective commensal skin bacteria, such as coagulase negative Staphylococcus strains, can inhibit the growth of S. aureus and eventually, lead to a cure of AD <xref ref-type="ref" rid="apm12934-bib-0235">235</xref> (Box <xref ref-type="boxed-text" rid="apm12934-fea-0005">5</xref>).</p>
<boxed-text content-type="Box" id="apm12934-fea-0005" orientation="portrait" position="float">
<label>Box 5</label>
<caption>
<title>Technical considerations – what to sample and what to measure?</title>
</caption>
<sec id="apm12934-sec-0046">
<p>As the eyes are said to be the mirror of our soul, so is the skin a two‐way mirror,<xref ref-type="fn" rid="apm12934-note-1018">18</xref> reflecting both our inner and outer environment <xref ref-type="ref" rid="apm12934-bib-0237">237</xref>. Therefore, the cutaneous inflammation observed in AD reflects both inherent skin barrier and immune system dysregulation (endotype) as well as the effect of external factors (exposome), such as allergens, bacterial toxins, detergents, and other irritants.</p>
<p>Fortunately, the skin is easily accessible, and as such, straightforward to sample and study by various techniques, from imaging (phenotype) to ‐omics analyses (molecular pathology) on biopsies. Standard 3–4 mm biopsies, however, damage the skin and are considered too invasive for routine use on children, who represent the majority of AD patients, which is why alternative sampling technologies should be considered. One alternative, is to take smaller, 1 mm ‘mini’ biopsies (for which commercial punches are available) with only minimal scarring, allowing for multiple biopsies to be sampled, but which still require the application of local anesthetics, as otherwise, the procedure is painful. Another, less invasive option is to apply tape stripping to remove the stratum corneum, enabling quick sampling of multiple epidermal layers. A third, and non‐invasive technology is the procedure of skin surface washings that within 30 min sampling time allows for quantification of stratum corneum associated cytokines <xref ref-type="ref" rid="apm12934-bib-0237">237</xref>.</p>
<p>Blood sampling is of course obvious, but first requires identification of adequate biomarkers <xref ref-type="ref" rid="apm12934-bib-0215">215</xref>. The advantage of a blood sample is that it can integrate the disease signature, and that it contains several subsets of inflammatory cells that can be identified, separated, and analyzed by flow cytometry. A disadvantage of blood‐based biomarkers is the dilution effect; if local skin inflammation is the dominating disease feature, it may be difficult to translate into a blood‐based biomarker.</p>
<p>Other sampling sites include urine <xref ref-type="ref" rid="apm12934-bib-0238">238</xref> and exhaled breath condensate, the latter containing markers of airway inflammation, which has been reported in children with AD <xref ref-type="ref" rid="apm12934-bib-0239">239</xref>.</p>
<p>A note on the analysis of skin biopsies: when we take a full thickness skin biopsy, it contains a heterogeneous mixture of cells, which are being homogenized before DNA, RNA, or protein is extracted for further analysis. Thus, the sample is blended into a ‘cellular smoothie’, where the individual cell characteristics are evened out or even lost. Thus, what we see, when we analyze the gene expression pattern from such a homogenized biopsy, is a snapshot in time and space; it is an average signal from many (millions) individual cells and several cell types, but where the individual, cell‐specific signals are averaged out. The problem is that we do not know the distribution of different cell types in the sample. Thus, we cannot tell whether the actual – average – signal measured is due to activation or inhibition of specific genes (up‐ or down‐regulation of gene expression), or whether it is due to redistribution of compartments. For example, FLG and LOR are highly expressed in the epidermis and are often seen to decrease following perturbation. But whether the observed differential gene expression is due to inhibition, or whether it is because of thinning of the epidermis (thus, decreasing the epidermis to dermis ratio) remains unknown. One way of solving the problem is by deconvolution of the cellular compartments, i.e. estimating the percentage of epidermis, dermis, and other skin compartments based on tissue‐ and cell type‐specific expression patterns <xref ref-type="ref" rid="apm12934-bib-0240">240</xref>, <xref ref-type="ref" rid="apm12934-bib-0241">241</xref>, <xref ref-type="ref" rid="apm12934-bib-0242">242</xref>. This ‘housekeeping’ approach may work in a well‐defined system, but such a system is rarely well defined. The cell‐specific signals can be identified by laser capture microdissection (LCM), which enables separation of the dermis from the epidermis signal, and thus increases the signal‐to‐noise ratio compared to that of a full thickness biopsy <xref ref-type="ref" rid="apm12934-bib-0222">222</xref>. LCM is rarely applied, however, mainly because it is a very laborsome technique, and also because it can affect the actual state of the cells <xref ref-type="ref" rid="apm12934-bib-0243">243</xref>. Another, more high‐throughput technique, is separation by e.g. microfluidics or flow cytometry into single cells followed by single‐cell sequencing, for example, by drop‐seq, made open source by Steve McCarroll et al. (<ext-link ext-link-type="uri" xlink:href="http://mccarrolllab.org/dropseq/">http://mccarrolllab.org/dropseq/</ext-link>). Thus, instead of a cellular smoothie, we now have a cellular fruit salad, where the characteristics of each individual piece of fruit are retained <xref ref-type="ref" rid="apm12934-bib-0244">244</xref>.<xref ref-type="fn" rid="apm12934-note-1019">19</xref>
</p>
</sec>
</boxed-text>
</sec>
<sec id="apm12934-sec-0021">
<title>How precise is precision medicine?</title>
<p>Usually, differences between diseased and healthy tissue are quantitative rather than qualitative. That is: a given target or pathway is rarely exclusive to just a single disease, tissue, or cell type. For example, cytokines and their receptors are expressed at highly variable levels across cell types and conditions, and while certain cells, such as Th2 cells, express and release high levels of IL‐4 and IL‐13, this is also the case for basophils and ILC2 cells <xref ref-type="ref" rid="apm12934-bib-0245">245</xref>. And conversely: the expression of cytokine receptors, e.g. the IL‐4Ra subunit, is not confined to just a single‐cell type, like keratinocytes (which themselves secrete numerous cytokines that act as both autocrine and paracrine mediators). Therefore, targeting the IL‐4 receptor pathway with a specific antibody like dupilumab may cause adverse effects – such as the conjunctivitis reported in 14–19% of AD patients treated with dupilumab <xref ref-type="ref" rid="apm12934-bib-0246">246</xref>. Of course, this concern also applies to any other targeted treatment, which is why it is important to evaluate and prioritize both the most relevant disease drivers, pathways, and targets (druggability considerations) as well as to take potential off‐target and on‐target adverse effects into consideration.</p>
<p>Finally, to evaluate the efficacy of novel medicine approaches and to identify the most important disease pathways, head‐to‐head comparisons against other targeted treatments are useful. A notable example of such a head‐to‐head comparison is the recent ECLIPSE study including 1048 moderate–severe PSO patients. In this Phase 3 study, the long‐term efficacy and safety of the IL‐17A inhibitor secukinumab was compared to that of the IL‐23 (p19) inhibitor guselkumab: at week 48, PASI90 was reached for 70% of patients on secukinumab, and for 85% of patients on guselkumab, while the PASI100 responses were 48% and 58%, respectively <xref ref-type="ref" rid="apm12934-bib-0247">247</xref>. Thus, for this patient group, the newer‐generation IL‐23 inhibitor demonstrated superior long‐term efficacy over the IL‐17A inhibitor.</p>
<p>In another head‐to‐head PSO study, the IL‐23 (p19) inhibitor risankizumab was compared to the dual IL‐12/23 inhibitor ustekinumab, and already at week 4 the p19 inhibitor showed a more pronounced effect than ustekinumab as assessed by molecular (RNA‐seq transcriptomics) and histopathologic profiling <xref ref-type="ref" rid="apm12934-bib-0153">153</xref>.</p>
<p>In a third PSO study, the effect of an anti‐IFN‐γ antibody was investigated, and although IFN‐γ was blocked at the molecular level, clinical efficacy could not be demonstrated <xref ref-type="ref" rid="apm12934-bib-0248">248</xref>. This – obviously – implies that it is not sufficient to demonstrate the molecular effect of target inhibition, if the target is not central for driving the disease.</p>
</sec>
<sec id="apm12934-sec-0022">
<title>Personalized medicine – strategies and candidates</title>
<p>Targeting signaling pathways in inflammatory skin diseases can be approached at different cellular levels: <italic>extracellularly</italic>, at the receptor level, either targeting the cytokine itself (e.g. tralokinumab for IL‐13), or its receptor (e.g. dupilumab for IL‐4RA) by monoclonal antibodies (or other biologics/biosimilars, such as nanobodies) or, alternatively, <italic>intracellularly</italic>, blocking the downstream signaling of e.g. the JAK‐STAT pathway (Fig. <xref ref-type="fig" rid="apm12934-fig-0003">3</xref>B‐C) by small‐molecule inhibitors of one or more of the four JAKs: JAK1, JAK2, JAK3, and TYK2 <xref ref-type="ref" rid="apm12934-bib-0249">249</xref>.</p>
<p>Currently, several JAK inhibitors – both systemic and topical –with different selectivities are in clinical development for treatment of inflammatory diseases (see Table <xref ref-type="table" rid="apm12934-tbl-0002">2</xref> for these and other compounds), including filgotinib (JAK1), upadacitinib (JAK1), abrocitinib (JAK1), ruxolitinib &amp; baricitinb (JAK1/2), tofacitinib (JAK1/3), BMS‐986165 (TYK2), ASN002 (TYK2/SYK), and delgocitinib (JTE‐052, pan‐JAK). Most of these candidates show promising efficacy and overlapping systemic safety profiles with increased risk of opportunistic virus infections and cytopenias <xref ref-type="ref" rid="apm12934-bib-0250">250</xref>. Therefore, to avoid the latter adverse effects of systemic treatment, topical formulations should also be (and are) considered.</p>
<table-wrap id="apm12934-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Future and emerging targeted treatment options for atopic dermatitis (AD) and psoriasis (PSO)</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Target</th>
<th align="left" colspan="1" rowspan="1" valign="top">Drug</th>
<th align="left" colspan="1" rowspan="1" valign="top">Literature reference</th>
<th align="left" colspan="1" rowspan="1" valign="top">clinicaltrials.gov reference<xref ref-type="fn" rid="apm12934-note-0003">a</xref>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">Indications</th>
<th align="left" colspan="1" rowspan="1" valign="top">Clinical phase, status</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">AhR (agonist)</td>
<td align="left" colspan="1" rowspan="1">
<p>Tapinarof (t)<xref ref-type="fn" rid="apm12934-note-0004">b</xref>
</p>
<p>(GSK2894512)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0294">294</xref>, <xref ref-type="ref" rid="apm12934-bib-0295">295</xref>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02564055</p>
<p>NCT03202004</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.II, completed</p>
<p>Ph.III, withdrawn</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CCL20</td>
<td align="left" colspan="1" rowspan="1">GSK3050002 (i)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0296">296</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02671188</td>
<td align="left" colspan="1" rowspan="1">PsA</td>
<td align="left" colspan="1" rowspan="1">Ph.I, withdrawn</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CD125 (IL5RA)</td>
<td align="left" colspan="1" rowspan="1">Benralizumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0297">297</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03563066</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">H4R</td>
<td align="left" colspan="1" rowspan="1">ZPL‐389 (o)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0294">294</xref>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT03517566</p>
<p>NCT02618616</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.II, recruiting</p>
<p>Ph.II, completed</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IgE</td>
<td align="left" colspan="1" rowspan="1">
<p>Omalizumab (sc)</p>
<p>QGE031 (sc)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0298">298</xref>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02300701</p>
<p>NCT01552629</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD pediatric</p>
<p>AD</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.IV, active,</p>
<p>Ph.II, completed</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐1a</td>
<td align="left" colspan="1" rowspan="1">Bermekimab (sc)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">NCT03496974</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">AD: Ph.2, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐4Ra</td>
<td align="left" colspan="1" rowspan="1">Dupilumab (sc) (Dupixent)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0200">200</xref>, <xref ref-type="ref" rid="apm12934-bib-0299">299</xref>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02612454</p>
<p>FDA approved</p>
</td>
<td align="left" colspan="1" rowspan="1">AD pediatric</td>
<td align="left" colspan="1" rowspan="1">Ph.III, enrolling</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐5</td>
<td align="left" colspan="1" rowspan="1">Mepolizumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0300">300</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03055195</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.I, terminated</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐12B (p40)</td>
<td align="left" colspan="1" rowspan="1">Ustekinumab (Stelara) (sc)</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0301">301</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0302">302</xref>, <xref ref-type="ref" rid="apm12934-bib-0303">303</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT01806662</p>
<p>NCT02698475</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.II, completed</p>
<p>Ph.III, pediatric PSO</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐13</td>
<td align="left" colspan="1" rowspan="1">Tralokinumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0304">304</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03587805</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.III, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐13</td>
<td align="left" colspan="1" rowspan="1">Lebrikizumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0299">299</xref>, <xref ref-type="ref" rid="apm12934-bib-0305">305</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03443024</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, active</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐17A</td>
<td align="left" colspan="1" rowspan="1">Ixekizumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0306">306</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03073200</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ph.III, pediatric PSO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐17A</td>
<td align="left" colspan="1" rowspan="1">Secukinumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0262">262</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0303">303</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02594098</p>
<p>NCT02409667</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.II, completed</p>
<p>Ph.III, completed</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐17A/IL‐17F</td>
<td align="left" colspan="1" rowspan="1">Bimekizumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0307">307</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03598790</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ph.III, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐17C</td>
<td align="left" colspan="1" rowspan="1">MOR106 (iv)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0308">308</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03568071</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐17RA</td>
<td align="left" colspan="1" rowspan="1">Brodalumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0174">174</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03403036</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ph.IV, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐22</td>
<td align="left" colspan="1" rowspan="1">Fezakinumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0161">161</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT01941537</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, active</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐23 (p19)</td>
<td align="left" colspan="1" rowspan="1">
<p>Guselkumab (sc)</p>
<p>Tildrakizumab (sc)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0309">309</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0169">169</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02905331</p>
<p>NCT01729754</p>
</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.III, completed</p>
<p>Ph.III, active</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐23 (p19)</td>
<td align="left" colspan="1" rowspan="1">
<p>Risankizumab (sc)</p>
<p>Mirikizumab (sc)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0310">310</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0311">311</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT03518047</p>
<p>NCT03482011</p>
</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.III, active</p>
<p>Ph.III, recruiting</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐31</td>
<td align="left" colspan="1" rowspan="1">BMS‐981164 (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0312">312</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT01614756</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.I, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐31RA</td>
<td align="left" colspan="1" rowspan="1">Nemolizumab (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0275">275</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03100344</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐33</td>
<td align="left" colspan="1" rowspan="1">Etokimab (sc) (ANB020)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">NCT03533751</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IL‐36R</td>
<td align="left" colspan="1" rowspan="1">ANB019 (sc)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">NCT03619902</td>
<td align="left" colspan="1" rowspan="1">PSO (GPP)</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">JAK1</td>
<td align="left" colspan="1" rowspan="1">
<p>Upadacitinib (o)</p>
<p>Abrocitinib (o) (PF‐04965842)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0313">313</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0299">299</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT03607422</p>
<p>NCT03575871</p>
</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.III, recruiting</p>
<p>Ph.III, recruiting</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">JAK1/2</td>
<td align="left" colspan="1" rowspan="1">Ruxolitinib (t)</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0314">314</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0315">315</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0316">316</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT03745638</p>
<p>NCT00820950</p>
<p>NCT02553330</p>
<p>NCT03099304</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
<p>AA</p>
<p>Vitiligo</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.III, recruiting</p>
<p>Ph.II, completed</p>
<p>Ph.II, terminated</p>
<p>Ph.II, recruiting</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">JAK1/2</td>
<td align="left" colspan="1" rowspan="1">Baricitinib (o)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0317">317</xref>, <xref ref-type="ref" rid="apm12934-bib-0318">318</xref>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT03334422</p>
<p>NCT01490632</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.III, active</p>
<p>Ph.II, completed</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">JAK1/3</td>
<td align="left" colspan="1" rowspan="1">Tofacitinib (o,t)</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0314">314</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0319">319</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0315">315</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02001181</p>
<p>NCT01241591</p>
<p>NCT02812342</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
<p>AA</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.II, completed</p>
<p>Ph.III, completed</p>
<p>Ph.II, active</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">JAK1/TYK2</td>
<td align="left" colspan="1" rowspan="1">PF‐06700841 (o)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0320">320</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02969018</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">JAK1/2/3, TYK2</td>
<td align="left" colspan="1" rowspan="1">
<p>Delgocitinib (t)</p>
<p>(JTE‐052)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0321">321</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03725722</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NK‐1R (TACR1)</td>
<td align="left" colspan="1" rowspan="1">Serlopitant (o)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0322">322</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02975206</td>
<td align="left" colspan="1" rowspan="1">AD, pruritus</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NK‐1R (Substance P)</td>
<td align="left" colspan="1" rowspan="1">Tradipitant (o)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0322">322</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03568331</td>
<td align="left" colspan="1" rowspan="1">AD, pruritus</td>
<td align="left" colspan="1" rowspan="1">Ph.III, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">OX40</td>
<td align="left" colspan="1" rowspan="1">GBR 830 (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0323">323</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03568162</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">OX40</td>
<td align="left" colspan="1" rowspan="1">KHK4083 (i)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">NCT03096223</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.I, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PDE4</td>
<td align="left" colspan="1" rowspan="1">Apremilast (o)</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0324">324</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0325">325</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02087943</p>
<p>NCT01194219</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.II, completed</p>
<p>Ph.III, completed</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PDE4</td>
<td align="left" colspan="1" rowspan="1">Crisaborole (t)</td>
<td align="left" colspan="1" rowspan="1">
<p>
<xref ref-type="ref" rid="apm12934-bib-0326">326</xref>
</p>
<p>
<xref ref-type="ref" rid="apm12934-bib-0327">327</xref>
</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT02118766</p>
<p>NCT01300052</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>AD</p>
<p>PSO</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.III, completed</p>
<p>Ph.II, completed</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PDE4</td>
<td align="left" colspan="1" rowspan="1">OPA‐15406 (t)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0328">328</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02068352</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">RIP1 kinase</td>
<td align="left" colspan="1" rowspan="1">GSK2982772 (o)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0329">329</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02776033</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ROR‐γ</td>
<td align="left" colspan="1" rowspan="1">ESR‐114 (t)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">NCT03630939</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SYK/JAK</td>
<td align="left" colspan="1" rowspan="1">ASN002 (o)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">NCT03531957</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.II, recruiting</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TNF‐α</td>
<td align="left" colspan="1" rowspan="1">Infliximab (i)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0169">169</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT00686595</td>
<td align="left" colspan="1" rowspan="1">PSO, PsA</td>
<td align="left" colspan="1" rowspan="1">Ph.IV, completed</td>
</tr>
<tr style="border-bottom:solid 1px #000000">
<td align="left" colspan="1" rowspan="1">TNF‐α</td>
<td align="left" colspan="1" rowspan="1">
<p>Adalimumab (Humira) (sc)</p>
<p>Etanercept (sc)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0330">330</xref>
</td>
<td align="left" colspan="1" rowspan="1">
<p>NCT01970488</p>
<p>NCT00332332</p>
</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">
<p>Ph.III, completed</p>
<p>Ph.IV, completed</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TNF‐α/IL‐17A</td>
<td align="left" colspan="1" rowspan="1">ABT‐122 (sc)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0331">331</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02349451</td>
<td align="left" colspan="1" rowspan="1">PsA</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TNF‐α/IL‐17A</td>
<td align="left" colspan="1" rowspan="1">COVA322 (i)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0183">183</xref>, <xref ref-type="ref" rid="apm12934-bib-0332">332</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02243787</td>
<td align="left" colspan="1" rowspan="1">PSO</td>
<td align="left" colspan="1" rowspan="1">Ph.I, terminated (safety)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TrkA</td>
<td align="left" colspan="1" rowspan="1">CT327/SNA‐120 (t)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0322">322</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT01808157</td>
<td align="left" colspan="1" rowspan="1">AD, pruritus</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TRPV1</td>
<td align="left" colspan="1" rowspan="1">PAC‐14028 (t)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0333">333</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT02748993</td>
<td align="left" colspan="1" rowspan="1">AD, pruritus</td>
<td align="left" colspan="1" rowspan="1">Ph.II, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TSLP</td>
<td align="left" colspan="1" rowspan="1">
<p>Tezepelumab (sc)</p>
<p>(AMG 157)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0323">323</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT00757042</td>
<td align="left" colspan="1" rowspan="1">AD</td>
<td align="left" colspan="1" rowspan="1">Ph.I, completed</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TYK2</td>
<td align="left" colspan="1" rowspan="1">BMS‐986165 (o)</td>
<td align="left" colspan="1" rowspan="1">
<xref ref-type="ref" rid="apm12934-bib-0178">178</xref>
</td>
<td align="left" colspan="1" rowspan="1">NCT03624127</td>
<td align="left" colspan="1" rowspan="1">PSO, PsA</td>
<td align="left" colspan="1" rowspan="1">Ph.III, recruiting</td>
</tr>
</tbody>
</table>
<table-wrap-foot id="apm12934-ntgp-0002">
<fn id="apm12934-note-0002">
<p>Sorted according to molecular target. Monoclonal antibody drugs can be identified by their names, which all end with ‘‐mab’.</p>
</fn>
<fn id="apm12934-note-0003">
<label>a</label>
<p>The list is not exhaustive. For up‐to‐date information on the clinical trials, please see <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>
</p>
</fn>
<fn id="apm12934-note-0004">
<label>b</label>
<p>(t) topical; (iv) intravenously; (o) oral; (sc) subcutaneously.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>Finally, new treatment modalities include those based on vaccination and allergen‐specific immunotherapy. The latter is effective in treating allergies and involves de‐sensitization via repeated exposure to increasing doses of allergens, but the effect on AD is still unresolved <xref ref-type="ref" rid="apm12934-bib-0251">251</xref>. Vaccination against S. aureus could in principle eliminate this pathogenic factor from susceptible AD patients, and several clinical trials are ongoing to evaluate the effect of active and passive vaccine candidates on AD <xref ref-type="ref" rid="apm12934-bib-0252">252</xref>.</p>
</sec>
</sec>
<sec id="apm12934-sec-0023">
<title>Conclusion</title>
<p>Historically, we have moved from ignorance, superstition (or act of God) and metaphysics, to a rational (Hippocratic), physical approach to personalized medicine, driven by major progress in technology; this has enabled us to zoom in, both on the cellular and the molecular (the omics revolution) basis of disease. And now – in the post‐genomic era, we are able to integrate the multiple levels of information: from molecular‐level genome, epigenome, metabolome, and proteome data, to higher level physiome, exposome, microbiome, and interactome data <xref ref-type="ref" rid="apm12934-bib-0253">253</xref>. Thus, we are aiming at a modern, systemic (systems biology), holistic disease understanding, where the gap between diagnostics and treatment options is steadily closing.</p>
<p>Oncology is leading the way in precision medicine <xref ref-type="ref" rid="apm12934-bib-0254">254</xref>, though for a critical review of precision oncology, see Brock and Huang <xref ref-type="ref" rid="apm12934-bib-0255">255</xref>. Immunology is catching up with asthma ahead, already linking phenotypes and endotypes to targeted therapy <xref ref-type="ref" rid="apm12934-bib-0256">256</xref>, and as a natural extension of this development, inflammatory skin diseases follow suit, with PSO ahead of AD <xref ref-type="ref" rid="apm12934-bib-0197">197</xref>.</p>
<p>In principle, chronic inflammatory skin diseases, like PSO and AD, and also alopecia and vitiligo, are (currently) incurable, but they do respond to treatment. They also, in particular AD, comprise complex and heterogeneous underlying endotypes, which are good candidates for a personalized medicine strategy. Thus, in order to apply endotype‐driven strategies for stratification and personalized medicine, it is necessary first to identify and understand these endotypes. Hopefully, such understanding can be obtained via an integrative, multi‐omics approach resulting in discovery of molecular biomarkers, both prognostic and predictive, for assessing the likelihood of comorbidity, disease progression, and response to novel, targeted treatments (Fig. <xref ref-type="fig" rid="apm12934-fig-0007">7</xref>). Additionally, and following the vision of P4 medicine being both personalized and participatory, patients will have the opportunity to monitor the health of their skin by using mobile apps <xref ref-type="ref" rid="apm12934-bib-0257">257</xref> that in real‐time (by use of artificial intelligence (AI) and cloud‐based deep learning) can perform image analysis, evaluate the degree of treatment response, and eventually, recommend to stop, continue, or change the treatment, essentially enabling truly individualized medicine (Box <xref ref-type="boxed-text" rid="apm12934-fea-0006">6</xref>).</p>
<fig fig-type="Figure" id="apm12934-fig-0007" orientation="portrait" position="float" xml:lang="en">
<label>Figure 7</label>
<caption>
<p>The vision of applied personalized medicine in inflammatory skin diseases. Risk factors (such as <styled-content style="fixed-case" toggle="no">FLG</styled-content> mutations in <styled-content style="fixed-case" toggle="no">AD</styled-content>) can be identified before birth, enabling preventive measures (such as use of emollients) in early childhood. Identification of endotypes can guide targeted treatment, and a combination of predictive biomarkers and skin monitoring (aided by machine learning, including <styled-content style="fixed-case" toggle="no">AI</styled-content>, integrating the information knowledge base) may help identify pre‐flares and optimal time and type of treatment.</p>
</caption>
<graphic id="nlm-graphic-13" xlink:href="APM-127-386-g007"></graphic>
</fig>
<boxed-text content-type="Box" id="apm12934-fea-0006" orientation="portrait" position="float">
<label>Box 6</label>
<caption>
<title>Key messages</title>
</caption>
<sec id="apm12934-sec-0047">
<p>As our mechanistic understanding of inflammatory skin conditions like PSO and AD increases, so does the potential for personalized treatment and prevention. In particular, because PSO and AD are both complex and heterogeneous diseases with variable course, treatment response, and hard to predict comorbidities, they pose paradigmatic obvious cases for a personalized medicine approach.</p>
<p>Inflammatory skin diseases are currently incurable, but not intractable.</p>
<p>Ideally, personalized management of PSO and AD is <italic>patient‐centric</italic>, i.e. taking the individual's needs into concern. Targeted treatment of the skin with emollients and topical corticosteroids may be sufficient to control disease in mild to moderate cases. Targeted, antibody‐based therapies have revolutionized the treatment of severe PSO and AD, and still more efficient (more patients reaching PASI 100/EASI 100) and safe medicines are in development.</p>
<p>Targeted therapies need to be tailored to the endotypes of AD, and thus, depend on identification of relevant biomarkers of the underlying pathways that drive the disease.</p>
<p>The move from personalized medicine to precision health can be achieved by early intervention (‘treat early and hard’) and prevention (see Fig. <xref ref-type="fig" rid="apm12934-fig-0007">7</xref>). Strategies include vaccination and avoidance of triggering factors in predisposed individuals, who can be identified even before birth by genotyping their DNA.</p>
</sec>
</boxed-text>
<p>The author would like to acknowledge Hanne Norsgaard, Paola Lovato, Jakob Felding, and Witte Rush Koopman Jr. for insightful comments and suggestions for improvements, Adrian Ewald and Mette Vesterager for rhetorical sparring, and Michala Litman for lending a scratching hand (Fig. <xref ref-type="fig" rid="apm12934-fig-0002">2</xref>).</p>
</sec>
</body>
<back>
<fn-group id="apm12934-ntgp-0003">
<title>Notes</title>
<fn id="apm12934-note-1001">
<label>1</label>
<p>And for less than 400 EUR. At this price for WGS, direct‐to‐consumer genomics is a reality.</p>
</fn>
<fn id="apm12934-note-1002">
<label>2</label>
<p>and is extremely useful for stratifying according to pharmacokinetics (responders/non‐responders, fast/slow metabolizers, etc.), risk factors and targets [such as the around 300 driver genes and 3400+ driver mutations identified in cancer, crucial for precision oncology <xref ref-type="ref" rid="apm12934-bib-0030">30</xref>], and an absolute prerequisite for pharmacogenomics.</p>
</fn>
<fn id="apm12934-note-1003">
<label>3</label>
<p>Endotype: a subtype of a disease or a subgroup of a population defined by a shared, underlying disease mechanism <xref ref-type="ref" rid="apm12934-bib-0031">31</xref>. Diseases like asthma <xref ref-type="ref" rid="apm12934-bib-0032">32</xref> and AD <xref ref-type="ref" rid="apm12934-bib-0033">33</xref> encompass several endotypes (for example, those with or without filaggrin mutations), each with their characteristic, underlying pathophysiology. This is in contrast to the Phenotype: the appearance of a disease or an individual, i.e. its observable features or traits (size, shape, pattern, color, behavior, etc.). The phenotype is determined by the sum of interactions between genotype, epigenetic factors, and the environment. Endophenotype: Also known as an ‘intermediate phenotype’ is a quantitative, biologic characteristic that lies between the phenotype and genotype, but is mechanistically closer to the disease than its clinical phenotype; in this context, it corresponds to a biomarker profile <xref ref-type="ref" rid="apm12934-bib-0034">34</xref>.</p>
</fn>
<fn id="apm12934-note-1004">
<label>4</label>
<p>Again, Hippocrates should be recognized for introducing the central concept of prognostics, about which he remarked: ‘he will manage the cure best who foresees what is to happen from the present state of matters. For it is impossible to make all the sick well.’ <xref ref-type="ref" rid="apm12934-bib-0039">39</xref>
</p>
</fn>
<fn id="apm12934-note-1005">
<label>5</label>
<p>Sometimes such identification of responders (theratypes) to therapy is also called theratyping <xref ref-type="ref" rid="apm12934-bib-0041">41</xref>.</p>
</fn>
<fn id="apm12934-note-1006">
<label>6</label>
<p>or ‘panoromic’, a term coined by Eric Topol to emphasize the wide‐angle view of multiple approaches <xref ref-type="ref" rid="apm12934-bib-0022">22</xref>, although one could argue that it is not only a wide, but also a <italic>deep</italic> view across layers.</p>
</fn>
<fn id="apm12934-note-1007">
<label>7</label>
<p>less than 200 EUR, including strand‐specific library preparation and 30 million paired‐end reads per sample</p>
</fn>
<fn id="apm12934-note-1008">
<label>8</label>
<p>The same consideration applies to ‘standard’ gene expression analysis, where the observed differential gene expression between two samples can be due to both redistribution of different compartments and to actual up‐ or down‐regulation of gene expression.</p>
</fn>
<fn id="apm12934-note-1009">
<label>9</label>
<p>This EWAS acronym is not to be confused with the epigenome‐wide association studies mentioned before.</p>
</fn>
<fn id="apm12934-note-1010">
<label>10</label>
<p>The principles for personalized medicine outlined for PSO and AD also apply to other inflammatory skin diseases, including allergic conditions such as contact dermatitis and urticaria, and autoimmune diseases like vitiligo, alopecia areata, and lichen planus.</p>
</fn>
<fn id="apm12934-note-1011">
<label>11</label>
<p>Based on a world population estimate of 7.7 billion <xref ref-type="ref" rid="apm12934-bib-0124">124</xref> of which 26% are children of age 0–14.</p>
</fn>
<fn id="apm12934-note-1012">
<label>12</label>
<p>Because genetic changes take much longer (evolutionary) time to manifest. In addition, increased disease awareness (such as access to the Internet) may also partly explain the increase in prevalence.</p>
</fn>
<fn id="apm12934-note-1013">
<label>13</label>
<p>According to opentargets.org</p>
</fn>
<fn id="apm12934-note-1014">
<label>14</label>
<p>PASI 75 is a response rate and indicates the percentage of patients who have reached a 75% or more improvement (reduction) in their Psoriasis Area and Severity Index (PASI) score compared to baseline. PASI is a quantitative, composite measure of the severity and extent of psoriatic lesions taking into account erythema, thickness, and scaling of the lesions as well as percentage area affected. It is the most widely used tool in clinical trials for assessing psoriasis severity, although alternative, simpler to apply approaches, such as the Physician Global Assessment (PGA), have recently been proposed <xref ref-type="ref" rid="apm12934-bib-0170">170</xref>. As treatments become more effective, higher response rates are often reported, including PASI 90 and even PASI 100 (complete clearance of all disease) <xref ref-type="ref" rid="apm12934-bib-0171">171</xref>.</p>
</fn>
<fn id="apm12934-note-1015">
<label>15</label>
<p>Note, however, that accumulation of neutrophils is not limited to pustular forms of psoriasis, as <italic>Munro's microabscesses</italic> containing large collections of neutrophils in the stratum corneum of psoriasis vulgaris are considered a hallmark of PSO.</p>
</fn>
<fn id="apm12934-note-1016">
<label>16</label>
<p>Albeit promising, the dual IL‐17A/TNF inhibitors have been terminated in development due to safety concerns.</p>
</fn>
<fn id="apm12934-note-1017">
<label>17</label>
<p>EASI 75 is the percentage of patients who have reached a 75% or more reduction in their Eczema Area and Severity Index (EASI) score compared to baseline, in this case after 16 weeks of treatment. Other commonly used clinical measures of AD severity include SCORAD (Severity Scoring of Atopic Dermatitis, which includes both objective physician estimates of disease severity as well as subjective patient estimates of itch and sleep loss), and IGA (Investigator's Global Assessment), and because the three scores complement each other, it has been recommended to apply at least two independent assessment schemes for a reliable evaluation of AD <xref ref-type="ref" rid="apm12934-bib-0198">198</xref>. What is not captured by the above scores is the actual disease burden on QoL (quality of life) of AD patients, which is why several questionnaire‐based schemes have been proposed for a standardized QoL assessment, including Patient‐Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), ItchyQOL, and 5‐dimensions (5‐D) itch scales, all of which show good validity and internal consistency <xref ref-type="ref" rid="apm12934-bib-0199">199</xref>. Another important aspect when assessing the clinical efficacy of treatment is the placebo effect, which is notoriously high in AD, and which should therefore always be compared to the drug effect. For example, EASI 50 for the placebo arm was 35% compared to 85% for dupilumab in an early‐phase 12‐week study <xref ref-type="ref" rid="apm12934-bib-0200">200</xref>.</p>
</fn>
<fn id="apm12934-note-1018">
<label>18</label>
<p>And a very large mirror indeed; while the conservative estimate of skin surface area is 2 m<sup>2</sup>, then, if one takes the presence of hair follicles, sweat, and sebaceous glands into account, the total skin area – and thus the interface for interaction with the skin microbiome – is probably closer to 30 m<sup>2</sup>, as pointed out by Richard Gallo <xref ref-type="ref" rid="apm12934-bib-0236">236</xref>.</p>
</fn>
<fn id="apm12934-note-1019">
<label>19</label>
<p>Please see this inspiring TED talk by Steve McCarroll for the fruit analogy: <ext-link ext-link-type="uri" xlink:href="https://www.ted.com/talks/steve_mccarroll_how_data_is_helping_us_unravel_the_mysteries_of_the_brain">https://www.ted.com/talks/steve_mccarroll_how_data_is_helping_us_unravel_the_mysteries_of_the_brain</ext-link>
</p>
</fn>
</fn-group>
<ref-list content-type="cited-references" id="apm12934-bibl-0001">
<title>References</title>
<ref id="apm12934-bib-0001">
<label>1</label>
<mixed-citation id="apm12934-cit-0001" publication-type="journal">
<string-name>
<surname>Atherton</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Topical corticosteroids in atopic dermatitis</article-title>. <source xml:lang="en"/>BMJ
<year>2003</year>;<volume>23</volume>:<fpage>942</fpage>–<lpage>3</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0002">
<label>2</label>
<mixed-citation id="apm12934-cit-0002" publication-type="journal">
<string-name>
<surname>Vail</surname>
<given-names>J</given-names>
</string-name>. <article-title>Pharmacogenomics: the end of trial‐and‐error medicine?</article-title>
<source xml:lang="en"/>Int J Pharm Compd
<year>2007</year>;<volume>11</volume>:<fpage>59</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">23974487</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0003">
<label>3</label>
<mixed-citation id="apm12934-cit-0003" publication-type="journal">
<string-name>
<surname>Morgan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Lennard</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Anderton</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Eriksson</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Impact of a five‐dimensional framework on R&amp;D productivity at AstraZeneca</article-title>. <source xml:lang="en"/>Nat Rev Drug Discov
<year>2018</year>;<volume>17</volume>:<fpage>167</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">29348681</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0004">
<label>4</label>
<mixed-citation id="apm12934-cit-0004" publication-type="journal">
<string-name>
<surname>Rhen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Cidlowski</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Antiinflammatory action of glucocorticoids–new mechanisms for old drugs</article-title>. <source xml:lang="en"/>N Engl J Med
<year>2005</year>;<volume>353</volume>:<fpage>1711</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">16236742</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0005">
<label>5</label>
<mixed-citation id="apm12934-cit-0005" publication-type="journal">
<string-name>
<surname>van der Velden</surname>
<given-names>VH</given-names>
</string-name>. <article-title>Glucocorticoids: mechanisms of action and anti‐inflammatory potential in asthma</article-title>. <source xml:lang="en"/>Mediators Inflamm
<year>1998</year>;<volume>7</volume>:<fpage>229</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">9792333</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0006">
<label>6</label>
<mixed-citation id="apm12934-cit-0006" publication-type="journal">
<string-name>
<surname>Baida</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bhalla</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Yemelyanov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stechschulte</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Shou</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Readhead</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid‐induced skin atrophy</article-title>. <source xml:lang="en"/>Oncotarget
<year>2018</year>;<volume>9</volume>:<fpage>34772</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">30410676</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0007">
<label>7</label>
<mixed-citation id="apm12934-cit-0007" publication-type="journal">
<string-name>
<surname>Dhar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Seth</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>D</given-names>
</string-name>. <article-title>Systemic side‐effects of topical corticosteroids</article-title>. <source xml:lang="en"/>Indian J Dermatol
<year>2014</year>;<volume>59</volume>:<fpage>460</fpage>.<pub-id pub-id-type="pmid">25284850</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0008">
<label>8</label>
<mixed-citation id="apm12934-cit-0008" publication-type="journal">
<string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?</article-title>
<source xml:lang="en"/>Curr Opin Immunol
<year>2017</year>;<volume>48</volume>:<fpage>68</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">28869867</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0009">
<label>9</label>
<mixed-citation id="apm12934-cit-0009" publication-type="journal">
<string-name>
<surname>Weidinger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Beck</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bieber</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kabashima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Atopic dermatitis</article-title>. <source xml:lang="en"/>Nat Rev Dis Primers
<year>2018</year>;<volume>4</volume>:<fpage>984</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0010">
<label>10</label>
<mixed-citation id="apm12934-cit-0010" publication-type="journal">
<string-name>
<surname>Griffiths</surname>
<given-names>CEM</given-names>
</string-name>, <string-name>
<surname>van de Kerkhof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Czarnecka‐Operacz</surname>
<given-names>M</given-names>
</string-name>. <article-title>Psoriasis and atopic dermatitis</article-title>. <source xml:lang="en"/>Dermatol Ther
<year>2017</year>;<volume>7</volume>(<issue>Suppl 1</issue>):<fpage>31</fpage>–<lpage>41</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0011">
<label>11</label>
<mixed-citation id="apm12934-cit-0011" publication-type="journal">
<string-name>
<surname>Bieber</surname>
<given-names>T</given-names>
</string-name>. <article-title>Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine</article-title>. <source xml:lang="en"/>Allergy
<year>2012</year>;<volume>67</volume>:<fpage>1475</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">23106343</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0012">
<label>12</label>
<mixed-citation id="apm12934-cit-0012" publication-type="journal">
<string-name>
<surname>Hawkes</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Psoriasis pathogenesis and the development of novel targeted immune therapies</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2017</year>;<volume>140</volume>:<fpage>645</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">28887948</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0013">
<label>13</label>
<mixed-citation id="apm12934-cit-0013" publication-type="journal">
<string-name>
<surname>Gibson</surname>
<given-names>WM</given-names>
</string-name>. <article-title>Can personalized medicine survive?</article-title>
<source xml:lang="en"/>Can Fam Physician
<year>1971</year>;<volume>17</volume>:<fpage>29</fpage>–<lpage>88</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0014">
<label>14</label>
<mixed-citation id="apm12934-cit-0014" publication-type="journal">
<string-name>
<surname>Arnold</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Forrow</surname>
<given-names>L</given-names>
</string-name>. <article-title>Rewarding medicine: good doctors and good behavior</article-title>. <source xml:lang="en"/>Ann Intern Med
<year>1990</year>;<volume>113</volume>:<fpage>794</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">2240883</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0015">
<label>15</label>
<mixed-citation id="apm12934-cit-0015" publication-type="book">
<string-name>
<surname>Abrahams</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Silver</surname>
<given-names>M</given-names>
</string-name>. <chapter-title>The history of personalized medicine</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Gordon</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Koslow</surname><given-names>S</given-names></name></person-group>, editors. <source xml:lang="en"/>Integrative Neuroscience and Personalized Medicine. <publisher-loc>England, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>2010</year>: <fpage>3</fpage>–<lpage>16</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0016">
<label>16</label>
<mixed-citation id="apm12934-cit-0016" publication-type="journal">
<string-name>
<surname>Lamberti</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Awatin</surname>
<given-names>J</given-names>
</string-name>. <article-title>Mapping the landscape of patient‐centric activities within clinical research</article-title>. <source xml:lang="en"/>Clin Ther
<year>2017</year>;<volume>39</volume>:<fpage>2196</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="pmid">29032849</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0017">
<label>17</label>
<mixed-citation id="apm12934-cit-0017" publication-type="book">
<collab collab-type="authors">National Research Council (US)</collab>
. <chapter-title>Committee on a framework for developing a new taxonomy of disease. Glossary</chapter-title>
<source xml:lang="en"/>Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>, <year>2011</year>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0018">
<label>18</label>
<mixed-citation id="apm12934-cit-0018" publication-type="journal">
<string-name>
<surname>Siest</surname>
<given-names>G</given-names>
</string-name>. <article-title>Systems medicine, stratified medicine, personalized medicine but not precision medicine</article-title>. <source xml:lang="en"/>Drug Metabol Drug Interact
<year>2014</year>;<volume>29</volume>:<fpage>1</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">24468611</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0019">
<label>19</label>
<mixed-citation id="apm12934-cit-0019" publication-type="journal">
<string-name>
<surname>Strebhardt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ullrich</surname>
<given-names>A</given-names>
</string-name>. <article-title>Paul Ehrlich's magic bullet concept: 100 years of progress</article-title>. <source xml:lang="en"/>Nat Rev Cancer
<year>2008</year>;<volume>8</volume>:<fpage>473</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">18469827</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0020">
<label>20</label>
<mixed-citation id="apm12934-cit-0020" publication-type="journal">
<string-name>
<surname>Pirmohamed</surname>
<given-names>M</given-names>
</string-name>. <article-title>Pharmacogenetics and pharmacogenomics</article-title>. <source xml:lang="en"/>Br J Clin Pharmacol
<year>2001</year>;<volume>52</volume>:<fpage>345</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">11678777</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0021">
<label>21</label>
<mixed-citation id="apm12934-cit-0021" publication-type="miscellaneous">
<collab collab-type="authors">Genetics Home Reference</collab>
. <article-title>What is pharmacogenomics? [Internet]</article-title>. Genetics Home Reference. Available from: <ext-link ext-link-type="uri" xlink:href="https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics">https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics</ext-link> [cited 2018 Sep 22].</mixed-citation>
</ref>
<ref id="apm12934-bib-0022">
<label>22</label>
<mixed-citation id="apm12934-cit-0022" publication-type="journal">
<string-name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Individualized medicine from prewomb to tomb</article-title>. <source xml:lang="en"/>Cell
<year>2014</year>;<volume>157</volume>:<fpage>241</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">24679539</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0023">
<label>23</label>
<mixed-citation id="apm12934-cit-0023" publication-type="journal">
<string-name>
<surname>Trusheim</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Berndt</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Douglas</surname>
<given-names>FL</given-names>
</string-name>. <article-title>Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers</article-title>. <source xml:lang="en"/>Nat Rev Drug Discov
<year>2007</year>;<volume>6</volume>:<fpage>287</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">17380152</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0024">
<label>24</label>
<mixed-citation id="apm12934-cit-0024" publication-type="journal">
<string-name>
<surname>Dias</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Paulo Silva Cunha</surname>
<given-names>J</given-names>
</string-name>. <article-title>Wearable Health devices‐vital sign monitoring, systems and technologies</article-title>. <source xml:lang="en"/>Sensors
<year>2018</year>;<volume>18</volume>:<fpage>pii: E2414</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0025">
<label>25</label>
<mixed-citation id="apm12934-cit-0025" publication-type="journal">
<string-name>
<surname>Flores</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Glusman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Brogaard</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Hood</surname>
<given-names>L</given-names>
</string-name>. <article-title>P4 medicine: how systems medicine will transform the healthcare sector and society</article-title>. <source xml:lang="en"/>Per Med
<year>2013</year>;<volume>10</volume>:<fpage>565</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">25342952</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0026">
<label>26</label>
<mixed-citation id="apm12934-cit-0026" publication-type="journal">
<string-name>
<surname>Reardon</surname>
<given-names>S</given-names>
</string-name>. <article-title>US tailored‐medicine project aims for ethnic balance</article-title>. <source xml:lang="en"/>Nature
<year>2015</year>;<volume>523</volume>:<fpage>391</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">26201574</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0027">
<label>27</label>
<mixed-citation id="apm12934-cit-0027" publication-type="journal">
<string-name>
<surname>Lemke</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Kernland‐Lang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hörtnagel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Itin</surname>
<given-names>P</given-names>
</string-name>. <article-title>Monogenic human skin disorders</article-title>. <source xml:lang="en"/>Dermatology
<year>2014</year>;<volume>229</volume>:<fpage>55</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">25012694</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0028">
<label>28</label>
<mixed-citation id="apm12934-cit-0028" publication-type="journal">
<string-name>
<surname>Litman</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Druley</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>WD</given-names>
</string-name>, <string-name>
<surname>Bates</surname>
<given-names>SE</given-names>
</string-name>. <article-title>From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance</article-title>. <source xml:lang="en"/>Cell Mol Life Sci
<year>2001</year>;<volume>58</volume>:<fpage>931</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">11497241</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0029">
<label>29</label>
<mixed-citation id="apm12934-cit-0029" publication-type="journal">
<string-name>
<surname>Hirsch</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rothoeft</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Teig</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Pellegrini</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>De Rosa</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Regeneration of the entire human epidermis using transgenic stem cells</article-title>. <source xml:lang="en"/>Nature
<year>2017</year>;<volume>551</volume>:<fpage>327</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">29144448</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0030">
<label>30</label>
<mixed-citation id="apm12934-cit-0030" publication-type="journal">
<string-name>
<surname>Bailey</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Tokheim</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Porta‐Pardo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sengupta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bertrand</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Weerasinghe</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Comprehensive characterization of cancer driver genes and mutations</article-title>. <source xml:lang="en"/>Cell
<year>2018</year>;<volume>174</volume>:<fpage>1034</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">30096302</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0031">
<label>31</label>
<mixed-citation id="apm12934-cit-0031" publication-type="journal">
<string-name>
<surname>Agache</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Rogozea</surname>
<given-names>L</given-names>
</string-name>. <article-title>Endotypes in allergic diseases</article-title>. <source xml:lang="en"/>Curr Opin Allergy Clin Immunol
<year>2018</year>;<volume>8</volume>:<fpage>177</fpage>–<lpage>83</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0032">
<label>32</label>
<mixed-citation id="apm12934-cit-0032" publication-type="journal">
<string-name>
<surname>Lötvall</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Akdis</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Bacharier</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Bjermer</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Casale</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Custovic</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2011</year>;<volume>127</volume>:<fpage>355</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">21281866</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0033">
<label>33</label>
<mixed-citation id="apm12934-cit-0033" publication-type="journal">
<string-name>
<surname>Carson</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Thyssen</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Menné</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bisgaard</surname>
<given-names>H</given-names>
</string-name>. <article-title>Clinical presentation of atopic dermatitis by filaggrin gene mutation status during the first 7 years of life in a prospective cohort study</article-title>. <source xml:lang="en"/>PLoS ONE
<year>2012</year>;<volume>7</volume>:<fpage>e48678</fpage>.<pub-id pub-id-type="pmid">23166590</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0034">
<label>34</label>
<mixed-citation id="apm12934-cit-0034" publication-type="journal">
<string-name>
<surname>Bieber</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>D'Erme</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Akdis</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Traidl‐Hoffmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lauener</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schäppi</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?</article-title>
<source xml:lang="en"/>J Allergy Clin Immunol
<year>2017</year>;<volume>139</volume>:<fpage>S58</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">28390478</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0035">
<label>35</label>
<mixed-citation id="apm12934-cit-0035" publication-type="journal">
<string-name>
<surname>Kearns</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>DW</given-names>
</string-name>. <article-title>Improving the specificity of PSA screening with serum and urine markers</article-title>. <source xml:lang="en"/>Curr Urol Rep
<year>2018</year>;<volume>19</volume>:<fpage>80</fpage>.<pub-id pub-id-type="pmid">30105509</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0036">
<label>36</label>
<mixed-citation id="apm12934-cit-0036" publication-type="journal">
<string-name>
<surname>Palmirotta</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lovero</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cafforio</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Felici</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mannavola</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Pellè</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology</article-title>. <source xml:lang="en"/>Ther Adv Med Oncol
<year>2018</year>;<volume>10</volume>:<fpage>1758835918794630</fpage>.<pub-id pub-id-type="pmid">30181785</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0037">
<label>37</label>
<mixed-citation id="apm12934-cit-0037" publication-type="journal">
<string-name>
<surname>Agache</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Akdis</surname>
<given-names>CA</given-names>
</string-name>. <article-title>Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine</article-title>. <source xml:lang="en"/>Allergol Int
<year>2016</year>;<volume>65</volume>:<fpage>243</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">27282212</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0038">
<label>38</label>
<mixed-citation id="apm12934-cit-0038" publication-type="miscellaneous">
<article-title>ICD‐11 [Internet]</article-title>. Available from: <ext-link ext-link-type="uri" xlink:href="https://icd.who.int/">https://icd.who.int/</ext-link> [cited 2018 Sep 27].</mixed-citation>
</ref>
<ref id="apm12934-bib-0039">
<label>39</label>
<mixed-citation id="apm12934-cit-0039" publication-type="book">
<string-name>
<surname>Adams</surname>
<given-names>F</given-names>
</string-name>. <source xml:lang="en"/>The Genuine Works of Hippocrates. <publisher-loc>London</publisher-loc>: <publisher-name>The Sydenham Society</publisher-name>, <year>1849</year>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0040">
<label>40</label>
<mixed-citation id="apm12934-cit-0040" publication-type="book">
<collab collab-type="authors">FDA‐NIH Biomarker Working Group</collab>
. <chapter-title>Prognostic biomarker</chapter-title>
<source xml:lang="en"/>BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>Food and Drug Administration</publisher-name>; <year>2016</year>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0041">
<label>41</label>
<mixed-citation id="apm12934-cit-0041" publication-type="journal">
<string-name>
<surname>Kucuksezer</surname>
<given-names>UC</given-names>
</string-name>, <string-name>
<surname>Ozdemir</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Akdis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Akdis</surname>
<given-names>CA</given-names>
</string-name>. <article-title>Precision/personalized medicine in allergic diseases and asthma</article-title>. <source xml:lang="en"/>Arch Immunol Ther Exp
<year>2018</year>;<volume>66</volume>:<fpage>431</fpage>–<lpage>42</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0042">
<label>42</label>
<mixed-citation id="apm12934-cit-0042" publication-type="journal">
<string-name>
<surname>Dong</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ong</surname>
<given-names>CE</given-names>
</string-name>. <article-title>Cytochrome P450 genotype‐guided drug therapies: an update on current states</article-title>. <source xml:lang="en"/>Clin Exp Pharmacol Physiol
<year>2018</year>;<volume>45</volume>:<fpage>991</fpage>–<lpage>1001</lpage>.<pub-id pub-id-type="pmid">29858511</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0043">
<label>43</label>
<mixed-citation id="apm12934-cit-0043" publication-type="journal">
<string-name>
<surname>Barbarino</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Whirl‐Carrillo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>TE</given-names>
</string-name>. <article-title>PharmGKB: a worldwide resource for pharmacogenomic information</article-title>. <source xml:lang="en"/>Wiley Interdiscip Rev Syst Biol Med
<year>2018</year>;<volume>10</volume>:<fpage>e1417</fpage>.<pub-id pub-id-type="pmid">29474005</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0044">
<label>44</label>
<mixed-citation id="apm12934-cit-0044" publication-type="journal">
<string-name>
<surname>Ovejero‐Benito</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Muñoz‐Aceituno</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Reolid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Saiz‐Rodríguez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Abad‐Santos</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Daudén</surname>
<given-names>E</given-names>
</string-name>. <article-title>Pharmacogenetics and pharmacogenomics in moderate‐to‐severe psoriasis</article-title>. <source xml:lang="en"/>Am J Clin Dermatol
<year>2018</year>;<volume>19</volume>:<fpage>209</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">28921458</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0045">
<label>45</label>
<mixed-citation id="apm12934-cit-0045" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fong</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Identifying optimal biomarker combinations for treatment selection via a robust kernel method</article-title>. <source xml:lang="en"/>Biometrics
<year>2014</year>;<volume>70</volume>:<fpage>891</fpage>–<lpage>901</lpage>.<pub-id pub-id-type="pmid">25124089</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0046">
<label>46</label>
<mixed-citation id="apm12934-cit-0046" publication-type="journal">
<string-name>
<surname>Ralfkiaer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Hagedorn</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Bangsgaard</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Løvendorf</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Ahler</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Svensson</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Diagnostic microRNA profiling in cutaneous T‐cell lymphoma (CTCL)</article-title>. <source xml:lang="en"/>Blood
<year>2011</year>;<volume>118</volume>:<fpage>5891</fpage>–<lpage>900</lpage>.<pub-id pub-id-type="pmid">21865341</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0047">
<label>47</label>
<mixed-citation id="apm12934-cit-0047" publication-type="journal">
<string-name>
<surname>Marstrand</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ahler</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Ralfkiaer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Clemmensen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kopp</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Sibbesen</surname>
<given-names>NA</given-names>
</string-name>, et al. <article-title>Validation of a diagnostic microRNA classifier in cutaneous T‐cell lymphomas</article-title>. <source xml:lang="en"/>Leuk Lymphoma
<year>2014</year>;<volume>55</volume>:<fpage>957</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">23772646</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0048">
<label>48</label>
<mixed-citation id="apm12934-cit-0048" publication-type="journal">
<string-name>
<surname>Augello</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Noll</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Distel</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Wainright</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Stout</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Ford</surname>
<given-names>BD</given-names>
</string-name>. <article-title>Identification of novel blood biomarker panels to detect ischemic stroke in patients and their responsiveness to therapeutic intervention</article-title>. <source xml:lang="en"/>Brain Res
<year>2018</year>;<volume>1698</volume>:<fpage>161</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">30099039</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0049">
<label>49</label>
<mixed-citation id="apm12934-cit-0049" publication-type="journal">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Venable</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Griswold</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pappas</surname>
<given-names>D</given-names>
</string-name>. <article-title>Combined CD25, CD64, and CD69 biomarker panel for flow cytometry diagnosis of sepsis</article-title>. <source xml:lang="en"/>Talanta
<year>2019</year>;<volume>191</volume>:<fpage>216</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">30262053</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0050">
<label>50</label>
<mixed-citation id="apm12934-cit-0050" publication-type="journal">
<string-name>
<surname>Kumar</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mandhani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sankhwar</surname>
<given-names>SN</given-names>
</string-name>. <article-title>Metabolomics‐derived prostate cancer biomarkers: fact or fiction?</article-title>
<source xml:lang="en"/>J Proteome Res
<year>2015</year>;<volume>14</volume>:<fpage>1455</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">25609016</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0051">
<label>51</label>
<mixed-citation id="apm12934-cit-0051" publication-type="journal">
<string-name>
<surname>Thijs</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Strickland</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bruijnzeel‐Koomen</surname>
<given-names>CAFM</given-names>
</string-name>, <string-name>
<surname>Nierkens</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Giovannone</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Csomor</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2017</year>;<volume>140</volume>:<fpage>730</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">28412391</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0052">
<label>52</label>
<mixed-citation id="apm12934-cit-0052" publication-type="journal">
<string-name>
<surname>Redenšek</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dolžan</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kunej</surname>
<given-names>T</given-names>
</string-name>. <article-title>From genomics to omics landscapes of Parkinson's disease: revealing the molecular mechanisms</article-title>. <source xml:lang="en"/>OMICS
<year>2018</year>;<volume>22</volume>:<fpage>1</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">29356624</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0053">
<label>53</label>
<mixed-citation id="apm12934-cit-0053" publication-type="journal">
<string-name>
<surname>Johnson</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Ivanisevic</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Siuzdak</surname>
<given-names>G</given-names>
</string-name>. <article-title>Metabolomics: beyond biomarkers and towards mechanisms</article-title>. <source xml:lang="en"/>Nat Rev Mol Cell Biol
<year>2016</year>;<volume>17</volume>:<fpage>451</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">26979502</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0054">
<label>54</label>
<mixed-citation id="apm12934-cit-0054" publication-type="journal">
<string-name>
<surname>Karczewski</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Snyder</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Integrative omics for health and disease</article-title>. <source xml:lang="en"/>Nat Rev Genet
<year>2018</year>;<volume>19</volume>:<fpage>299</fpage>–<lpage>310</lpage>.<pub-id pub-id-type="pmid">29479082</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0055">
<label>55</label>
<mixed-citation id="apm12934-cit-0055" publication-type="journal">
<string-name>
<surname>Caspar</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Dubacher</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kopps</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Meienberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Henggeler</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Matyas</surname>
<given-names>G</given-names>
</string-name>. <article-title>Clinical sequencing: from raw data to diagnosis with lifetime value</article-title>. <source xml:lang="en"/>Clin Genet
<year>2018</year>;<volume>93</volume>:<fpage>508</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="pmid">29206278</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0056">
<label>56</label>
<mixed-citation id="apm12934-cit-0056" publication-type="journal">
<string-name>
<surname>Ortiz</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>M</given-names>
</string-name>. <article-title>Analyzing circulating tumor cells one at a time</article-title>. <source xml:lang="en"/>Trends Cell Biol
<year>2018</year>;<volume>28</volume>:<fpage>764</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">29891227</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0057">
<label>57</label>
<mixed-citation id="apm12934-cit-0057" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>XS</given-names>
</string-name>. <article-title>Single‐cell whole‐genome amplification and sequencing: methodology and applications</article-title>. <source xml:lang="en"/>Annu Rev Genomics Hum Genet
<year>2015</year>;<volume>16</volume>:<fpage>79</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">26077818</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0058">
<label>58</label>
<mixed-citation id="apm12934-cit-0058" publication-type="journal">
<string-name>
<surname>Ichinohe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Miyama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kawase</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Honjo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kitaura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Next‐generation immune repertoire sequencing as a clue to elucidate the landscape of immune modulation by host‐gut microbiome interactions</article-title>. <source xml:lang="en"/>Front Immunol
<year>2018</year>;<volume>9</volume>:<fpage>668</fpage>.<pub-id pub-id-type="pmid">29666626</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0059">
<label>59</label>
<mixed-citation id="apm12934-cit-0059" publication-type="journal">
<string-name>
<surname>Auer</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Newsom</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Kornacker</surname>
<given-names>K</given-names>
</string-name>. <article-title>Expression profiling using Affymetrix genechip microarrays</article-title>. <source xml:lang="en"/>Methods Mol Biol
<year>2009</year>;<volume>509</volume>:<fpage>35</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">19212713</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0060">
<label>60</label>
<mixed-citation id="apm12934-cit-0060" publication-type="journal">
<string-name>
<surname>McGettigan</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Transcriptomics in the RNA‐seq era</article-title>. <source xml:lang="en"/>Curr Opin Chem Biol
<year>2013</year>;<volume>17</volume>:<fpage>4</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">23290152</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0061">
<label>61</label>
<mixed-citation id="apm12934-cit-0061" publication-type="journal">
<string-name>
<surname>Spies</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ciaudo</surname>
<given-names>C</given-names>
</string-name>. <article-title>Dynamics in transcriptomics: advancements in RNA‐seq time course and downstream analysis</article-title>. <source xml:lang="en"/>Comput Struct Biotechnol J
<year>2015</year>;<volume>13</volume>:<fpage>469</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">26430493</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0062">
<label>62</label>
<mixed-citation id="apm12934-cit-0062" publication-type="journal">
<string-name>
<surname>Nguyen</surname>
<given-names>QH</given-names>
</string-name>, <string-name>
<surname>Pervolarakis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nee</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kessenbrock</surname>
<given-names>K</given-names>
</string-name>. <article-title>Experimental considerations for single‐cell RNA sequencing approaches</article-title>. <source xml:lang="en"/>Front Cell Dev Biol
<year>2018</year>;<volume>6</volume>:<fpage>108</fpage>.<pub-id pub-id-type="pmid">30234113</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0063">
<label>63</label>
<mixed-citation id="apm12934-cit-0063" publication-type="journal">
<string-name>
<surname>Dasgupta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bader</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Goyal</surname>
<given-names>S</given-names>
</string-name>. <article-title>Single‐cell RNA sequencing: a new window into cell scale dynamics</article-title>. <source xml:lang="en"/>Biophys J
<year>2018</year>;<volume>115</volume>:<fpage>429</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">30033145</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0064">
<label>64</label>
<mixed-citation id="apm12934-cit-0064" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Daugharthy</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Scheiman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kalhor</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ferrante</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Terry</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues</article-title>. <source xml:lang="en"/>Nat Protoc
<year>2015</year>;<volume>10</volume>:<fpage>442</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">25675209</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0065">
<label>65</label>
<mixed-citation id="apm12934-cit-0065" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Sylwestrak</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Samusik</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Vesuna</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Three‐dimensional intact‐tissue sequencing of single‐cell transcriptional states</article-title>. <source xml:lang="en"/>Science
<year>2018</year>;<volume>361</volume>:<fpage>pii: eaat5691</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0066">
<label>66</label>
<mixed-citation id="apm12934-cit-0066" publication-type="journal">
<string-name>
<surname>Strell</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hilscher</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Laxman</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Svedlund</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Yokota</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Placing RNA in context and space ‐ methods for spatially resolved transcriptomics</article-title>. <source xml:lang="en"/>FEBS J
<year>2018</year>
<pub-id pub-id-type="doi">10.1111/febs.14435</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0067">
<label>67</label>
<mixed-citation id="apm12934-cit-0067" publication-type="journal">
<string-name>
<surname>Tost</surname>
<given-names>J</given-names>
</string-name>. <article-title>A translational perspective on epigenetics in allergic diseases</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>142</volume>:<fpage>715</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">30195377</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0068">
<label>68</label>
<mixed-citation id="apm12934-cit-0068" publication-type="journal">
<string-name>
<surname>Jin</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>. <article-title>DNA methylation in human diseases</article-title>. <source xml:lang="en"/>Genes Dis
<year>2018</year>;<volume>5</volume>:<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">30258928</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0069">
<label>69</label>
<mixed-citation id="apm12934-cit-0069" publication-type="journal">
<string-name>
<surname>Rivera</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>B</given-names>
</string-name>. <article-title>Mapping human epigenomes</article-title>. <source xml:lang="en"/>Cell
<year>2013</year>;<volume>155</volume>:<fpage>39</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">24074860</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0070">
<label>70</label>
<mixed-citation id="apm12934-cit-0070" publication-type="journal">
<string-name>
<surname>Costa‐Pinheiro</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Montezuma</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Henrique</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jerónimo</surname>
<given-names>C</given-names>
</string-name>. <article-title>Diagnostic and prognostic epigenetic biomarkers in cancer</article-title>. <source xml:lang="en"/>Epigenomics
<year>2015</year>;<volume>7</volume>:<fpage>1003</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">26479312</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0071">
<label>71</label>
<mixed-citation id="apm12934-cit-0071" publication-type="journal">
<string-name>
<surname>Luchenko</surname>
<given-names>VL</given-names>
</string-name>, <string-name>
<surname>Litman</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chakraborty</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Heffner</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Devor</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wilkerson</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Histone deacetylase inhibitor‐mediated cell death is distinct from its global effect on chromatin</article-title>. <source xml:lang="en"/>Mol Oncol
<year>2014</year>;<volume>8</volume>:<fpage>1379</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">24954856</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0072">
<label>72</label>
<mixed-citation id="apm12934-cit-0072" publication-type="journal">
<string-name>
<surname>Calin</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Sevignani</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dumitru</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Hyslop</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Noch</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Yendamuri</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci U S A
<year>2004</year>;<volume>101</volume>:<fpage>2999</fpage>–<lpage>3004</lpage>.<pub-id pub-id-type="pmid">14973191</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0073">
<label>73</label>
<mixed-citation id="apm12934-cit-0073" publication-type="journal">
<string-name>
<surname>Nygaard</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jacobsen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lindow</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eriksen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Balslev</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Flyger</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Identification and analysis of miRNAs in human breast cancer and teratoma samples using deep sequencing</article-title>. <source xml:lang="en"/>BMC Med Genomics
<year>2009</year>;<volume>2</volume>:<fpage>35</fpage>.<pub-id pub-id-type="pmid">19508715</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0074">
<label>74</label>
<mixed-citation id="apm12934-cit-0074" publication-type="journal">
<string-name>
<surname>Martens‐Uzunova</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Jalava</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Dits</surname>
<given-names>NF</given-names>
</string-name>, <string-name>
<surname>van Leenders</surname>
<given-names>GJLH</given-names>
</string-name>, <string-name>
<surname>Møller</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Trapman</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Diagnostic and prognostic signatures from the small non‐coding RNA transcriptome in prostate cancer</article-title>. <source xml:lang="en"/>Oncogene
<year>2012</year>;<volume>31</volume>:<fpage>978</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">21765474</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0075">
<label>75</label>
<mixed-citation id="apm12934-cit-0075" publication-type="journal">
<string-name>
<surname>Gaedcke</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Grade</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Camps</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sokilde</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kaczkowski</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Schetter</surname>
<given-names>AJ</given-names>
</string-name>, et al. <article-title>The rectal cancer microRNAome ‐ microRNA expression in rectal cancer and matched normal mucosa</article-title>. <source xml:lang="en"/>Clin Cancer Res
<year>2012</year>;<volume>18</volume>:<fpage>4919</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">22850566</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0076">
<label>76</label>
<mixed-citation id="apm12934-cit-0076" publication-type="journal">
<string-name>
<surname>Søkilde</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Møller</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Høiby</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Blondal</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Efficient identification of miRNAs for classification of tumor origin</article-title>. <source xml:lang="en"/>J Mol Diagn
<year>2014</year>;<volume>16</volume>:<fpage>106</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">24211363</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0077">
<label>77</label>
<mixed-citation id="apm12934-cit-0077" publication-type="journal">
<string-name>
<surname>Lindahl</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Besenbacher</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rittig</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Celis</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Willerslev‐Olsen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gjerdrum</surname>
<given-names>LMR</given-names>
</string-name>, et al. <article-title>Prognostic miRNA classifier in early‐stage mycosis fungoides: development and validation in a Danish nationwide study</article-title>. <source xml:lang="en"/>Blood
<year>2017</year>;<volume>131</volume>:<fpage>759</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">29208599</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0078">
<label>78</label>
<mixed-citation id="apm12934-cit-0078" publication-type="journal">
<string-name>
<surname>Bork‐Jensen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Scheele</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Christophersen</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Nilsson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Friedrichsen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fernandez‐Twinn</surname>
<given-names>DS</given-names>
</string-name>, et al. <article-title>Glucose tolerance is associated with differential expression of microRNAs in skeletal muscle: results from studies of twins with and without type 2 diabetes</article-title>. <source xml:lang="en"/>Diabetologia
<year>2015</year>;<volume>58</volume>:<fpage>363</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">25403480</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0079">
<label>79</label>
<mixed-citation id="apm12934-cit-0079" publication-type="journal">
<string-name>
<surname>Zibert</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Løvendorf</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Litman</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kaczkowski</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Skov</surname>
<given-names>L</given-names>
</string-name>. <article-title>MicroRNAs and potential target interactions in psoriasis</article-title>. <source xml:lang="en"/>J Dermatol Sci
<year>2010</year>;<volume>58</volume>:<fpage>177</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">20417062</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0080">
<label>80</label>
<mixed-citation id="apm12934-cit-0080" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>R‐Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>M‐J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>X‐M</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Q‐C</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>C‐J</given-names>
</string-name>. <article-title>An exploration of the role of MicroRNAs in psoriasis: a systematic review of the literature</article-title>. <source xml:lang="en"/>Medicine
<year>2015</year>;<volume>94</volume>:<fpage>e2030</fpage>.<pub-id pub-id-type="pmid">26559308</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0081">
<label>81</label>
<mixed-citation id="apm12934-cit-0081" publication-type="journal">
<string-name>
<surname>Løvendorf</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Skov</surname>
<given-names>L</given-names>
</string-name>. <article-title>miRNAs in inflammatory skin diseases and their clinical implications</article-title>. <source xml:lang="en"/>Expert Rev Clin Immunol
<year>2015</year>;<volume>11</volume>:<fpage>467</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">25719822</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0082">
<label>82</label>
<mixed-citation id="apm12934-cit-0082" publication-type="journal">
<string-name>
<surname>Rożalski</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rudnicka</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Samochocki</surname>
<given-names>Z</given-names>
</string-name>. <article-title>MiRNA in atopic dermatitis</article-title>. <source xml:lang="en"/>Postepy Dermatol Alergol
<year>2016</year>;<volume>33</volume>:<fpage>157</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">27512348</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0083">
<label>83</label>
<mixed-citation id="apm12934-cit-0083" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sood</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Dang</surname>
<given-names>CV</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>
<given-names>X</given-names>
</string-name>. <article-title>Shedding light on the dark cancer genomes: long noncoding RNAs as novel biomarkers and potential therapeutic targets for cancer</article-title>. <source xml:lang="en"/>Mol Cancer Ther
<year>2018</year>;<volume>17</volume>:<fpage>1816</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">30181330</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0084">
<label>84</label>
<mixed-citation id="apm12934-cit-0084" publication-type="journal">
<string-name>
<surname>Elling</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fitzgerald</surname>
<given-names>KA</given-names>
</string-name>. <article-title>Emerging role of long noncoding RNAs as regulators of innate immune cell development and inflammatory gene expression</article-title>. <source xml:lang="en"/>Eur J Immunol
<year>2016</year>;<volume>46</volume>:<fpage>504</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">26820238</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0085">
<label>85</label>
<mixed-citation id="apm12934-cit-0085" publication-type="journal">
<string-name>
<surname>Rogers</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Girolami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kolch</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Waters</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Thrall</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models</article-title>. <source xml:lang="en"/>Bioinformatics
<year>2008</year>;<volume>24</volume>:<fpage>2894</fpage>–<lpage>900</lpage>.<pub-id pub-id-type="pmid">18974169</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0086">
<label>86</label>
<mixed-citation id="apm12934-cit-0086" publication-type="journal">
<string-name>
<surname>Hausser</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zavolan</surname>
<given-names>M</given-names>
</string-name>. <article-title>Identification and consequences of miRNA‐target interactions–beyond repression of gene expression</article-title>. <source xml:lang="en"/>Nat Rev Genet
<year>2014</year>;<volume>15</volume>:<fpage>599</fpage>–<lpage>612</lpage>.<pub-id pub-id-type="pmid">25022902</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0087">
<label>87</label>
<mixed-citation id="apm12934-cit-0087" publication-type="journal">
<string-name>
<surname>Petsalaki</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Helbig</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Gopal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pasculescu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Roth</surname>
<given-names>FP</given-names>
</string-name>, <string-name>
<surname>Pawson</surname>
<given-names>T</given-names>
</string-name>. <article-title>SELPHI: correlation‐based identification of kinase‐associated networks from global phospho‐proteomics data sets</article-title>. <source xml:lang="en"/>Nucleic Acids Res
<year>2015</year>;<volume>43</volume>
<issue>W1</issue>:<fpage>W276</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">25948583</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0088">
<label>88</label>
<mixed-citation id="apm12934-cit-0088" publication-type="journal">
<string-name>
<surname>Peng</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>X‐X</given-names>
</string-name>. <article-title>Functional metabolomics: from biomarker discovery to metabolome reprogramming</article-title>. <source xml:lang="en"/>Protein Cell
<year>2015</year>;<volume>6</volume>:<fpage>628</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">26135925</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0089">
<label>89</label>
<mixed-citation id="apm12934-cit-0089" publication-type="journal">
<string-name>
<surname>Rattray</surname>
<given-names>NJW</given-names>
</string-name>, <string-name>
<surname>Hamrang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Trivedi</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Goodacre</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fowler</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Taking your breath away: metabolomics breathes life in to personalized medicine</article-title>. <source xml:lang="en"/>Trends Biotechnol
<year>2014</year>;<volume>32</volume>:<fpage>538</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">25179940</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0090">
<label>90</label>
<mixed-citation id="apm12934-cit-0090" publication-type="journal">
<string-name>
<surname>Hao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Greer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Vezina</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Macoska</surname>
<given-names>JA</given-names>
</string-name>, et al. <article-title>In‐depth characterization and validation of human urine metabolomes reveal novel metabolic signatures of lower urinary tract symptoms</article-title>. <source xml:lang="en"/>Sci Rep
<year>2016</year>;<volume>6</volume>:<fpage>30869</fpage>.<pub-id pub-id-type="pmid">27502322</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0091">
<label>91</label>
<mixed-citation id="apm12934-cit-0091" publication-type="journal">
<string-name>
<surname>Røpke</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Alonso</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Norsgaard</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Richter</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Darvin</surname>
<given-names>ME</given-names>
</string-name>, et al. <article-title>Effects of glucocorticoids on stratum corneum lipids and function in human skin—A detailed lipidomic analysis</article-title>. <source xml:lang="en"/>J Dermatol Sci
<year>2017</year>;<volume>88</volume>:<fpage>330</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">28911799</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0092">
<label>92</label>
<mixed-citation id="apm12934-cit-0092" publication-type="journal">
<string-name>
<surname>Lauc</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pezer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rudan</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>H</given-names>
</string-name>. <article-title>Mechanisms of disease: the human N‐glycome</article-title>. <source xml:lang="en"/>Biochim Biophys Acta
<year>2016</year>;<volume>1860</volume>:<fpage>1574</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">26500099</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0093">
<label>93</label>
<mixed-citation id="apm12934-cit-0093" publication-type="journal">
<string-name>
<surname>Almeida</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kolarich</surname>
<given-names>D</given-names>
</string-name>. <article-title>The promise of protein glycosylation for personalised medicine</article-title>. <source xml:lang="en"/>Biochim Biophys Acta
<year>2016</year>;<volume>1860</volume>:<fpage>1583</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">26987810</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0094">
<label>94</label>
<mixed-citation id="apm12934-cit-0094" publication-type="journal">
<string-name>
<surname>Russell</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Adua</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ugrina</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Laws</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>. <article-title>Unravelling immunoglobulin G Fc N‐glycosylation: a dynamic marker potentiating predictive, preventive and personalised medicine</article-title>. <source xml:lang="en"/>Int J Mol Sci
<year>2018</year>;<volume>19</volume>:<fpage>pii: E390</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0095">
<label>95</label>
<mixed-citation id="apm12934-cit-0095" publication-type="journal">
<string-name>
<surname>Houle</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Govindaraju</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Omholt</surname>
<given-names>S</given-names>
</string-name>. <article-title>Phenomics: the next challenge</article-title>. <source xml:lang="en"/>Nat Rev Genet
<year>2010</year>;<volume>11</volume>:<fpage>855</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">21085204</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0096">
<label>96</label>
<mixed-citation id="apm12934-cit-0096" publication-type="journal">
<string-name>
<surname>Robinson</surname>
<given-names>PN</given-names>
</string-name>. <article-title>Deep phenotyping for precision medicine</article-title>. <source xml:lang="en"/>Hum Mutat
<year>2012</year>;<volume>33</volume>:<fpage>777</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">22504886</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0097">
<label>97</label>
<mixed-citation id="apm12934-cit-0097" publication-type="journal">
<string-name>
<surname>Köhler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Doelken</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Mungall</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Firth</surname>
<given-names>HV</given-names>
</string-name>, <string-name>
<surname>Bailleul‐Forestier</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data</article-title>. <source xml:lang="en"/>Nucleic Acids Res
<year>2014</year>;<volume>42</volume>(<issue>Database issue</issue>):<fpage>D966</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">24217912</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0098">
<label>98</label>
<mixed-citation id="apm12934-cit-0098" publication-type="journal">
<string-name>
<surname>Graham</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wasiak</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lees</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ramagopalan</surname>
<given-names>S</given-names>
</string-name>. <article-title>Time to really share real‐world data?</article-title>
<source xml:lang="en"/>F1000Res
<year>2018</year>;<volume>7</volume>:<fpage>1054</fpage>.<pub-id pub-id-type="pmid">30364186</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0099">
<label>99</label>
<mixed-citation id="apm12934-cit-0099" publication-type="journal">
<string-name>
<surname>Jensen</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Moseley</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Oprea</surname>
<given-names>TI</given-names>
</string-name>, <string-name>
<surname>Ellesøe</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Eriksson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schmock</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Temporal disease trajectories condensed from population‐wide registry data covering 6.2 million patients</article-title>. <source xml:lang="en"/>Nat Commun
<year>2014</year>;<volume>5</volume>:<fpage>4022</fpage>.<pub-id pub-id-type="pmid">24959948</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0100">
<label>100</label>
<mixed-citation id="apm12934-cit-0100" publication-type="journal">
<string-name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Ley</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Hamady</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fraser‐Liggett</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Knight</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gordon</surname>
<given-names>JI</given-names>
</string-name>. <article-title>The human microbiome project</article-title>. <source xml:lang="en"/>Nature
<year>2007</year>;<volume>449</volume>:<fpage>804</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">17943116</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0101">
<label>101</label>
<mixed-citation id="apm12934-cit-0101" publication-type="journal">
<string-name>
<surname>Valdes</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Segal</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Spector</surname>
<given-names>TD</given-names>
</string-name>. <article-title>Role of the gut microbiota in nutrition and health</article-title>. <source xml:lang="en"/>BMJ
<year>2018</year>;<volume>361</volume>:<fpage>k2179</fpage>.<pub-id pub-id-type="pmid">29899036</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0102">
<label>102</label>
<mixed-citation id="apm12934-cit-0102" publication-type="journal">
<string-name>
<surname>Bull</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Plummer</surname>
<given-names>NT</given-names>
</string-name>. <article-title>Part 1: The human gut microbiome in health and disease</article-title>. <source xml:lang="en"/>Integr Med
<year>2014</year>;<volume>13</volume>:<fpage>17</fpage>–<lpage>22</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0103">
<label>103</label>
<mixed-citation id="apm12934-cit-0103" publication-type="journal">
<string-name>
<surname>Rosenfeld</surname>
<given-names>CS</given-names>
</string-name>. <article-title>Microbiome disturbances and autism spectrum disorders</article-title>. <source xml:lang="en"/>Drug Metab Dispos
<year>2015</year>;<volume>43</volume>:<fpage>1557</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">25852213</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0104">
<label>104</label>
<mixed-citation id="apm12934-cit-0104" publication-type="journal">
<string-name>
<surname>ElRakaiby</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dutilh</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Rizkallah</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Boleij</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Aziz</surname>
<given-names>RK</given-names>
</string-name>. <article-title>Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics</article-title>. <source xml:lang="en"/>OMICS
<year>2014</year>;<volume>18</volume>:<fpage>402</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">24785449</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0105">
<label>105</label>
<mixed-citation id="apm12934-cit-0105" publication-type="journal">
<string-name>
<surname>Doestzada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vila</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Zhernakova</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Koonen</surname>
<given-names>DPY</given-names>
</string-name>, <string-name>
<surname>Weersma</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Touw</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>Pharmacomicrobiomics: a novel route towards personalized medicine?</article-title>
<source xml:lang="en"/>Protein Cell
<year>2018</year>;<volume>9</volume>:<fpage>432</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">29705929</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0106">
<label>106</label>
<mixed-citation id="apm12934-cit-0106" publication-type="journal">
<string-name>
<surname>Haiser</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Gootenberg</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Chatman</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sirasani</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Balskus</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Turnbaugh</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta</article-title>. <source xml:lang="en"/>Science
<year>2013</year>;<volume>341</volume>:<fpage>295</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">23869020</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0107">
<label>107</label>
<mixed-citation id="apm12934-cit-0107" publication-type="journal">
<string-name>
<surname>Langan</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>
<given-names>CEM</given-names>
</string-name>, <string-name>
<surname>Solbach</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Knobloch</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Zillikens</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Thaçi</surname>
<given-names>D</given-names>
</string-name>. <article-title>The role of the microbiome in psoriasis: moving from disease description to treatment selection?</article-title>
<source xml:lang="en"/>Br J Dermatol
<year>2018</year>;<volume>178</volume>:<fpage>1020</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">29071712</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0108">
<label>108</label>
<mixed-citation id="apm12934-cit-0108" publication-type="journal">
<string-name>
<surname>Pascal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Perez‐Gordo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Caballero</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Escribese</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Lopez Longo</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Luengo</surname>
<given-names>O</given-names>
</string-name>, et al. <article-title>Microbiome and allergic diseases</article-title>. <source xml:lang="en"/>Front Immunol
<year>2018</year>;<volume>9</volume>:<fpage>1584</fpage>.<pub-id pub-id-type="pmid">30065721</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0109">
<label>109</label>
<mixed-citation id="apm12934-cit-0109" publication-type="journal">
<string-name>
<surname>Kong</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Segre</surname>
<given-names>JA</given-names>
</string-name>. <article-title>The molecular revolution in cutaneous biology: investigating the skin microbiome</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2017</year>;<volume>137</volume>:<fpage>e119</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">28411842</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0110">
<label>110</label>
<mixed-citation id="apm12934-cit-0110" publication-type="journal">
<string-name>
<surname>Thaiss</surname>
<given-names>CA</given-names>
</string-name>. <article-title>Microbiome dynamics in obesity</article-title>. <source xml:lang="en"/>Science
<year>2018</year>;<volume>362</volume>:<fpage>903</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">30467161</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0111">
<label>111</label>
<mixed-citation id="apm12934-cit-0111" publication-type="journal">
<string-name>
<surname>Aguiar‐Pulido</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Suarez‐Ulloa</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cickovski</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mathee</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Narasimhan</surname>
<given-names>G</given-names>
</string-name>. <article-title>Metagenomics, metatranscriptomics, and metabolomics approaches for microbiome analysis</article-title>. <source xml:lang="en"/>Evol Bioinform Online
<year>2016</year>;<volume>12</volume>(<issue>Suppl 1</issue>):<fpage>5</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">27199545</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0112">
<label>112</label>
<mixed-citation id="apm12934-cit-0112" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Environment, genome and cancer</article-title>. <source xml:lang="en"/>C R Acad Sci III
<year>2001</year>;<volume>324</volume>:<fpage>1085</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">11803807</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0113">
<label>113</label>
<mixed-citation id="apm12934-cit-0113" publication-type="journal">
<string-name>
<surname>Wild</surname>
<given-names>CP</given-names>
</string-name>. <article-title>The exposome: from concept to utility</article-title>. <source xml:lang="en"/>Int J Epidemiol
<year>2012</year>;<volume>41</volume>:<fpage>24</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">22296988</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0114">
<label>114</label>
<mixed-citation id="apm12934-cit-0114" publication-type="journal">
<string-name>
<surname>Sharma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gilbert</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Microbial exposure and human health</article-title>. <source xml:lang="en"/>Curr Opin Microbiol
<year>2018</year>;<volume>44</volume>:<fpage>79</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">30195150</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0115">
<label>115</label>
<mixed-citation id="apm12934-cit-0115" publication-type="journal">
<string-name>
<surname>Bessonneau</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Pawliszyn</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rappaport</surname>
<given-names>SM</given-names>
</string-name>. <article-title>The saliva exposome for monitoring of individuals’ health trajectories</article-title>. <source xml:lang="en"/>Environ Health Perspect
<year>2017</year>;<volume>125</volume>:<fpage>077014</fpage>.<pub-id pub-id-type="pmid">28743678</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0116">
<label>116</label>
<mixed-citation id="apm12934-cit-0116" publication-type="journal">
<string-name>
<surname>Steckling</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gotti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bose‐O'Reilly</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chapizanis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Costopoulou</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>De Vocht</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Biomarkers of exposure in environment‐wide association studies ‐ Opportunities to decode the exposome using human biomonitoring data</article-title>. <source xml:lang="en"/>Environ Res
<year>2018</year>;<volume>164</volume>:<fpage>597</fpage>–<lpage>624</lpage>.<pub-id pub-id-type="pmid">29626821</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0117">
<label>117</label>
<mixed-citation id="apm12934-cit-0117" publication-type="journal">
<string-name>
<surname>Patel</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Analytical complexity in detection of gene variant‐by‐environment exposure interactions in high‐throughput genomic and exposomic research</article-title>. <source xml:lang="en"/>Curr Environ Health Rep
<year>2016</year>;<volume>3</volume>:<fpage>64</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">26809563</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0118">
<label>118</label>
<mixed-citation id="apm12934-cit-0118" publication-type="journal">
<string-name>
<surname>Yang</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>L</given-names>
</string-name>. <article-title>The internet of things (IoT): informatics methods for IoT‐enabled health care</article-title>. <source xml:lang="en"/>J Biomed Inform
<year>2018</year>;<volume>87</volume>:<fpage>154</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">30342221</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0119">
<label>119</label>
<mixed-citation id="apm12934-cit-0119" publication-type="journal">
<string-name>
<surname>Swan</surname>
<given-names>M</given-names>
</string-name>. <article-title>The quantified self: fundamental disruption in big data science and biological discovery</article-title>. <source xml:lang="en"/>Big Data
<year>2013</year>;<volume>1</volume>:<fpage>85</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">27442063</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0120">
<label>120</label>
<mixed-citation id="apm12934-cit-0120" publication-type="journal">
<string-name>
<surname>Ristevski</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Big data analytics in medicine and healthcare</article-title>. <source xml:lang="en"/>J Integr Bioinform
<year>2018</year>;<volume>15</volume>:<fpage>1</fpage>–<lpage>5</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0121">
<label>121</label>
<mixed-citation id="apm12934-cit-0121" publication-type="journal">
<string-name>
<surname>Griffiths</surname>
<given-names>CEM</given-names>
</string-name>, <string-name>
<surname>van der Walt</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Ashcroft</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Flohr</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Naldi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nijsten</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>The global state of psoriasis disease epidemiology: a workshop report</article-title>. <source xml:lang="en"/>Br J Dermatol
<year>2017</year>;<volume>177</volume>:<fpage>e4</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">28555722</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0122">
<label>122</label>
<mixed-citation id="apm12934-cit-0122" publication-type="journal">
<string-name>
<surname>Grozdev</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Korman</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tsankov</surname>
<given-names>N</given-names>
</string-name>. <article-title>Psoriasis as a systemic disease</article-title>. <source xml:lang="en"/>Clin Dermatol
<year>2014</year>;<volume>32</volume>:<fpage>343</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">24767182</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0123">
<label>123</label>
<mixed-citation id="apm12934-cit-0123" publication-type="journal">
<string-name>
<surname>Sacotte</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>. <article-title>Epidemiology of adult atopic dermatitis</article-title>. <source xml:lang="en"/>Clin Dermatol
<year>2018</year>;<volume>36</volume>:<fpage>595</fpage>–<lpage>605</lpage>.<pub-id pub-id-type="pmid">30217272</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0124">
<label>124</label>
<mixed-citation id="apm12934-cit-0124" publication-type="miscellaneous">
<article-title>World Population Clock: 7.7 Billion People (2018) ‐ Worldometers [Internet]</article-title>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.worldometers.info/world-population/">http://www.worldometers.info/world-population/</ext-link> [cited 2018 Sep 21].</mixed-citation>
</ref>
<ref id="apm12934-bib-0125">
<label>125</label>
<mixed-citation id="apm12934-cit-0125" publication-type="journal">
<string-name>
<surname>Nutten</surname>
<given-names>S</given-names>
</string-name>. <article-title>Atopic dermatitis: global epidemiology and risk factors</article-title>. <source xml:lang="en"/>Ann Nutr Metab
<year>2015</year>;<volume>66</volume>(<issue>Suppl 1</issue>):<fpage>8</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">25925336</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0126">
<label>126</label>
<mixed-citation id="apm12934-cit-0126" publication-type="journal">
<string-name>
<surname>Di Meglio</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Villanova</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nestle</surname>
<given-names>FO</given-names>
</string-name>. <article-title>Psoriasis</article-title>. <source xml:lang="en"/>Cold Spring Harb Perspect Med
<year>2014</year>;<volume>4</volume>:<fpage>pii: a015354</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0127">
<label>127</label>
<mixed-citation id="apm12934-cit-0127" publication-type="journal">
<string-name>
<surname>Thomsen</surname>
<given-names>SF</given-names>
</string-name>. <article-title>Epidemiology and natural history of atopic diseases</article-title>. <source xml:lang="en"/>Eur Respir J
<year>2015</year>;<volume>2</volume>:<fpage>1</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0128">
<label>128</label>
<mixed-citation id="apm12934-cit-0128" publication-type="journal">
<string-name>
<surname>Strachan</surname>
<given-names>DP</given-names>
</string-name>. <article-title>Hay fever, hygiene, and household size</article-title>. <source xml:lang="en"/>BMJ
<year>1989</year>;<volume>299</volume>:<fpage>1259</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">2513902</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0129">
<label>129</label>
<mixed-citation id="apm12934-cit-0129" publication-type="journal">
<string-name>
<surname>Karimkhani</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dellavalle</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Coffeng</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Flohr</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hay</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Langan</surname>
<given-names>SM</given-names>
</string-name>, et al. <article-title>Global skin disease morbidity and mortality: an update from the global burden of disease study 2013</article-title>. <source xml:lang="en"/>JAMA Dermatol
<year>2017</year>;<volume>153</volume>:<fpage>406</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">28249066</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0130">
<label>130</label>
<mixed-citation id="apm12934-cit-0130" publication-type="journal">
<string-name>
<surname>Steinke</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zeidler</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Riepe</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bruland</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Soto‐Rey</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Storck</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross‐sectional trial</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>79</volume>
<issue>457–63</issue>:<fpage>e5</fpage>.<pub-id pub-id-type="pmid">29908823</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0131">
<label>131</label>
<mixed-citation id="apm12934-cit-0131" publication-type="book">
<string-name>
<surname>van de Kerkhof</surname>
<given-names>PCM</given-names>
</string-name>, <string-name>
<surname>Nestlé</surname>
<given-names>FO</given-names>
</string-name>. <chapter-title>Psoriasis</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Bolognia</surname><given-names>JL</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Schaffer</surname><given-names>JV</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Cerroni</surname><given-names>L</given-names></name></person-group>, editors. <source xml:lang="en"/>Dermatology. <publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2017</year>: <fpage>138</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0132">
<label>132</label>
<mixed-citation id="apm12934-cit-0132" publication-type="book">
<string-name>
<surname>McAleer</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>O'Regan</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>AM</given-names>
</string-name>. <chapter-title>Atopic dermatitis</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Bolognia</surname><given-names>JL</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Schaffer</surname><given-names>JV</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Cerroni</surname><given-names>L</given-names></name></person-group>, editors. <source xml:lang="en"/>Dermatology. <publisher-loc>Amsterdam, Netherlands</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2017</year>: <fpage>208</fpage>–<lpage>26</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0133">
<label>133</label>
<mixed-citation id="apm12934-cit-0133" publication-type="journal">
<string-name>
<surname>Bisgaard</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>
<given-names>CNA</given-names>
</string-name>, <string-name>
<surname>Bønnelykke</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mukhopadhyay</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Gene‐environment interaction in the onset of eczema in infancy: filaggrin loss‐of‐function mutations enhanced by neonatal cat exposure</article-title>. <source xml:lang="en"/>PLoS Med
<year>2008</year>;<volume>5</volume>:<fpage>e131</fpage>.<pub-id pub-id-type="pmid">18578563</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0134">
<label>134</label>
<mixed-citation id="apm12934-cit-0134" publication-type="journal">
<string-name>
<surname>Noda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>. <article-title>The translational revolution and use of biologics in patients with inflammatory skin diseases</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2015</year>;<volume>135</volume>:<fpage>324</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">25541257</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0135">
<label>135</label>
<mixed-citation id="apm12934-cit-0135" publication-type="journal">
<string-name>
<surname>Lønnberg</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Skov</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Skytthe</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kyvik</surname>
<given-names>KO</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>
<given-names>OB</given-names>
</string-name>, <string-name>
<surname>Thomsen</surname>
<given-names>SF</given-names>
</string-name>. <article-title>Heritability of psoriasis in a large twin sample</article-title>. <source xml:lang="en"/>Br J Dermatol
<year>2013</year>;<volume>169</volume>:<fpage>412</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">23574549</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0136">
<label>136</label>
<mixed-citation id="apm12934-cit-0136" publication-type="journal">
<string-name>
<surname>Elmose</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Thomsen</surname>
<given-names>SF</given-names>
</string-name>. <article-title>Twin studies of atopic dermatitis: interpretations and applications in the filaggrin era</article-title>. <source xml:lang="en"/>J Allergy
<year>2015</year>;<volume>2015</volume>:<fpage>902359</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0137">
<label>137</label>
<mixed-citation id="apm12934-cit-0137" publication-type="journal">
<string-name>
<surname>Capon</surname>
<given-names>F</given-names>
</string-name>. <article-title>The genetic basis of psoriasis</article-title>. <source xml:lang="en"/>Int J Mol Sci
<year>2017</year>;<volume>18</volume>:<fpage>pii: E2526</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0138">
<label>138</label>
<mixed-citation id="apm12934-cit-0138" publication-type="journal">
<string-name>
<surname>Palmer</surname>
<given-names>CNA</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Terron‐Kwiatkowski</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SP</given-names>
</string-name>, et al. <article-title>Common loss‐of‐function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis</article-title>. <source xml:lang="en"/>Nat Genet
<year>2006</year>;<volume>38</volume>:<fpage>441</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">16550169</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0139">
<label>139</label>
<mixed-citation id="apm12934-cit-0139" publication-type="journal">
<string-name>
<surname>Al‐Shobaili</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Alnomair</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Alobead</surname>
<given-names>ZA</given-names>
</string-name>, <string-name>
<surname>Rasheed</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Molecular genetic of atopic dermatitis: an update</article-title>. <source xml:lang="en"/>Int J Health Sci
<year>2016</year>;<volume>10</volume>:<fpage>96</fpage>–<lpage>120</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0140">
<label>140</label>
<mixed-citation id="apm12934-cit-0140" publication-type="journal">
<string-name>
<surname>Thomsen</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Elmose</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Szecsi</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Stender</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kyvik</surname>
<given-names>KO</given-names>
</string-name>, <string-name>
<surname>Backer</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Filaggrin gene loss‐of‐function mutations explain discordance of atopic dermatitis within dizygotic twin pairs</article-title>. <source xml:lang="en"/>Int J Dermatol
<year>2016</year>;<volume>55</volume>:<fpage>1341</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">27653621</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0141">
<label>141</label>
<mixed-citation id="apm12934-cit-0141" publication-type="journal">
<string-name>
<surname>Paternoster</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Standl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Waage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Baurecht</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hotze</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Strachan</surname>
<given-names>DP</given-names>
</string-name>, et al. <article-title>Multi‐ancestry genome‐wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis</article-title>. <source xml:lang="en"/>Nat Genet
<year>2015</year>;<volume>47</volume>:<fpage>1449</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">26482879</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0142">
<label>142</label>
<mixed-citation id="apm12934-cit-0142" publication-type="journal">
<string-name>
<surname>Liang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Q</given-names>
</string-name>. <article-title>The genetics and epigenetics of atopic dermatitis‐filaggrin and other polymorphisms</article-title>. <source xml:lang="en"/>Clin Rev Allergy Immunol
<year>2016</year>;<volume>51</volume>:<fpage>315</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">26385242</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0143">
<label>143</label>
<mixed-citation id="apm12934-cit-0143" publication-type="journal">
<string-name>
<surname>Yao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Richman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Morehouse</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>de los Reyes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Higgs</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Boutrin</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Type I interferon: potential therapeutic target for psoriasis?</article-title>
<source xml:lang="en"/>PLoS ONE
<year>2008</year>;<volume>3</volume>:<fpage>e2737</fpage>.<pub-id pub-id-type="pmid">18648529</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0144">
<label>144</label>
<mixed-citation id="apm12934-cit-0144" publication-type="journal">
<string-name>
<surname>Tian</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jabbari</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Brodmerkel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lowes</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>Meta‐analysis derived (MAD) transcriptome of psoriasis defines the “core” pathogenesis of disease</article-title>. <source xml:lang="en"/>PLoS ONE
<year>2012</year>;<volume>7</volume>:<fpage>e44274</fpage>.<pub-id pub-id-type="pmid">22957057</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0145">
<label>145</label>
<mixed-citation id="apm12934-cit-0145" publication-type="journal">
<string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tintle</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Shemer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chiricozzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nograles</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cardinale</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2011</year>;<volume>127</volume>
<issue>954–64</issue>:<fpage>e1</fpage>–<lpage>4</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0146">
<label>146</label>
<mixed-citation id="apm12934-cit-0146" publication-type="journal">
<string-name>
<surname>Ewald</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Malajian</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Workman</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Meta‐analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways</article-title>. <source xml:lang="en"/>BMC Med Genomics
<year>2015</year>;<volume>8</volume>:<fpage>60</fpage>.<pub-id pub-id-type="pmid">26459294</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0147">
<label>147</label>
<mixed-citation id="apm12934-cit-0147" publication-type="journal">
<string-name>
<surname>Witte</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kokolakis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Witte</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Philipp</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Doecke</surname>
<given-names>W‐D</given-names>
</string-name>, <string-name>
<surname>Babel</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>IL‐19 is a component of the pathogenetic IL‐23/IL‐17 cascade in psoriasis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2014</year>;<volume>134</volume>:<fpage>2757</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">25046339</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0148">
<label>148</label>
<mixed-citation id="apm12934-cit-0148" publication-type="journal">
<string-name>
<surname>Solberg</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Sandvik</surname>
<given-names>LF</given-names>
</string-name>, <string-name>
<surname>Eidsheim</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jonsson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bryceson</surname>
<given-names>YT</given-names>
</string-name>, <string-name>
<surname>Appel</surname>
<given-names>S</given-names>
</string-name>. <article-title>Serum cytokine measurements and biological therapy of psoriasis ‐ Prospects for personalized treatment?</article-title>
<source xml:lang="en"/>Scand J Immunol
<year>2018</year>;<volume>88</volume>:<fpage>e12725</fpage>.<pub-id pub-id-type="pmid">30307657</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0149">
<label>149</label>
<mixed-citation id="apm12934-cit-0149" publication-type="journal">
<string-name>
<surname>Zaba</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nograles</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cardinale</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Effective treatment of psoriasis with etanercept is linked to suppression of IL‐17 signaling, not immediate response TNF genes</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2009</year>;<volume>124</volume>
<issue>1022–10</issue>:<fpage>e1</fpage>–<lpage>395</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0150">
<label>150</label>
<mixed-citation id="apm12934-cit-0150" publication-type="journal">
<string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Fretzin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Haslett</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Phipps</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Cameron</surname>
<given-names>GS</given-names>
</string-name>, et al. <article-title>IL‐17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2012</year>;<volume>130</volume>:<fpage>145</fpage>–<lpage>54</lpage>. e9.<pub-id pub-id-type="pmid">22677045</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0151">
<label>151</label>
<mixed-citation id="apm12934-cit-0151" publication-type="journal">
<string-name>
<surname>Russell</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Rand</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bigler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kerkof</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Timour</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bautista</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti‐IL‐17 receptor monoclonal antibody</article-title>. <source xml:lang="en"/>J Immunol
<year>2014</year>;<volume>192</volume>:<fpage>3828</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">24646743</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0152">
<label>152</label>
<mixed-citation id="apm12934-cit-0152" publication-type="journal">
<string-name>
<surname>Sofen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matheson</surname>
<given-names>RT</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Calderon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Brodmerkel</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Guselkumab (an IL‐23‐specific mAb) demonstrates clinical and molecular response in patients with moderate‐to‐severe psoriasis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2014</year>;<volume>133</volume>:<fpage>1032</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">24679469</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0153">
<label>153</label>
<mixed-citation id="apm12934-cit-0153" publication-type="journal">
<string-name>
<surname>Visvanathan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baum</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vinisko</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Flack</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lalovic</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Psoriatic skin molecular and histopathological profiles following treatment with risankizumab versus ustekinumab</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.jaci.2018.11.042</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0154">
<label>154</label>
<mixed-citation id="apm12934-cit-0154" publication-type="journal">
<string-name>
<surname>Paternoster</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Savenije</surname>
<given-names>OEM</given-names>
</string-name>, <string-name>
<surname>Heron</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Vonk</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Brunekreef</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>141</volume>:<fpage>964</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">29129583</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0155">
<label>155</label>
<mixed-citation id="apm12934-cit-0155" publication-type="journal">
<string-name>
<surname>Thijs</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>de Bruin‐Weller</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Hijnen</surname>
<given-names>D</given-names>
</string-name>. <article-title>Current and future biomarkers in atopic dermatitis</article-title>. <source xml:lang="en"/>Immunol Allergy Clin North Am
<year>2017</year>;<volume>37</volume>:<fpage>51</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">27886910</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0156">
<label>156</label>
<mixed-citation id="apm12934-cit-0156" publication-type="journal">
<string-name>
<surname>Tamagawa‐Mineoka</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Okuzawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Masuda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Katoh</surname>
<given-names>N</given-names>
</string-name>. <article-title>Increased serum levels of interleukin 33 in patients with atopic dermatitis</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2014</year>;<volume>70</volume>:<fpage>882</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">24569114</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0157">
<label>157</label>
<mixed-citation id="apm12934-cit-0157" publication-type="journal">
<string-name>
<surname>Tintle</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shemer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fujita</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gilleaudeau</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sullivan‐Whalen</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Reversal of atopic dermatitis with narrow‐band UVB phototherapy and biomarkers for therapeutic response</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2011</year>;<volume>128</volume>
<issue>583–93</issue>:<fpage>e1</fpage>–<lpage>4</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0158">
<label>158</label>
<mixed-citation id="apm12934-cit-0158" publication-type="journal">
<string-name>
<surname>Khattri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shemer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rozenblit</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dhingra</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Czarnowicki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Finney</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2014</year>;<volume>133</volume>:<fpage>1626</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">24786238</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0159">
<label>159</label>
<mixed-citation id="apm12934-cit-0159" publication-type="journal">
<string-name>
<surname>Hamilton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dhingra</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Cardinale</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Kostic</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Dupilumab improves the molecular signature in skin of patients with moderate‐to‐severe atopic dermatitis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2014</year>;<volume>134</volume>:<fpage>1293</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">25482871</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0160">
<label>160</label>
<mixed-citation id="apm12934-cit-0160" publication-type="miscellaneous">
<article-title>GEO Accession viewer [Internet]</article-title>. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120899">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120899</ext-link> [cited 2018 Nov 1].</mixed-citation>
</ref>
<ref id="apm12934-bib-0161">
<label>161</label>
<mixed-citation id="apm12934-cit-0161" publication-type="journal">
<string-name>
<surname>Brunner</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Pavel</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Khattri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Malik</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Rose</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Baseline IL‐22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>143</volume>:<fpage>142</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">30121291</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0162">
<label>162</label>
<mixed-citation id="apm12934-cit-0162" publication-type="journal">
<string-name>
<surname>Moscaliuc</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Heller</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Koo</surname>
<given-names>J</given-names>
</string-name>. <article-title>Goeckerman therapy: a very effective, yet often forgotten treatment for severe generalized psoriasis</article-title>. <source xml:lang="en"/>J Dermatolog Treat
<year>2013</year>;<volume>24</volume>:<fpage>34</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">22329632</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0163">
<label>163</label>
<mixed-citation id="apm12934-cit-0163" publication-type="journal">
<string-name>
<surname>Wollenberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schnopp</surname>
<given-names>C</given-names>
</string-name>. <article-title>Evolution of conventional therapy in atopic dermatitis</article-title>. <source xml:lang="en"/>Immunol Allergy Clin North Am
<year>2010</year>;<volume>30</volume>:<fpage>351</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">20670818</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0164">
<label>164</label>
<mixed-citation id="apm12934-cit-0164" publication-type="journal">
<string-name>
<surname>Griffiths</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Powles</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Fry</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Valdimarsson</surname>
<given-names>H</given-names>
</string-name>. <article-title>Clearance of psoriasis with low dose cyclosporin</article-title>. <source xml:lang="en"/>Br Med J
<year>1986</year>;<volume>293</volume>:<fpage>731</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">3094629</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0165">
<label>165</label>
<mixed-citation id="apm12934-cit-0165" publication-type="journal">
<string-name>
<surname>Eedy</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Burrows</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bridges</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>FG</given-names>
</string-name>. <article-title>Clearance of severe psoriasis after allogenic bone marrow transplantation</article-title>. <source xml:lang="en"/>BMJ
<year>1990</year>;<volume>300</volume>:<fpage>908</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0166">
<label>166</label>
<mixed-citation id="apm12934-cit-0166" publication-type="journal">
<string-name>
<surname>Cua</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Sherlock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Joyce</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Seymour</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Interleukin‐23 rather than interleukin‐12 is the critical cytokine for autoimmune inflammation of the brain</article-title>. <source xml:lang="en"/>Nature
<year>2003</year>;<volume>421</volume>:<fpage>744</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">12610626</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0167">
<label>167</label>
<mixed-citation id="apm12934-cit-0167" publication-type="journal">
<string-name>
<surname>Lowes</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kikuchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cardinale</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Zaba</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Haider</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2008</year>;<volume>128</volume>:<fpage>1207</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">18200064</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0168">
<label>168</label>
<mixed-citation id="apm12934-cit-0168" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Trepicchio</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Oestreicher</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Pittman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Chamian</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris</article-title>. <source xml:lang="en"/>J Exp Med
<year>2004</year>;<volume>199</volume>:<fpage>125</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">14707118</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0169">
<label>169</label>
<mixed-citation id="apm12934-cit-0169" publication-type="journal">
<string-name>
<surname>Hawkes</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>BY</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Discovery of the IL‐23/IL‐17 signaling pathway and the treatment of psoriasis</article-title>. <source xml:lang="en"/>J Immunol
<year>2018</year>;<volume>201</volume>:<fpage>1605</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">30181299</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0170">
<label>170</label>
<mixed-citation id="apm12934-cit-0170" publication-type="journal">
<string-name>
<surname>Walsh</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mallbris</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Duffin</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Clegg</surname>
<given-names>DO</given-names>
</string-name>, et al. <article-title>The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA</article-title>. <source xml:lang="en"/>Psoriasis (Auckl)
<year>2018</year>;<volume>8</volume>:<fpage>65</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">30324088</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0171">
<label>171</label>
<mixed-citation id="apm12934-cit-0171" publication-type="journal">
<string-name>
<surname>Carrera</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Dapavo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Malagoli</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Naldi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Arancio</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gaiani</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>PACE study: real‐life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate‐severe psoriasis</article-title>. <source xml:lang="en"/>J Dermatolog Treat
<year>2018</year>;<volume>29</volume>:<fpage>481</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">29058948</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0172">
<label>172</label>
<mixed-citation id="apm12934-cit-0172" publication-type="journal">
<string-name>
<surname>Campa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mansouri</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Warren</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Menter</surname>
<given-names>A</given-names>
</string-name>. <article-title>A review of biologic therapies targeting IL‐23 and IL‐17 for use in moderate‐to‐severe plaque psoriasis</article-title>. <source xml:lang="en"/>Dermatol Ther
<year>2016</year>;<volume>6</volume>:<fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0173">
<label>173</label>
<mixed-citation id="apm12934-cit-0173" publication-type="journal">
<string-name>
<surname>Canavan</surname>
<given-names>TN</given-names>
</string-name>, <string-name>
<surname>Elmets</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Cantrell</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Evans</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Elewski</surname>
<given-names>BE</given-names>
</string-name>. <article-title>Anti‐IL‐17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review</article-title>. <source xml:lang="en"/>Am J Clin Dermatol
<year>2016</year>;<volume>17</volume>:<fpage>33</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">26649440</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0174">
<label>174</label>
<mixed-citation id="apm12934-cit-0174" publication-type="journal">
<string-name>
<surname>Menter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sobell</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rastogi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pillai</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Long‐term efficacy of brodalumab for the treatment of moderate‐to‐severe psoriasis: data from a pivotal phase 3 clinical trial</article-title>. <source xml:lang="en"/>SKIN J Cutaneous Med
<year>2018</year>;<volume>2</volume>
<issue>S1</issue>
<pub-id pub-id-type="doi">10.25251/skin.2.supp.9</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0175">
<label>175</label>
<mixed-citation id="apm12934-cit-0175" publication-type="journal">
<string-name>
<surname>Brembilla</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Senra</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Boehncke</surname>
<given-names>W‐H</given-names>
</string-name>. <article-title>The IL‐17 family of cytokines in psoriasis: IL‐17A and beyond</article-title>. <source xml:lang="en"/>Front Immunol
<year>2018</year>;<volume>9</volume>:<fpage>1682</fpage>.<pub-id pub-id-type="pmid">30127781</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0176">
<label>176</label>
<mixed-citation id="apm12934-cit-0176" publication-type="journal">
<string-name>
<surname>Blair</surname>
<given-names>HA</given-names>
</string-name>. <article-title>Brodalumab: a review in moderate to severe plaque psoriasis</article-title>. <source xml:lang="en"/>Drugs
<year>2018</year>;<volume>78</volume>:<fpage>495</fpage>–<lpage>504</lpage>.<pub-id pub-id-type="pmid">29516365</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0177">
<label>177</label>
<mixed-citation id="apm12934-cit-0177" publication-type="journal">
<string-name>
<surname>Sawyer</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Cornic</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Levin</surname>
<given-names>LÅ</given-names>
</string-name>, <string-name>
<surname>Gibbons</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Møller</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Jemec</surname>
<given-names>GB</given-names>
</string-name>. <article-title>Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response</article-title>. <source xml:lang="en"/>J Eur Acad Dermatol Venereol
<year>2019</year>;<volume>33</volume>:<fpage>355</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">30289198</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0178">
<label>178</label>
<mixed-citation id="apm12934-cit-0178" publication-type="journal">
<string-name>
<surname>Papp</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gordon</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Thaçi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Morita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gooderham</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Foley</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Phase 2 trial of selective tyrosine Kinase 2 inhibition in psoriasis</article-title>. <source xml:lang="en"/>N Engl J Med
<year>2018</year>;<volume>379</volume>:<fpage>1313</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">30205746</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0179">
<label>179</label>
<mixed-citation id="apm12934-cit-0179" publication-type="journal">
<string-name>
<surname>Conrad</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gilliet</surname>
<given-names>M</given-names>
</string-name>. <article-title>Psoriasis: from pathogenesis to targeted therapies</article-title>. <source xml:lang="en"/>Clin Rev Allergy Immunol
<year>2018</year>;<volume>54</volume>:<fpage>102</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">29349534</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0180">
<label>180</label>
<mixed-citation id="apm12934-cit-0180" publication-type="journal">
<string-name>
<surname>Torres</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Romanelli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chiricozzi</surname>
<given-names>A</given-names>
</string-name>. <article-title>A revolutionary therapeutic approach for psoriasis: bispecific biological agents</article-title>. <source xml:lang="en"/>Expert Opin Investig Drugs
<year>2016</year>;<volume>25</volume>:<fpage>751</fpage>–<lpage>4</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0181">
<label>181</label>
<mixed-citation id="apm12934-cit-0181" publication-type="journal">
<string-name>
<surname>Santibanez</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Bjelica</surname>
<given-names>S</given-names>
</string-name>. <article-title>Novel patents targeting interleukin‐17A; implications in cancer and inflammation</article-title>. <source xml:lang="en"/>Recent Pat Anticancer Drug Discov
<year>2018</year>;<volume>13</volume>:<fpage>133</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">29468982</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0182">
<label>182</label>
<mixed-citation id="apm12934-cit-0182" publication-type="journal">
<string-name>
<surname>Wu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Demarest</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Building blocks for bispecific and trispecific antibodies</article-title>. <source xml:lang="en"/>Methods
<year>2018</year>;<volume>154</volume>:<fpage>3</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">30172007</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0183">
<label>183</label>
<mixed-citation id="apm12934-cit-0183" publication-type="journal">
<string-name>
<surname>Campa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Menter</surname>
<given-names>A</given-names>
</string-name>. <article-title>A review of emerging IL‐17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies</article-title>. <source xml:lang="en"/>Expert Opin Investig Drugs
<year>2016</year>;<volume>25</volume>:<fpage>1337</fpage>–<lpage>44</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0184">
<label>184</label>
<mixed-citation id="apm12934-cit-0184" publication-type="journal">
<string-name>
<surname>Pollock</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Abji</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gladman</surname>
<given-names>DD</given-names>
</string-name>. <article-title>Epigenetics of psoriatic disease: a systematic review and critical appraisal</article-title>. <source xml:lang="en"/>J Autoimmun
<year>2017</year>;<volume>78</volume>:<fpage>29</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">27965059</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0185">
<label>185</label>
<mixed-citation id="apm12934-cit-0185" publication-type="journal">
<string-name>
<surname>Chandra</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Senapati</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Roy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chatterjee</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chatterjee</surname>
<given-names>R</given-names>
</string-name>. <article-title>Epigenome‐wide DNA methylation regulates cardinal pathological features of psoriasis</article-title>. <source xml:lang="en"/>Clin Epigenetics
<year>2018</year>;<volume>10</volume>:<fpage>108</fpage>.<pub-id pub-id-type="pmid">30092825</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0186">
<label>186</label>
<mixed-citation id="apm12934-cit-0186" publication-type="journal">
<string-name>
<surname>Ovejero‐Benito</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Reolid</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sánchez‐Jiménez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Saiz‐Rodríguez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Muñoz‐Aceituno</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Llamas‐Velasco</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Histone modifications associated with biological drug response in moderate‐to‐severe psoriasis</article-title>. <source xml:lang="en"/>Exp Dermatol
<year>2018</year>;<volume>27</volume>:<fpage>1361</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">30260532</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0187">
<label>187</label>
<mixed-citation id="apm12934-cit-0187" publication-type="journal">
<string-name>
<surname>Løvendorf</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Mitsui</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zibert</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Røpke</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Hafner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dyring‐Andersen</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Laser capture microdissection followed by next‐generation sequencing identifies disease‐related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis</article-title>. <source xml:lang="en"/>Exp Dermatol
<year>2015</year>;<volume>24</volume>:<fpage>187</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">25431026</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0188">
<label>188</label>
<mixed-citation id="apm12934-cit-0188" publication-type="journal">
<string-name>
<surname>Hawkes</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Fujita</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Florell</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Callis Duffin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>GG</given-names>
</string-name>, et al. <article-title>microRNAs in Psoriasis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2016</year>;<volume>136</volume>:<fpage>365</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">26802234</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0189">
<label>189</label>
<mixed-citation id="apm12934-cit-0189" publication-type="journal">
<string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Haider</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Lowes</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept</article-title>. <source xml:lang="en"/>BMC Dermatol
<year>2010</year>;<volume>10</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">20152045</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0190">
<label>190</label>
<mixed-citation id="apm12934-cit-0190" publication-type="journal">
<string-name>
<surname>Codoñer</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Ramírez‐Bosca</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Climent</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Carrión‐Gutierrez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Guerrero</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pérez‐Orquín</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>Gut microbial composition in patients with psoriasis</article-title>. <source xml:lang="en"/>Sci Rep
<year>2018</year>;<volume>8</volume>:<fpage>3812</fpage>.<pub-id pub-id-type="pmid">29491401</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0191">
<label>191</label>
<mixed-citation id="apm12934-cit-0191" publication-type="journal">
<string-name>
<surname>Tham</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>DY</given-names>
</string-name>. <article-title>Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march</article-title>. <source xml:lang="en"/>Allergy Asthma Immunol Res
<year>2019</year>;<volume>11</volume>:<fpage>4</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">30479073</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0192">
<label>192</label>
<mixed-citation id="apm12934-cit-0192" publication-type="journal">
<string-name>
<surname>Belgrave</surname>
<given-names>DCM</given-names>
</string-name>, <string-name>
<surname>Granell</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Guiver</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bishop</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Buchan</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Developmental profiles of eczema, wheeze, and rhinitis: two population‐based birth cohort studies</article-title>. <source xml:lang="en"/>PLoS Med
<year>2014</year>;<volume>11</volume>
<issue>10</issue>:<fpage>e1001748</fpage>.<pub-id pub-id-type="pmid">25335105</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0193">
<label>193</label>
<mixed-citation id="apm12934-cit-0193" publication-type="journal">
<string-name>
<surname>Leung</surname>
<given-names>DYM</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>. <article-title>Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2014</year>;<volume>134</volume>:<fpage>769</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">25282559</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0194">
<label>194</label>
<mixed-citation id="apm12934-cit-0194" publication-type="journal">
<string-name>
<surname>Reinhold</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kukel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goeden</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Kreysel</surname>
<given-names>HW</given-names>
</string-name>. <article-title>Functional characterization of skin‐infiltrating lymphocytes in atopic dermatitis</article-title>. <source xml:lang="en"/>Clin Exp Immunol
<year>1991</year>;<volume>86</volume>:<fpage>444</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">1721013</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0195">
<label>195</label>
<mixed-citation id="apm12934-cit-0195" publication-type="journal">
<string-name>
<surname>Eyerich</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Novak</surname>
<given-names>N</given-names>
</string-name>. <article-title>Immunology of atopic eczema: overcoming the Th1/Th2 paradigm</article-title>. <source xml:lang="en"/>Allergy
<year>2013</year>;<volume>68</volume>:<fpage>974</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">23889510</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0196">
<label>196</label>
<mixed-citation id="apm12934-cit-0196" publication-type="journal">
<string-name>
<surname>Gittler</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Shemer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gulewicz</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>CQF</given-names>
</string-name>, et al. <article-title>Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2012</year>;<volume>130</volume>:<fpage>1344</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">22951056</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0197">
<label>197</label>
<mixed-citation id="apm12934-cit-0197" publication-type="journal">
<string-name>
<surname>No</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Amin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Egeberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Thyssen</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Atopic dermatitis 2017: where we were 10‐15 years ago in psoriasis</article-title>. <source xml:lang="en"/>J Dermatolog Treat
<year>2018</year>;<volume>29</volume>
<issue>1</issue>:<fpage>100</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="pmid">28604121</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0198">
<label>198</label>
<mixed-citation id="apm12934-cit-0198" publication-type="journal">
<string-name>
<surname>Bożek</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reich</surname>
<given-names>A</given-names>
</string-name>. <article-title>Assessment of Intra‐ and Inter‐Rater Reliability of Three Methods for Measuring Atopic Dermatitis Severity: EASI, Objective SCORAD, and IGA</article-title>. <source xml:lang="en"/>Dermatology
<year>2017</year>;<volume>233</volume>:<fpage>16</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">28494438</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0199">
<label>199</label>
<mixed-citation id="apm12934-cit-0199" publication-type="journal">
<string-name>
<surname>Patel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Singam</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Vakharia</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Chopra</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sacotte</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Measurement properties of three assessments of burden used in atopic dermatitis in adults</article-title>. <source xml:lang="en"/>Br J Dermatol
<year>2018</year> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1111/bjd.17243</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0200">
<label>200</label>
<mixed-citation id="apm12934-cit-0200" publication-type="journal">
<string-name>
<surname>Gooderham</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>HC‐H</given-names>
</string-name>, <string-name>
<surname>Eshtiaghi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Papp</surname>
<given-names>KA</given-names>
</string-name>. <article-title>Dupilumab: a review of its use in the treatment of atopic dermatitis</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>(<issue>3S1</issue>):<fpage>S28</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">29471919</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0201">
<label>201</label>
<mixed-citation id="apm12934-cit-0201" publication-type="journal">
<string-name>
<surname>Muraro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lemanske</surname>
<given-names>RF</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Hellings</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Akdis</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Bieber</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Casale</surname>
<given-names>TB</given-names>
</string-name>, et al. <article-title>Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis‐PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &amp; Immunology</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2016</year>;<volume>137</volume>:<fpage>1347</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">27155030</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0202">
<label>202</label>
<mixed-citation id="apm12934-cit-0202" publication-type="journal">
<string-name>
<surname>Silverberg</surname>
<given-names>NB</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>. <article-title>Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis?</article-title>
<source xml:lang="en"/>Cutis
<year>2015</year>;<volume>96</volume>:<fpage>359</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">26761930</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0203">
<label>203</label>
<mixed-citation id="apm12934-cit-0203" publication-type="journal">
<string-name>
<surname>McAleer</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>AD</given-names>
</string-name>. <article-title>The multifunctional role of filaggrin in allergic skin disease</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2013</year>;<volume>131</volume>:<fpage>280</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">23374260</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0204">
<label>204</label>
<mixed-citation id="apm12934-cit-0204" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>WHI</given-names>
</string-name>. <article-title>One remarkable molecule: filaggrin</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2012</year>;<volume>132</volume>(<issue>3 Pt 2</issue>):<fpage>751</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">22158554</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0205">
<label>205</label>
<mixed-citation id="apm12934-cit-0205" publication-type="journal">
<string-name>
<surname>Chalmers</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Haines</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Ridd</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Effectiveness and cost‐effectiveness of daily all‐over‐body application of emollient during the first year of life for preventing atopic eczema in high‐risk children (The BEEP trial): protocol for a randomised controlled trial</article-title>. <source xml:lang="en"/>Trials
<year>2017</year>;<volume>18</volume>:<fpage>343</fpage>.<pub-id pub-id-type="pmid">28732519</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0206">
<label>206</label>
<mixed-citation id="apm12934-cit-0206" publication-type="journal">
<string-name>
<surname>De Benedetto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rafaels</surname>
<given-names>NM</given-names>
</string-name>, <string-name>
<surname>McGirt</surname>
<given-names>LY</given-names>
</string-name>, <string-name>
<surname>Ivanov</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Georas</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Cheadle</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Tight junction defects in patients with atopic dermatitis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2011</year>;<volume>127</volume>:<fpage>773</fpage>–<lpage>86</lpage>. e1–7.<pub-id pub-id-type="pmid">21163515</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0207">
<label>207</label>
<mixed-citation id="apm12934-cit-0207" publication-type="journal">
<string-name>
<surname>Ryu</surname>
<given-names>W‐I</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Jeon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ryu</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>IL‐33 down‐regulates CLDN1 expression through the ERK/STAT3 pathway in keratinocytes</article-title>. <source xml:lang="en"/>J Dermatol Sci
<year>2018</year>;<volume>90</volume>:<fpage>313</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">29534857</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0208">
<label>208</label>
<mixed-citation id="apm12934-cit-0208" publication-type="journal">
<string-name>
<surname>Sugita</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Steer</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Martinez‐Gonzalez</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Altunbulakli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Morita</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Castro‐Giner</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL‐13 in asthmatic patients</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>141</volume>:<fpage>300</fpage>–<lpage>10</lpage>. e11.<pub-id pub-id-type="pmid">28392332</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0209">
<label>209</label>
<mixed-citation id="apm12934-cit-0209" publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>Y‐E</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Cheon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>KK</given-names>
</string-name>. <article-title>Bortezomib, a proteasome inhibitor, alleviates atopic dermatitis by increasing claudin 1 protein expression</article-title>. <source xml:lang="en"/>Biochem Biophys Res Commun
<year>2017</year>;<volume>493</volume>:<fpage>744</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">28859979</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0210">
<label>210</label>
<mixed-citation id="apm12934-cit-0210" publication-type="journal">
<string-name>
<surname>Xian</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wawrzyniak</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rückert</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Duan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Meng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sokolowska</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2016</year>;<volume>138</volume>:<fpage>890</fpage>–<lpage>3</lpage>. e9.<pub-id pub-id-type="pmid">27596709</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0211">
<label>211</label>
<mixed-citation id="apm12934-cit-0211" publication-type="journal">
<string-name>
<surname>Clough</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>T</given-names>
</string-name>. <article-title>The gene expression omnibus database</article-title>. <source xml:lang="en"/>Methods Mol Biol
<year>2016</year>;<volume>1418</volume>:<fpage>93</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="pmid">27008011</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0212">
<label>212</label>
<mixed-citation id="apm12934-cit-0212" publication-type="journal">
<string-name>
<surname>Brunner</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Israel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>H‐C</given-names>
</string-name>, <string-name>
<surname>Huynh</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Early‐onset pediatric atopic dermatitis is characterized by T2/T17/T22‐centered inflammation and lipid alterations</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>141</volume>:<fpage>2094</fpage>–<lpage>106</lpage>.<pub-id pub-id-type="pmid">29731129</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0213">
<label>213</label>
<mixed-citation id="apm12934-cit-0213" publication-type="journal">
<string-name>
<surname>Dyjack</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Goleva</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rios</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Bin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2‐high atopic dermatitis disease endotype</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>141</volume>:<fpage>1298</fpage>–<lpage>309</lpage>.<pub-id pub-id-type="pmid">29309794</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0214">
<label>214</label>
<mixed-citation id="apm12934-cit-0214" publication-type="journal">
<string-name>
<surname>Wen</surname>
<given-names>H‐C</given-names>
</string-name>, <string-name>
<surname>Czarnowicki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Noda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Malik</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pavel</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Nakajima</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Serum from Asian patients with atopic dermatitis is characterized by T2/T22 activation, which is highly correlated with nonlesional skin measures</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>142</volume>:<fpage>324</fpage>–<lpage>8</lpage>. e11.<pub-id pub-id-type="pmid">29653116</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0215">
<label>215</label>
<mixed-citation id="apm12934-cit-0215" publication-type="journal">
<string-name>
<surname>Thijs</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Strickland</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bruijnzeel‐Koomen</surname>
<given-names>CAFM</given-names>
</string-name>, <string-name>
<surname>Nierkens</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Giovannone</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Knol</surname>
<given-names>EF</given-names>
</string-name>, et al. <article-title>Serum biomarker profiles suggest that atopic dermatitis is a systemic disease</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>141</volume>:<fpage>1523</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">29410314</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0216">
<label>216</label>
<mixed-citation id="apm12934-cit-0216" publication-type="journal">
<string-name>
<surname>Noda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ungar</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>de Guzman Strong</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2015</year>;<volume>136</volume>:<fpage>1254</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">26428954</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0217">
<label>217</label>
<mixed-citation id="apm12934-cit-0217" publication-type="journal">
<string-name>
<surname>Kaufman</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Alexis</surname>
<given-names>AF</given-names>
</string-name>. <article-title>Atopic dermatitis in diverse racial and ethnic groups‐Variations in epidemiology, genetics, clinical presentation and treatment</article-title>. <source xml:lang="en"/>Exp Dermatol
<year>2018</year>;<volume>27</volume>:<fpage>340</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">29457272</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0218">
<label>218</label>
<mixed-citation id="apm12934-cit-0218" publication-type="journal">
<string-name>
<surname>Brunner</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>. <article-title>Racial differences in atopic dermatitis</article-title>. <source xml:lang="en"/>Ann Allergy Asthma Immunol
<year>2018</year> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.anai.2018.11.015</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0219">
<label>219</label>
<mixed-citation id="apm12934-cit-0219" publication-type="journal">
<string-name>
<surname>Czarnowicki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>. <article-title>Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol Pract
<year>2014</year>;<volume>2</volume>:<fpage>371</fpage>–<lpage>9</lpage>; quiz 380–1.<pub-id pub-id-type="pmid">25017523</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0220">
<label>220</label>
<mixed-citation id="apm12934-cit-0220" publication-type="journal">
<string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lowes</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Resolved psoriasis lesions retain expression of a subset of disease‐related genes</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2011</year>;<volume>131</volume>:<fpage>391</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="pmid">20861854</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0221">
<label>221</label>
<mixed-citation id="apm12934-cit-0221" publication-type="book">
<string-name>
<surname>Shimizu</surname>
<given-names>H</given-names>
</string-name>. <source xml:lang="en"/>Shimizu's Dermatology. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>2017</year>: <fpage>664</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0222">
<label>222</label>
<mixed-citation id="apm12934-cit-0222" publication-type="journal">
<string-name>
<surname>Esaki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ewald</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Ungar</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rozenblit</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2015</year>;<volume>135</volume>:<fpage>153</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">25567045</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0223">
<label>223</label>
<mixed-citation id="apm12934-cit-0223" publication-type="journal">
<string-name>
<surname>Rodríguez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Baurecht</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wahn</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Kretschmer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hotze</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zeilinger</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>An integrated epigenetic and transcriptomic analysis reveals distinct tissue‐specific patterns of DNA methylation associated with atopic dermatitis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2014</year>;<volume>134</volume>:<fpage>1873</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">24739813</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0224">
<label>224</label>
<mixed-citation id="apm12934-cit-0224" publication-type="journal">
<string-name>
<surname>Weiss</surname>
<given-names>ST</given-names>
</string-name>. <article-title>Eat dirt–the hygiene hypothesis and allergic diseases</article-title>. <source xml:lang="en"/>N Engl J Med
<year>2002</year>;<volume>347</volume>:<fpage>930</fpage>–<lpage>1</lpage>.<pub-id pub-id-type="pmid">12239263</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0225">
<label>225</label>
<mixed-citation id="apm12934-cit-0225" publication-type="journal">
<string-name>
<surname>Laforest‐Lapointe</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Arrieta</surname>
<given-names>M‐C</given-names>
</string-name>. <article-title>Patterns of early‐life gut microbial colonization during human immune development: an ecological perspective</article-title>. <source xml:lang="en"/>Front Immunol
<year>2017</year>;<volume>8</volume>:<fpage>788</fpage>.<pub-id pub-id-type="pmid">28740492</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0226">
<label>226</label>
<mixed-citation id="apm12934-cit-0226" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>M‐J</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>M‐J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S‐Y</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Won</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Perturbations of gut microbiome genes in infants with atopic dermatitis according to feeding type</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>141</volume>:<fpage>1310</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29339259</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0227">
<label>227</label>
<mixed-citation id="apm12934-cit-0227" publication-type="journal">
<string-name>
<surname>Brüssow</surname>
<given-names>H</given-names>
</string-name>. <article-title>Turning the inside out: the microbiology of atopic dermatitis</article-title>. <source xml:lang="en"/>Environ Microbiol
<year>2016</year>;<volume>18</volume>:<fpage>2089</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">26373255</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0228">
<label>228</label>
<mixed-citation id="apm12934-cit-0228" publication-type="journal">
<string-name>
<surname>Simpson</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Villarreal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jepson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rafaels</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>David</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hanifin</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Patients with atopic dermatitis colonized with staphylococcus aureus have a distinct phenotype and endotype</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2018</year>;<volume>138</volume>:<fpage>2224</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">29604251</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0229">
<label>229</label>
<mixed-citation id="apm12934-cit-0229" publication-type="journal">
<string-name>
<surname>Kong</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Oh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Deming</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Conlan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Grice</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Beatson</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis</article-title>. <source xml:lang="en"/>Genome Res
<year>2012</year>;<volume>22</volume>:<fpage>850</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">22310478</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0230">
<label>230</label>
<mixed-citation id="apm12934-cit-0230" publication-type="journal">
<string-name>
<surname>Glatz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jo</surname>
<given-names>J‐H</given-names>
</string-name>, <string-name>
<surname>Kennedy</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Polley</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Segre</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>EL</given-names>
</string-name>, et al. <article-title>Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis</article-title>. <source xml:lang="en"/>PLoS ONE
<year>2018</year>;<volume>13</volume>:<fpage>e0192443</fpage>.<pub-id pub-id-type="pmid">29489859</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0231">
<label>231</label>
<mixed-citation id="apm12934-cit-0231" publication-type="journal">
<string-name>
<surname>Novak</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gros</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bieber</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Allam</surname>
<given-names>J‐P</given-names>
</string-name>. <article-title>Human skin and oral mucosal dendritic cells as “good guys” and “bad guys” in allergic immune responses</article-title>. <source xml:lang="en"/>Clin Exp Immunol
<year>2010</year>;<volume>161</volume>:<fpage>28</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">20408854</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0232">
<label>232</label>
<mixed-citation id="apm12934-cit-0232" publication-type="journal">
<string-name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Oscherwitz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cease</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Muñoz‐Planillo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hasegawa</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Staphylococcus δ‐toxin induces allergic skin disease by activating mast cells</article-title>. <source xml:lang="en"/>Nature
<year>2013</year>;<volume>503</volume>:<fpage>397</fpage>–<lpage>401</lpage>.<pub-id pub-id-type="pmid">24172897</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0233">
<label>233</label>
<mixed-citation id="apm12934-cit-0233" publication-type="journal">
<string-name>
<surname>Ong</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Ohtake</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Brandt</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Strickland</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Boguniewicz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ganz</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Endogenous antimicrobial peptides and skin infections in atopic dermatitis</article-title>. <source xml:lang="en"/>N Engl J Med
<year>2002</year>;<volume>347</volume>:<fpage>1151</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">12374875</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0234">
<label>234</label>
<mixed-citation id="apm12934-cit-0234" publication-type="journal">
<string-name>
<surname>Oliva</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Renert‐Yuval</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>. <article-title>The, “omics” revolution: redefining the understanding and treatment of allergic skin diseases</article-title>. <source xml:lang="en"/>Curr Opin Allergy Clin Immunol
<year>2016</year>;<volume>16</volume>:<fpage>469</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">27490125</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0235">
<label>235</label>
<mixed-citation id="apm12934-cit-0235" publication-type="journal">
<string-name>
<surname>Nakatsuji</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Narala</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chun</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Two</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Yun</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Antimicrobials from human skin commensal bacteria protect against and are deficient in atopic dermatitis</article-title>. <source xml:lang="en"/>Sci Transl Med
<year>2017</year>;<volume>9</volume>:<fpage>pii: eaah4680</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0236">
<label>236</label>
<mixed-citation id="apm12934-cit-0236" publication-type="journal">
<string-name>
<surname>Gallo</surname>
<given-names>RL</given-names>
</string-name>. <article-title>Human skin is the largest epithelial surface for interaction with microbes</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2017</year>;<volume>137</volume>:<fpage>1213</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">28395897</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0237">
<label>237</label>
<mixed-citation id="apm12934-cit-0237" publication-type="journal">
<string-name>
<surname>Portugal‐Cohen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kohen</surname>
<given-names>R</given-names>
</string-name>. <article-title>Non‐invasive evaluation of skin cytokines secretion: an innovative complementary method for monitoring skin disorders</article-title>. <source xml:lang="en"/>Methods
<year>2013</year>;<volume>61</volume>:<fpage>63</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">23063704</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0238">
<label>238</label>
<mixed-citation id="apm12934-cit-0238" publication-type="journal">
<string-name>
<surname>Assfalg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bortoletti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>D'Onofrio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pigozzi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Molinari</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Boner</surname>
<given-names>AL</given-names>
</string-name>, et al. <article-title>An exploratory (1) H‐nuclear magnetic resonance metabolomics study reveals altered urine spectral profiles in infants with atopic dermatitis</article-title>. <source xml:lang="en"/>Br J Dermatol
<year>2012</year>;<volume>166</volume>:<fpage>1123</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">22032695</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0239">
<label>239</label>
<mixed-citation id="apm12934-cit-0239" publication-type="journal">
<string-name>
<surname>Peroni</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Bodini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Corradi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coghi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Boner</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Piacentini</surname>
<given-names>GL</given-names>
</string-name>. <article-title>Markers of oxidative stress are increased in exhaled breath condensates of children with atopic dermatitis</article-title>. <source xml:lang="en"/>Br J Dermatol
<year>2012</year>;<volume>166</volume>:<fpage>839</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">22175656</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0240">
<label>240</label>
<mixed-citation id="apm12934-cit-0240" publication-type="journal">
<string-name>
<surname>Bandyopadhyay</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Connolly</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Jabado</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Ye</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Maldonado</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial</article-title>. <source xml:lang="en"/>Lupus Sci Med
<year>2017</year>;<volume>4</volume>:<fpage>e000206</fpage>.<pub-id pub-id-type="pmid">29214034</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0241">
<label>241</label>
<mixed-citation id="apm12934-cit-0241" publication-type="journal">
<string-name>
<surname>Chen</surname>
<given-names>S‐H</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>
<given-names>W‐Y</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>S‐Y</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>W‐C</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>J‐M</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>HH‐S</given-names>
</string-name>, et al. <article-title>A gene profiling deconvolution approach to estimating immune cell composition from complex tissues</article-title>. <source xml:lang="en"/>BMC Bioinformatics
<year>2018</year>;<volume>19</volume>(<issue>Suppl 4</issue>):<fpage>154</fpage>.<pub-id pub-id-type="pmid">29745829</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0242">
<label>242</label>
<mixed-citation id="apm12934-cit-0242" publication-type="journal">
<string-name>
<surname>Abbas</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Wolslegel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Seshasayee</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Modrusan</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>HF</given-names>
</string-name>. <article-title>Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus</article-title>. <source xml:lang="en"/>PLoS ONE
<year>2009</year>;<volume>4</volume>:<fpage>e6098</fpage>.<pub-id pub-id-type="pmid">19568420</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0243">
<label>243</label>
<mixed-citation id="apm12934-cit-0243" publication-type="journal">
<string-name>
<surname>Laczmanska</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Sasiadek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Laczmanski</surname>
<given-names>L</given-names>
</string-name>. <article-title>The comparison between molecular tumour profiling in microdissected and surgical tissue samples</article-title>. <source xml:lang="en"/>Anticancer Res
<year>2018</year>;<volume>38</volume>:<fpage>1415</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">29491066</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0244">
<label>244</label>
<mixed-citation id="apm12934-cit-0244" publication-type="journal">
<string-name>
<surname>Macosko</surname>
<given-names>EZ</given-names>
</string-name>, <string-name>
<surname>Basu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Satija</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nemesh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shekhar</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Highly parallel genome‐wide expression profiling of individual cells using nanoliter droplets</article-title>. <source xml:lang="en"/>Cell
<year>2015</year>;<volume>161</volume>:<fpage>1202</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">26000488</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0245">
<label>245</label>
<mixed-citation id="apm12934-cit-0245" publication-type="journal">
<string-name>
<surname>Dainichi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kitoh</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Otsuka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakajima</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nomura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kaplan</surname>
<given-names>DH</given-names>
</string-name>, et al. <article-title>The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis</article-title>. <source xml:lang="en"/>Nat Immunol
<year>2018</year>;<volume>19</volume>:<fpage>1286</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">30446754</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0246">
<label>246</label>
<mixed-citation id="apm12934-cit-0246" publication-type="journal">
<string-name>
<surname>Shen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jwo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mosaed</surname>
<given-names>S</given-names>
</string-name>. <article-title>Dupilumab‐induced follicular conjunctivitis</article-title>. <source xml:lang="en"/>Ocul Immunol Inflamm
<year>2018</year> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1080/09273948.2018.1533567</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0247">
<label>247</label>
<mixed-citation id="apm12934-cit-0247" publication-type="miscellaneous">
<article-title>MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head‐to‐Head Study ECLIPSE Demonstrating Superiority of Tremfya(R) vs. Cosentyx(R) as Measured by PASI 90 at Week 48 in the Treatment of Plaque Psoriasis [Internet]</article-title>. MorphoSys AG. <year>2018</year> Available from: <ext-link ext-link-type="uri" xlink:href="https://www.morphosys.com/media-investors/media-center/morphosyss-licensee-janssen-announces-data-from-the-phase-3-head-to">https://www.morphosys.com/media-investors/media-center/morphosyss-licensee-janssen-announces-data-from-the-phase-3-head-to</ext-link> [cited 2018 Dec 31].</mixed-citation>
</ref>
<ref id="apm12934-bib-0248">
<label>248</label>
<mixed-citation id="apm12934-cit-0248" publication-type="journal">
<string-name>
<surname>Harden</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Johnson‐Huang</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Chamian</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pearce</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>CL</given-names>
</string-name>, et al. <article-title>Humanized anti‐IFN‐γ (HuZAF) in the treatment of psoriasis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2015</year>;<volume>135</volume>:<fpage>553</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">25085340</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0249">
<label>249</label>
<mixed-citation id="apm12934-cit-0249" publication-type="journal">
<string-name>
<surname>Gadina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bonelli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hasni</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kanno</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Translational and clinical advances in JAK‐STAT biology: the present and future of jakinibs</article-title>. <source xml:lang="en"/>J Leukoc Biol
<year>2018</year>;<volume>104</volume>:<fpage>499</fpage>–<lpage>514</lpage>.<pub-id pub-id-type="pmid">29999544</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0250">
<label>250</label>
<mixed-citation id="apm12934-cit-0250" publication-type="journal">
<string-name>
<surname>He</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>. <article-title>JAK inhibitors for atopic dermatitis: an update</article-title>. <source xml:lang="en"/>Am J Clin Dermatol
<year>2018</year> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1007/s40257-018-0413-2</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0251">
<label>251</label>
<mixed-citation id="apm12934-cit-0251" publication-type="journal">
<string-name>
<surname>Tam</surname>
<given-names>HH</given-names>
</string-name>, <string-name>
<surname>Calderon</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Manikam</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Nankervis</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Núñez</surname>
<given-names>IG</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>HC</given-names>
</string-name>, et al. <article-title>Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review</article-title>. <source xml:lang="en"/>Allergy
<year>2016</year>;<volume>71</volume>:<fpage>1345</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">27184158</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0252">
<label>252</label>
<mixed-citation id="apm12934-cit-0252" publication-type="journal">
<string-name>
<surname>Clowry</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>McLoughlin</surname>
<given-names>RM</given-names>
</string-name>. <article-title>Next‐generation anti‐Staphylococcus aureus vaccines: a potential new therapeutic option for atopic dermatitis?</article-title>
<source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>143</volume>:<fpage>78</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">30218675</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0253">
<label>253</label>
<mixed-citation id="apm12934-cit-0253" publication-type="journal">
<string-name>
<surname>Ghosh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bernstein</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Khurana Hershey</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Rothenberg</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Mersha</surname>
<given-names>TB</given-names>
</string-name>. <article-title>Leveraging multilayered “OMICS” data for atopic dermatitis: a road map to precision medicine</article-title>. <source xml:lang="en"/>Front Immunol
<year>2018</year>;<volume>9</volume>:<fpage>2727</fpage>.<pub-id pub-id-type="pmid">30631320</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0254">
<label>254</label>
<mixed-citation id="apm12934-cit-0254" publication-type="journal">
<string-name>
<surname>Janiaud</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Serghiou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ioannidis</surname>
<given-names>JPA</given-names>
</string-name>. <article-title>New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology</article-title>. <source xml:lang="en"/>Cancer Treat Rev
<year>2018</year>;<volume>73</volume>:<fpage>20</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">30572165</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0255">
<label>255</label>
<mixed-citation id="apm12934-cit-0255" publication-type="journal">
<string-name>
<surname>Brock</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>S</given-names>
</string-name>. <article-title>Precision oncology: between vaguely right and precisely wrong</article-title>. <source xml:lang="en"/>Cancer Res
<year>2017</year>;<volume>77</volume>:<fpage>6473</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29162615</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0256">
<label>256</label>
<mixed-citation id="apm12934-cit-0256" publication-type="journal">
<string-name>
<surname>Chung</surname>
<given-names>KF</given-names>
</string-name>. <article-title>Precision medicine in asthma: linking phenotypes to targeted treatments</article-title>. <source xml:lang="en"/>Curr Opin Pulm Med
<year>2018</year>;<volume>24</volume>:<fpage>4</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">29036018</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0257">
<label>257</label>
<mixed-citation id="apm12934-cit-0257" publication-type="journal">
<string-name>
<surname>Greis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Meier Zürcher</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Djamei</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Moser</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lautenschlager</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Navarini</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Unmet digital health service needs in dermatology patients</article-title>. <source xml:lang="en"/>J Dermatolog Treat
<year>2018</year>;<volume>29</volume>:<fpage>643</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">29455570</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0258">
<label>258</label>
<mixed-citation id="apm12934-cit-0258" publication-type="journal">
<string-name>
<surname>Lande</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Botti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jandus</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dojcinovic</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fanelli</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Conrad</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>The antimicrobial peptide LL37 is a T‐cell autoantigen in psoriasis</article-title>. <source xml:lang="en"/>Nat Commun
<year>2014</year>;<volume>5</volume>:<fpage>5621</fpage>.<pub-id pub-id-type="pmid">25470744</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0259">
<label>259</label>
<mixed-citation id="apm12934-cit-0259" publication-type="journal">
<string-name>
<surname>Clayton</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Vallejo</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sirvent</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Polak</surname>
<given-names>ME</given-names>
</string-name>. <article-title>Langerhans Cells‐Programmed by the Epidermis</article-title>. <source xml:lang="en"/>Front Immunol
<year>2017</year>;<volume>8</volume>:<fpage>1676</fpage>.<pub-id pub-id-type="pmid">29238347</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0260">
<label>260</label>
<mixed-citation id="apm12934-cit-0260" publication-type="journal">
<string-name>
<surname>Martinez‐Gonzalez</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ghaedi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Steer</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Mathä</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Vivier</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Takei</surname>
<given-names>F</given-names>
</string-name>. <article-title>ILC2 memory: recollection of previous activation</article-title>. <source xml:lang="en"/>Immunol Rev
<year>2018</year>;<volume>283</volume>:<fpage>41</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">29664572</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0261">
<label>261</label>
<mixed-citation id="apm12934-cit-0261" publication-type="journal">
<string-name>
<surname>Streilein</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Skin‐associated lymphoid tissues (SALT): origins and functions</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>1983</year>;<volume>80</volume>(<issue>Suppl</issue>):<fpage>12s</fpage>–<lpage>6s</lpage>.<pub-id pub-id-type="pmid">6602189</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0262">
<label>262</label>
<mixed-citation id="apm12934-cit-0262" publication-type="journal">
<string-name>
<surname>Vakharia</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>. <article-title>Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential</article-title>. <source xml:lang="en"/>BioDrugs
<year>2017</year>;<volume>31</volume>:<fpage>409</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">28853008</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0263">
<label>263</label>
<mixed-citation id="apm12934-cit-0263" publication-type="journal">
<string-name>
<surname>Leung</surname>
<given-names>DY</given-names>
</string-name>. <article-title>Atopic dermatitis: new insights and opportunities for therapeutic intervention</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2000</year>;<volume>105</volume>:<fpage>860</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">10808164</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0264">
<label>264</label>
<mixed-citation id="apm12934-cit-0264" publication-type="journal">
<string-name>
<surname>Leung</surname>
<given-names>DYM</given-names>
</string-name>, <string-name>
<surname>Boguniewicz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Howell</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Nomura</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hamid</surname>
<given-names>QA</given-names>
</string-name>. <article-title>New insights into atopic dermatitis</article-title>. <source xml:lang="en"/>J Clin Invest
<year>2004</year>;<volume>113</volume>
<issue>5</issue>:<fpage>651</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">14991059</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0265">
<label>265</label>
<mixed-citation id="apm12934-cit-0265" publication-type="journal">
<string-name>
<surname>Paller</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Kabashima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bieber</surname>
<given-names>T</given-names>
</string-name>. <article-title>Therapeutic pipeline for atopic dermatitis: end of the drought?</article-title>
<source xml:lang="en"/>J Allergy Clin Immunol
<year>2017</year>;<volume>140</volume>:<fpage>633</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">28887947</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0266">
<label>266</label>
<mixed-citation id="apm12934-cit-0266" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Tran</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>VY</given-names>
</string-name>. <article-title>New and emerging targeted systemic therapies: a new era for atopic dermatitis</article-title>. <source xml:lang="en"/>J Dermatolog Treat
<year>2018</year>;<volume>29</volume>:<fpage>364</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">28853956</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0267">
<label>267</label>
<mixed-citation id="apm12934-cit-0267" publication-type="journal">
<string-name>
<surname>Brunner</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>DYM</given-names>
</string-name>. <article-title>The immunology of atopic dermatitis and its reversibility with broad‐spectrum and targeted therapies</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2017</year>;<volume>139</volume>(<issue>4S</issue>):<fpage>S65</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">28390479</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0268">
<label>268</label>
<mixed-citation id="apm12934-cit-0268" publication-type="journal">
<string-name>
<surname>Brunner</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>DYM</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>. <article-title>Immunologic, microbial, and epithelial interactions in atopic dermatitis</article-title>. <source xml:lang="en"/>Ann Allergy Asthma Immunol
<year>2018</year>;<volume>120</volume>:<fpage>34</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">29126710</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0269">
<label>269</label>
<mixed-citation id="apm12934-cit-0269" publication-type="miscellaneous">
<article-title>A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis ‐ Full Text View ‐ ClinicalTrials.gov [Internet]</article-title>. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03568071">https://clinicaltrials.gov/ct2/show/NCT03568071</ext-link> [cited 2018 Oct 27]</mixed-citation>
</ref>
<ref id="apm12934-bib-0270">
<label>270</label>
<mixed-citation id="apm12934-cit-0270" publication-type="journal">
<string-name>
<surname>Teng</surname>
<given-names>MWL</given-names>
</string-name>, <string-name>
<surname>Bowman</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>McElwee</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Smyth</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Casanova</surname>
<given-names>J‐L</given-names>
</string-name>, <string-name>
<surname>Cooper</surname>
<given-names>AM</given-names>
</string-name>, et al. <article-title>IL‐12 and IL‐23 cytokines: from discovery to targeted therapies for immune‐mediated inflammatory diseases</article-title>. <source xml:lang="en"/>Nat Med
<year>2015</year>;<volume>21</volume>:<fpage>719</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">26121196</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0271">
<label>271</label>
<mixed-citation id="apm12934-cit-0271" publication-type="journal">
<string-name>
<surname>Koutruba</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Emer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>M</given-names>
</string-name>. <article-title>Review of ustekinumab, an interleukin‐12 and interleukin‐23 inhibitor used for the treatment of plaque psoriasis</article-title>. <source xml:lang="en"/>Ther Clin Risk Manag
<year>2010</year>;<volume>6</volume>:<fpage>123</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">20421912</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0272">
<label>272</label>
<mixed-citation id="apm12934-cit-0272" publication-type="journal">
<string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Kantor</surname>
<given-names>R</given-names>
</string-name>. <article-title>The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis</article-title>. <source xml:lang="en"/>Dermatol Clin
<year>2017</year>;<volume>35</volume>:<fpage>327</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">28577802</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0273">
<label>273</label>
<mixed-citation id="apm12934-cit-0273" publication-type="journal">
<string-name>
<surname>Daines</surname>
<given-names>MO</given-names>
</string-name>, <string-name>
<surname>Tabata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Warrier</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Basu</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Level of expression of IL‐13R alpha 2 impacts receptor distribution and IL‐13 signaling</article-title>. <source xml:lang="en"/>J Immunol
<year>2006</year>;<volume>176</volume>:<fpage>7495</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">16751396</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0274">
<label>274</label>
<mixed-citation id="apm12934-cit-0274" publication-type="journal">
<string-name>
<surname>Hermanns</surname>
<given-names>HM</given-names>
</string-name>. <article-title>Oncostatin M and interleukin‐31: Cytokines, receptors, signal transduction and physiology</article-title>. <source xml:lang="en"/>Cytokine Growth Factor Rev
<year>2015</year>;<volume>26</volume>:<fpage>545</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">26198770</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0275">
<label>275</label>
<mixed-citation id="apm12934-cit-0275" publication-type="journal">
<string-name>
<surname>Kabashima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Furue</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hanifin</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Pulka</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wollenberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Galus</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Nemolizumab in patients with moderate‐to‐severe atopic dermatitis: randomized, phase II, long‐term extension study</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>142</volume>:<fpage>1121</fpage>–<lpage>30</lpage>. e7.<pub-id pub-id-type="pmid">29753033</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0276">
<label>276</label>
<mixed-citation id="apm12934-cit-0276" publication-type="journal">
<string-name>
<surname>Szklarczyk</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Cook</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kuhn</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wyder</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Simonovic</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The STRING database in 2017: quality‐controlled protein–protein association networks, made broadly accessible</article-title>. <source xml:lang="en"/>Nucleic Acids Res
<year>2017</year>;<volume>45</volume>
<issue>D1</issue>:<fpage>D362</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">27924014</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0277">
<label>277</label>
<mixed-citation id="apm12934-cit-0277" publication-type="journal">
<string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chiricozzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nograles</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Shemer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2009</year>;<volume>124</volume>:<fpage>1235</fpage>–<lpage>44</lpage>. e58.<pub-id pub-id-type="pmid">20004782</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0278">
<label>278</label>
<mixed-citation id="apm12934-cit-0278" publication-type="journal">
<string-name>
<surname>Martel</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Litman</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hald</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Norsgaard</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lovato</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dyring‐Andersen</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis</article-title>. <source xml:lang="en"/>Exp Dermatol
<year>2016</year>;<volume>25</volume>:<fpage>453</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">26841714</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0279">
<label>279</label>
<mixed-citation id="apm12934-cit-0279" publication-type="journal">
<string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ungar</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Correa da Rosa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ewald</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Rozenblit</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2015</year>;<volume>135</volume>:<fpage>1218</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">25840722</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0280">
<label>280</label>
<mixed-citation id="apm12934-cit-0280" publication-type="journal">
<string-name>
<surname>Ewald</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Noda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oliva</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Litman</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nakajima</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2017</year>;<volume>139</volume>:<fpage>562</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">27702671</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0281">
<label>281</label>
<mixed-citation id="apm12934-cit-0281" publication-type="journal">
<string-name>
<surname>Nair</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Duffin</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Helms</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stuart</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Goldgar</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Genome‐wide scan reveals association of psoriasis with IL‐23 and NF‐kappaB pathways</article-title>. <source xml:lang="en"/>Nat Genet
<year>2009</year>;<volume>41</volume>:<fpage>199</fpage>–<lpage>204</lpage>.<pub-id pub-id-type="pmid">19169254</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0282">
<label>282</label>
<mixed-citation id="apm12934-cit-0282" publication-type="journal">
<string-name>
<surname>Joyce</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Thrash</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Menter</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome</article-title>. <source xml:lang="en"/>Hum Mol Genet
<year>2011</year>;<volume>20</volume>:<fpage>4025</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">21807764</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0283">
<label>283</label>
<mixed-citation id="apm12934-cit-0283" publication-type="journal">
<string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hayden</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Brodmerkel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate‐to‐severe psoriasis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2012</year>;<volume>132</volume>:<fpage>2552</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">22763790</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0284">
<label>284</label>
<mixed-citation id="apm12934-cit-0284" publication-type="journal">
<string-name>
<surname>Mitsui</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Belkin</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Levenkova</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Coats</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease‐related genes in focal regions of psoriasis vulgaris skin lesions</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2012</year>;<volume>132</volume>:<fpage>1615</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">22402443</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0285">
<label>285</label>
<mixed-citation id="apm12934-cit-0285" publication-type="journal">
<string-name>
<surname>Wang</surname>
<given-names>CQF</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nograles</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Mimoso</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Shrom</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dow</surname>
<given-names>ER</given-names>
</string-name>, et al. <article-title>IL‐17 induces inflammation‐associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2014</year>;<volume>134</volume>:<fpage>2990</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">24999591</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0286">
<label>286</label>
<mixed-citation id="apm12934-cit-0286" publication-type="journal">
<string-name>
<surname>Krueger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cueto</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>CQ</given-names>
</string-name>, et al. <article-title>Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2016</year>;<volume>137</volume>:<fpage>1079</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">27059729</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0287">
<label>287</label>
<mixed-citation id="apm12934-cit-0287" publication-type="journal">
<string-name>
<surname>Correa da Rosa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tomalin</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>. <article-title>Shrinking the psoriasis assessment gap: early gene‐expression profiling accurately predicts response to long‐term treatment</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2017</year>;<volume>137</volume>:<fpage>305</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">27667537</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0288">
<label>288</label>
<mixed-citation id="apm12934-cit-0288" publication-type="journal">
<string-name>
<surname>Li</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Tsoi</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Swindell</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Gudjonsson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Tejasvi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Transcriptome analysis of psoriasis in a large case‐control sample: RNA‐seq provides insights into disease mechanisms</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2014</year>;<volume>134</volume>:<fpage>1828</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">24441097</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0289">
<label>289</label>
<mixed-citation id="apm12934-cit-0289" publication-type="journal">
<string-name>
<surname>Quaranta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Knapp</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Garzorz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mattii</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pullabhatla</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Pennino</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema</article-title>. <source xml:lang="en"/>Sci Transl Med
<year>2014</year>;<volume>6</volume>:<fpage>244ra90</fpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0290">
<label>290</label>
<mixed-citation id="apm12934-cit-0290" publication-type="journal">
<string-name>
<surname>D'Erme</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Wilsmann‐Theis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wagenpfeil</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hölzel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ferring‐Schmitt</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sternberg</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>IL‐36γ (IL‐1F9) is a biomarker for psoriasis skin lesions</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2015</year>;<volume>135</volume>:<fpage>1025</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">25525775</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0291">
<label>291</label>
<mixed-citation id="apm12934-cit-0291" publication-type="journal">
<string-name>
<surname>Bissonnette</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Suárez‐Fariñas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Bonifacio</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Brodmerkel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fuentes‐Duculan</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris</article-title>. <source xml:lang="en"/>PLoS ONE
<year>2016</year>;<volume>11</volume>:<fpage>e0155215</fpage>.<pub-id pub-id-type="pmid">27152848</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0292">
<label>292</label>
<mixed-citation id="apm12934-cit-0292" publication-type="journal">
<string-name>
<surname>Xing</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sarkar</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Wolterink</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Swindell</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Voorhees</surname>
<given-names>JJ</given-names>
</string-name>, et al. <article-title>IL‐17 responses are the dominant inflammatory signal linking inverse, erythrodermic, and chronic plaque psoriasis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2016</year>;<volume>136</volume>:<fpage>2498</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">27448749</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0293">
<label>293</label>
<mixed-citation id="apm12934-cit-0293" publication-type="journal">
<string-name>
<surname>Zhou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zuo</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Epigenome‐wide association analysis identified nine skin DNA methylation loci for psoriasis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2016</year>;<volume>136</volume>:<fpage>779</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">26743604</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0294">
<label>294</label>
<mixed-citation id="apm12934-cit-0294" publication-type="journal">
<string-name>
<surname>Vakharia</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>. <article-title>New therapies for atopic dermatitis: additional treatment classes</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>(<issue>3S1</issue>):<fpage>S76</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">29248520</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0295">
<label>295</label>
<mixed-citation id="apm12934-cit-0295" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Jayawickreme</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rickard</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Nicodeme</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bui</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Simmons</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Tapinarof is a natural Ahr agonist that resolves skin inflammation in mice and humans</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2017</year>;<volume>137</volume>:<fpage>2110</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">28595996</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0296">
<label>296</label>
<mixed-citation id="apm12934-cit-0296" publication-type="journal">
<string-name>
<surname>Bouma</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zamuner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hicks</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Want</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Choudhury</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6 cells in an experimental suction blister</article-title>. <source xml:lang="en"/>Br J Clin Pharmacol
<year>2017</year>;<volume>83</volume>:<fpage>1976</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">28295451</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0297">
<label>297</label>
<mixed-citation id="apm12934-cit-0297" publication-type="journal">
<string-name>
<surname>Molfino</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Gossage</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kolbeck</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Parker</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Geba</surname>
<given-names>GP</given-names>
</string-name>. <article-title>Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor</article-title>. <source xml:lang="en"/>Clin Exp Allergy
<year>2012</year>;<volume>42</volume>:<fpage>712</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">22092535</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0298">
<label>298</label>
<mixed-citation id="apm12934-cit-0298" publication-type="journal">
<string-name>
<surname>Holm</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Agner</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sand</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Thomsen</surname>
<given-names>SF</given-names>
</string-name>. <article-title>Omalizumab for atopic dermatitis: case series and a systematic review of the literature</article-title>. <source xml:lang="en"/>Int J Dermatol
<year>2017</year>;<volume>56</volume>:<fpage>18</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">27337170</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0299">
<label>299</label>
<mixed-citation id="apm12934-cit-0299" publication-type="journal">
<string-name>
<surname>Kaufman</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Alexis</surname>
<given-names>AF</given-names>
</string-name>. <article-title>Biologics and small molecule agents in allergic and immunologic skin diseases</article-title>. <source xml:lang="en"/>Curr Allergy Asthma Rep
<year>2018</year>;<volume>18</volume>:<fpage>55</fpage>.<pub-id pub-id-type="pmid">30171358</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0300">
<label>300</label>
<mixed-citation id="apm12934-cit-0300" publication-type="journal">
<string-name>
<surname>Gandhi</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>NMH</given-names>
</string-name>, <string-name>
<surname>Pirozzi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Stahl</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yancopoulos</surname>
<given-names>GD</given-names>
</string-name>. <article-title>Targeting key proximal drivers of type 2 inflammation in disease</article-title>. <source xml:lang="en"/>Nat Rev Drug Discov
<year>2016</year>;<volume>15</volume>:<fpage>35</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">26471366</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0301">
<label>301</label>
<mixed-citation id="apm12934-cit-0301" publication-type="journal">
<string-name>
<surname>Pan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Qiao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fang</surname>
<given-names>H</given-names>
</string-name>. <article-title>A systematic review of ustekinumab in the treatment of atopic dermatitis</article-title>. <source xml:lang="en"/>J Dermatolog Treat
<year>2018</year>;<volume>29</volume>:<fpage>539</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">29164954</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0302">
<label>302</label>
<mixed-citation id="apm12934-cit-0302" publication-type="journal">
<string-name>
<surname>Yiu</surname>
<given-names>ZZ</given-names>
</string-name>, <string-name>
<surname>Warren</surname>
<given-names>RB</given-names>
</string-name>. <article-title>Ustekinumab for the treatment of psoriasis: an evidence update</article-title>. <source xml:lang="en"/>Semin Cutan Med Surg
<year>2018</year>;<volume>37</volume>:<fpage>143</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">30215630</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0303">
<label>303</label>
<mixed-citation id="apm12934-cit-0303" publication-type="journal">
<string-name>
<surname>Thaçi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Blauvelt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reich</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>T‐F</given-names>
</string-name>, <string-name>
<surname>Vanaclocha</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kingo</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2015</year>;<volume>73</volume>:<fpage>400</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">26092291</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0304">
<label>304</label>
<mixed-citation id="apm12934-cit-0304" publication-type="journal">
<string-name>
<surname>Wollenberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Howell</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Kell</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ranade</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Treatment of atopic dermatitis with tralokinumab, an anti‐IL‐13 mAb</article-title>. <source xml:lang="en"/>J Allergy Clin Immunol
<year>2018</year>;<volume>143</volume>:<fpage>135</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">29906525</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0305">
<label>305</label>
<mixed-citation id="apm12934-cit-0305" publication-type="journal">
<string-name>
<surname>Simpson</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Flohr</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Eichenfield</surname>
<given-names>LF</given-names>
</string-name>, <string-name>
<surname>Bieber</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sofen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Taïeb</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo‐controlled phase II trial (TREBLE)</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>:<fpage>863</fpage>–<lpage>71</lpage>. e11.<pub-id pub-id-type="pmid">29353026</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0306">
<label>306</label>
<mixed-citation id="apm12934-cit-0306" publication-type="journal">
<string-name>
<surname>Griffiths</surname>
<given-names>CEM</given-names>
</string-name>, <string-name>
<surname>Reich</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van de Kerkhof</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Menter</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Comparison of ixekizumab with etanercept or placebo in moderate‐to‐severe psoriasis (UNCOVER‐2 and UNCOVER‐3): results from two phase 3 randomised trials</article-title>. <source xml:lang="en"/>Lancet
<year>2015</year>;<volume>386</volume>:<fpage>541</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">26072109</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0307">
<label>307</label>
<mixed-citation id="apm12934-cit-0307" publication-type="journal">
<string-name>
<surname>Papp</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Merola</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Gottlieb</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Griffiths</surname>
<given-names>CEM</given-names>
</string-name>, <string-name>
<surname>Cross</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12‐week randomized, double‐blinded, placebo‐controlled phase 2b trial</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>79</volume>:<fpage>277</fpage>–<lpage>86</lpage>. e10.<pub-id pub-id-type="pmid">29609013</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0308">
<label>308</label>
<mixed-citation id="apm12934-cit-0308" publication-type="journal">
<string-name>
<surname>Vandeghinste</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Klattig</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jagerschmidt</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lavazais</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Marsais</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Haas</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>Neutralization of IL‐17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2018</year>;<volume>138</volume>:<fpage>1555</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">29474945</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0309">
<label>309</label>
<mixed-citation id="apm12934-cit-0309" publication-type="journal">
<string-name>
<surname>Machado</surname>
<given-names>Á</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>T</given-names>
</string-name>. <article-title>Guselkumab for the treatment of psoriasis</article-title>. <source xml:lang="en"/>BioDrugs
<year>2018</year>;<volume>32</volume>:<fpage>119</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">29470778</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0310">
<label>310</label>
<mixed-citation id="apm12934-cit-0310" publication-type="journal">
<string-name>
<surname>Gordon</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Strober</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Augustin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blauvelt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Poulin</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Efficacy and safety of risankizumab in moderate‐to‐severe plaque psoriasis (UltIMMa‐1 and UltIMMa‐2): results from two double‐blind, randomised, placebo‐controlled and ustekinumab‐controlled phase 3 trials</article-title>. <source xml:lang="en"/>Lancet
<year>2018</year>;<volume>392</volume>:<fpage>650</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">30097359</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0311">
<label>311</label>
<mixed-citation id="apm12934-cit-0311" publication-type="journal">
<string-name>
<surname>Chan</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Hawkes</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment</article-title>. <source xml:lang="en"/>Ther Adv Chronic Dis
<year>2018</year>;<volume>9</volume>:<fpage>111</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29796240</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0312">
<label>312</label>
<mixed-citation id="apm12934-cit-0312" publication-type="journal">
<string-name>
<surname>Hamann</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Thyssen</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>(<issue>3S1</issue>):<fpage>S37</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">29248521</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0313">
<label>313</label>
<mixed-citation id="apm12934-cit-0313" publication-type="journal">
<string-name>
<surname>Cotter</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Schairer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Eichenfield</surname>
<given-names>L</given-names>
</string-name>. <article-title>Emerging therapies for atopic dermatitis: JAK inhibitors</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>(<issue>3S1</issue>):<fpage>S53</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">29248518</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0314">
<label>314</label>
<mixed-citation id="apm12934-cit-0314" publication-type="journal">
<string-name>
<surname>Cinats</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Heck</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>L</given-names>
</string-name>. <article-title>Janus kinase inhibitors: a review of their emerging applications in dermatology</article-title>. <source xml:lang="en"/>Skin Therapy Lett
<year>2018</year>;<volume>23</volume>:<fpage>5</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0315">
<label>315</label>
<mixed-citation id="apm12934-cit-0315" publication-type="journal">
<string-name>
<surname>Almutairi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nour</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Hussain</surname>
<given-names>NH</given-names>
</string-name>. <article-title>Janus kinase inhibitors for the treatment of severe alopecia areata: an open‐label comparative study</article-title>. <source xml:lang="en"/>Dermatology
<year>2019</year>;<volume>235</volume>:<fpage>130</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">30566941</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0316">
<label>316</label>
<mixed-citation id="apm12934-cit-0316" publication-type="journal">
<string-name>
<surname>Joshipura</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Alomran</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zancanaro</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rosmarin</surname>
<given-names>D</given-names>
</string-name>. <article-title>Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32‐week open‐label extension study with optional narrow‐band ultraviolet B</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>:<fpage>1205</fpage>–<lpage>7</lpage>. e1.<pub-id pub-id-type="pmid">29438765</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0317">
<label>317</label>
<mixed-citation id="apm12934-cit-0317" publication-type="journal">
<string-name>
<surname>Guttman‐Yassky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Nemoto</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Wilke</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Prescilla</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Baricitinib in adult patients with moderate‐to‐severe atopic dermatitis: a phase 2 parallel, double‐blinded, randomized placebo‐controlled multiple‐dose study</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1016/j.jaad.2018.01.018</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0318">
<label>318</label>
<mixed-citation id="apm12934-cit-0318" publication-type="journal">
<string-name>
<surname>Papp</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Menter</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Raman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Disch</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schlichting</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Gaich</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis</article-title>. <source xml:lang="en"/>Br J Dermatol
<year>2016</year>;<volume>174</volume>:<fpage>1266</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">26800231</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0319">
<label>319</label>
<mixed-citation id="apm12934-cit-0319" publication-type="journal">
<string-name>
<surname>Azevedo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>T</given-names>
</string-name>. <article-title>Tofacitinib: a new oral therapy for psoriasis</article-title>. <source xml:lang="en"/>Clin Drug Investig
<year>2018</year>;<volume>38</volume>:<fpage>101</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="apm12934-bib-0320">
<label>320</label>
<mixed-citation id="apm12934-cit-0320" publication-type="journal">
<string-name>
<surname>Banfield</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Scaramozza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Kieras</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Fensome</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF‐06700841) in healthy subjects and patients with plaque psoriasis</article-title>. <source xml:lang="en"/>J Clin Pharmacol
<year>2018</year>;<volume>58</volume>:<fpage>434</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">29266308</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0321">
<label>321</label>
<mixed-citation id="apm12934-cit-0321" publication-type="journal">
<string-name>
<surname>Nakagawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nemoto</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Igarashi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nagata</surname>
<given-names>T</given-names>
</string-name>. <article-title>Efficacy and safety of topical JTE‐052, a Janus kinase inhibitor, in Japanese adult patients with moderate‐to‐severe atopic dermatitis: a phase II, multicentre, randomized, vehicle‐controlled clinical study</article-title>. <source xml:lang="en"/>Br J Dermatol
<year>2018</year>;<volume>178</volume>:<fpage>424</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">28960254</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0322">
<label>322</label>
<mixed-citation id="apm12934-cit-0322" publication-type="journal">
<string-name>
<surname>Bonchak</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Swerlick</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Emerging therapies for atopic dermatitis: TRPV1 antagonists</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>(<issue>3S1</issue>):<fpage>S63</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">29248524</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0323">
<label>323</label>
<mixed-citation id="apm12934-cit-0323" publication-type="journal">
<string-name>
<surname>Tidwell</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Fowler</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>T‐cell inhibitors for atopic dermatitis</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>(<issue>3S1</issue>):<fpage>S67</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">29248519</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0324">
<label>324</label>
<mixed-citation id="apm12934-cit-0324" publication-type="journal">
<string-name>
<surname>Abrouk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Farahnik</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2017</year>;<volume>77</volume>:<fpage>177</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">28619562</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0325">
<label>325</label>
<mixed-citation id="apm12934-cit-0325" publication-type="journal">
<string-name>
<surname>Pincelli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schafer</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Augustin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Krueger</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Mechanisms underlying the clinical effects of apremilast for psoriasis</article-title>. <source xml:lang="en"/>J Drugs Dermatol
<year>2018</year>;<volume>17</volume>:<fpage>835</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">30124722</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0326">
<label>326</label>
<mixed-citation id="apm12934-cit-0326" publication-type="journal">
<string-name>
<surname>Yosipovitch</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gold</surname>
<given-names>LF</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Silverberg</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Tallman</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Zane</surname>
<given-names>LT</given-names>
</string-name>. <article-title>Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non‐steroidal, phosphodiesterase 4 inhibitor</article-title>. <source xml:lang="en"/>Acta Derm Venereol
<year>2018</year>;<volume>98</volume>:<fpage>484</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29363715</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0327">
<label>327</label>
<mixed-citation id="apm12934-cit-0327" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Treatment of psoriasis with crisaborole</article-title>. <source xml:lang="en"/>J Dermatolog Treat
<year>2018</year> [Epub ahead of print]. <pub-id pub-id-type="doi">10.1080/09546634.2018.1480747</pub-id>
</mixed-citation>
</ref>
<ref id="apm12934-bib-0328">
<label>328</label>
<mixed-citation id="apm12934-cit-0328" publication-type="journal">
<string-name>
<surname>Zebda</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Paller</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Phosphodiesterase 4 inhibitors</article-title>. <source xml:lang="en"/>J Am Acad Dermatol
<year>2018</year>;<volume>78</volume>(<issue>3S1</issue>):<fpage>S43</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">29248522</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0329">
<label>329</label>
<mixed-citation id="apm12934-cit-0329" publication-type="journal">
<string-name>
<surname>Harris</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>
<given-names>JU</given-names>
</string-name>, <string-name>
<surname>Nagilla</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bandyopadhyay</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Campobasso</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Discovery of a first‐in‐class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases</article-title>. <source xml:lang="en"/>J Med Chem
<year>2017</year>;<volume>60</volume>:<fpage>1247</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">28151659</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0330">
<label>330</label>
<mixed-citation id="apm12934-cit-0330" publication-type="journal">
<string-name>
<surname>Chima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lebwohl</surname>
<given-names>M</given-names>
</string-name>. <article-title>TNF inhibitors for psoriasis</article-title>. <source xml:lang="en"/>Semin Cutan Med Surg
<year>2018</year>;<volume>37</volume>:<fpage>134</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">30215629</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0331">
<label>331</label>
<mixed-citation id="apm12934-cit-0331" publication-type="journal">
<string-name>
<surname>Mease</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Genovese</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Weinblatt</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Peloso</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Othman</surname>
<given-names>AA</given-names>
</string-name>, et al. <article-title>Phase 2 study of ABT‐122, a TNF‐ and IL‐17A‐targeted dual variable domain immunoglobulin, in psoriatic arthritis with inadequate methotrexate response</article-title>. <source xml:lang="en"/>Arthritis Rheumatol
<year>2018</year>;<volume>70</volume>:<fpage>1778</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">29855175</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0332">
<label>332</label>
<mixed-citation id="apm12934-cit-0332" publication-type="journal">
<string-name>
<surname>Silacci</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lembke</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Attinger‐Toller</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Baenziger‐Tobler</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Batey</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Discovery and characterization of COVA322, a clinical‐stage bispecific TNF/IL‐17A inhibitor for the treatment of inflammatory diseases</article-title>. <source xml:lang="en"/>MAbs
<year>2016</year>;<volume>8</volume>:<fpage>141</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">26390837</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0333">
<label>333</label>
<mixed-citation id="apm12934-cit-0333" publication-type="journal">
<string-name>
<surname>Yun</surname>
<given-names>J‐W</given-names>
</string-name>, <string-name>
<surname>Seo</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Bae</surname>
<given-names>I‐H</given-names>
</string-name>, <string-name>
<surname>Jang</surname>
<given-names>W‐H</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>TRPV1 antagonist can suppress the atopic dermatitis‐like symptoms by accelerating skin barrier recovery</article-title>. <source xml:lang="en"/>J Dermatol Sci
<year>2011</year>;<volume>62</volume>:<fpage>8</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">21345654</pub-id></mixed-citation>
</ref>
<ref id="apm12934-bib-0334">
<label>334</label>
<mixed-citation id="apm12934-cit-0334" publication-type="journal">
<string-name>
<surname>Tsoi</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Degenhardt</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Baurecht</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wehkamp</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Volks</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Atopic dermatitis is an IL‐13 dominant disease with greater molecular heterogeneity compared to psoriasis</article-title>. <source xml:lang="en"/>J Invest Dermatol
<year>2019</year> [Epub ahead of print].</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>